

# CLINICAL PRACTICE GUIDELINES

MIA ERICKSON, PT, EdD • MARSHA LAWRENCE, PT, DPT • CAROLINE W. STEGINK JANSEN, PT, PhD  
DIANE COKER, PT, DPT • PETER AMADIO, MD • CARLA CLEARY, PT, DPT

## Hand Pain and Sensory Deficits: Carpal Tunnel Syndrome

*Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Hand and Upper Extremity Physical Therapy and the Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association*

*J Orthop Sports Phys Ther.* 2019;49(5):CPG1-CPG85. doi:10.2519/jospt.2019.0301

SUMMARY OF RECOMMENDATIONS .....	CPG2
INTRODUCTION .....	CPG4
METHODS .....	CPG5
CLINICAL PRACTICE GUIDELINES	
<i>Impairment/Function-Based Diagnosis</i> .....	CPG8
CLINICAL PRACTICE GUIDELINES:	
<i>Examination</i> .....	CPG32
CLINICAL PRACTICE GUIDELINES:	
<i>Interventions</i> .....	CPG37
AUTHOR/REVIEWER AFFILIATIONS AND CONTACTS ..	CPG51
REFERENCES .....	CPG52
APPENDICES (ONLINE) .....	CPG61

REVIEWERS: Roy Altman, MD • Paul Beattie, PT, PhD • Eugene Boeglin, DPT • John Dewitt, DPT • Lauren Detullio, OT  
Amanda Ferland, DPT • Christopher Hughes, PT, PhD • Sandra Kaplan, PT, PhD • David Killoran, PhD  
Murray E. Maitland, PT, PhD • Saurabh Mehta, PT, MS, PhD • Leslie Torburn, DPT • Emmanuel Yung, PT, DPT



For author, editor, contributor, and reviewer affiliations, see end of text. ©2019 Academy of Orthopaedic Physical Therapy, American Physical Therapy Association (APTA), Inc; Academy of Hand and Upper Extremity Physical Therapy, APTA, Inc; and the *Journal of Orthopaedic & Sports Physical Therapy*. The Academy of Orthopaedic Physical Therapy, APTA, Inc and the *Journal of Orthopaedic & Sports Physical Therapy* consent to reproducing and distributing this guideline for educational purposes. Address correspondence to Brenda Johnson, ICF-Based Clinical Practice Guidelines Coordinator, Academy of Orthopaedic Physical Therapy, APTA, Inc, 2920 East Avenue South, Suite 200, La Crosse, WI 54601. E-mail: icf@orthopt.org

## Summary of Recommendations\*

### DIAGNOSIS

**A** When examining a patient with suspected carpal tunnel syndrome (CTS), clinicians should use Semmes-Weinstein monofilament testing (SWMT), using the 2.83 or 3.22 monofilament as the threshold for normal light touch sensation and static 2-point discrimination on the middle finger to aid in determining the extent of nerve damage. In those with suspected moderate to severe CTS, clinicians should assess any radial finger using the 3.22 filament as the threshold for normal. Semmes-Weinstein monofilament testing should be repeated by the same provider.

**B** In those with suspected CTS, clinicians should use the Katz hand diagram, Phalen test, Tinel sign, and carpal compression test to determine the likelihood of CTS and interpret examination results in the context of all clinical exam findings.

Clinicians should assess and document patient age (older than 45 years), whether shaking their hands relieves their symptoms, sensory loss in the thumb, the wrist ratio index (greater than 0.67), and scores from the Boston Carpal Tunnel Questionnaire-symptom severity scale (CTQ-SSS) (greater than 1.9). The presence of more than 3 of these clinical findings has shown acceptable diagnostic accuracy.

**D** There is conflicting evidence on the diagnostic accuracy and clinical utility of the upper-limb neurodynamic tests, scratch-collapse test, and tests of vibration sense in the diagnosis of CTS, and therefore no recommendation can be made.

### EXAMINATION – OUTCOME MEASURES: ACTIVITY LIMITATIONS/SELF-REPORTED MEASURES

**B** Clinicians should use the CTQ-SSS to assess symptoms and the Boston Carpal Tunnel Questionnaire functional scale (CTQ-FS) or the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire to assess function when examining patients with CTS. Clinicians should use the CTQ-SSS to assess change in those undergoing nonsurgical management.

### EXAMINATION – ACTIVITY LIMITATIONS/ PHYSICAL PERFORMANCE MEASURES

**C** Clinicians may use the Purdue Pegboard (PPB) or the Delon-modified Moberg pick-up test (DMPUT) to quantify dexterity at the onset of treatment and compare scores with established norms. Clinicians should **not** use the PPB test, Jebsen-Taylor Hand Function Test, or the Nine-Hole Peg Test to assess clinical change following carpal tunnel release (CTR) surgery. Clinicians may use the DMPUT to assess change following CTR surgery.

### EXAMINATION – ACTIVITY LIMITATIONS/ PHYSICAL IMPAIRMENT MEASURES

#### Strength Measures

**A** Clinicians should **not** use lateral pinch strength as an outcome measure for patients with nonsurgically or surgically managed CTS.

**B** Clinicians should **not** use grip strength when assessing short-term (less than 3 months) change in individuals following CTR surgery.

**C** Clinicians may assess grip strength and 3-point or tip pinch strength in individuals presenting with signs and symptoms of CTS and compare scores with established norms.

**D** There is conflicting evidence on the use of tip and 3-point pinch strength and abductor pollicis brevis muscle strength testing in individuals following CTR surgery.

#### Sensory and Provocative Measures

**C** Clinicians should **not** use threshold or vibration testing to assess change in individuals with CTS undergoing nonsurgical management until more evidence becomes available. Clinicians may use the Phalen test to assess change in those with CTR surgery at long-term follow-ups.

**D** There is conflicting evidence on the use of sensory measures, including 2-point discrimination and threshold testing, to assess change over time in patients with surgically managed CTS.

### INTERVENTIONS – ASSISTIVE TECHNOLOGY

**C** Clinicians may educate their patients regarding the effects of mouse use on carpal tunnel pressure and assist patients in developing alternate strategies, including the use of arrow keys, touch screens, or alternating the mouse hand. Clinicians may recommend keyboards with reduced strike force for patients with CTS who report pain with keyboard use.

### INTERVENTIONS – ORTHOSES

**B** Clinicians should recommend a neutral-positioned wrist orthosis worn at night for short-term symptom relief and functional improvement for individuals with CTS seeking nonsurgical management.

**C** Clinicians may suggest adjusting wear time to include daytime, symptomatic, or full-time use when night-only use is ineffective at controlling symptoms in individuals with mild to moderate CTS. Clinicians may also add metacarpophalangeal joint immobilization or modify the wrist joint position for individuals with CTS who fail to experience relief. Clinicians may add patient educa-

tion on pathology, risk identification, symptom self-management, and postures/activities that aggravate symptoms.

**C** Clinicians should recommend an orthosis for women experiencing CTS during pregnancy and should provide a postpartum follow-up evaluation to examine the resolution of symptoms.

**INTERVENTIONS – BIOPHYSICAL AGENTS**

**C** Clinicians may recommend a trial of superficial heat for short-term symptom relief for individuals with CTS.

**C** Clinicians may recommend the application of microwave or shortwave diathermy for short-term pain and symptom relief for patients with mild to moderate idiopathic CTS.

**C** Clinicians may offer a trial of interferential current for short-term pain symptom relief in adults without pacemakers with idiopathic, mild to moderate CTS. As with all electrical modalities, contraindications should be taken into consideration before choosing this intervention.

**B** Clinicians should **not** use low-level laser therapy or other types of nonlaser light therapy for individuals with CTS.

**C** Clinicians should **not** use thermal ultrasound in the treatment of patients with mild to moderate CTS.

**D** There is conflicting evidence on the use of nonthermal ultrasound in the treatment of patients with mild to moderate CTS, and therefore no recommendation can be made.

**B** Clinicians should **not** use iontophoresis in the management of mild to moderate CTS.

**C** Clinicians may perform phonophoresis within nonsurgical management of patients with mild to moderate CTS for the treatment of clinical signs and symptoms.

**B** Clinicians should **not** use or recommend the use of magnets in the intervention for individuals with CTS.

**INTERVENTIONS – MANUAL THERAPY TECHNIQUES**

**C** Clinicians may perform manual therapy, directed at the cervical spine and upper extremity, for individuals with mild to moderate CTS in the short term.

**D** There is conflicting evidence on the use of neurodynamic mobilizations in the management of mild to moderate CTS.

**INTERVENTIONS – THERAPEUTIC EXERCISE**

**C** Clinicians may use a combined orthotic/stretching program in individuals with mild to moderate CTS who do not have thenar atrophy and have normal 2-point discrimination. Clinicians should monitor those undergoing treatment for clinically significant improvement.

\*These recommendations and clinical practice guidelines are based on the scientific literature accepted for publication prior to November 2018.

List of Abbreviations

**2PD:** 2-point discrimination  
**APB:** abductor pollicis brevis  
**APTA:** American Physical Therapy Association  
**BMI:** body mass index  
**CI:** confidence interval  
**CMAP:** compound muscle action potential  
**CPG:** clinical practice guideline  
**CTQ-6:** 6-item version of the Boston Carpal Tunnel Questionnaire-symptom severity scale  
**CTQ-FS:** Boston Carpal Tunnel Questionnaire-functional scale  
**CTQ-SSS:** Boston Carpal Tunnel Questionnaire-symptom severity scale  
**CTR:** carpal tunnel release  
**CTS:** carpal tunnel syndrome  
**DASH:** Disabilities of the Arm, Shoulder and Hand questionnaire

**DIP:** distal interphalangeal  
**DM:** diabetes mellitus  
**DML:** distal motor latency  
**DMPUT:** Dellon-modified Moberg pick-up test  
**DSL:** distal sensory latency  
**ES:** effect size  
**FDP:** flexor digitorum profundus  
**FDS:** flexor digitorum superficialis  
**FPL:** flexor pollicis longus  
**HR:** hazard ratio  
**ICC:** intraclass correlation coefficient  
**ICD:** International Classification of Diseases  
**ICF:** International Classification of Functioning, Disability and Health  
**IFC:** interferential current  
**LDL:** low-density lipoprotein  
**-LR:** negative likelihood ratio

## List of Abbreviations (*continued*)

<b>+LR:</b> positive likelihood ratio	<b>QuickDASH:</b> 11-item version of the DASH
<b>MCID:</b> minimal clinically important difference	<b>RCT:</b> randomized controlled trial
<b>MD:</b> mean difference	<b>SNAP:</b> sensory nerve action potential
<b>MP:</b> metacarpophalangeal	<b>SNCV:</b> sensory nerve conduction velocity
<b>NCS:</b> nerve conduction studies	<b>SRM:</b> standardized response mean
<b>NCV:</b> nerve conduction velocity	<b>SSCT:</b> subsynovial connective tissue
<b>NPV:</b> negative predictive value	<b>SWMT:</b> Semmes-Weinstein monofilament testing
<b>OR:</b> odds ratio	<b>TENS:</b> transcutaneous electrical nerve stimulation
<b>PIP:</b> proximal interphalangeal	<b>ULNT:</b> upper-limb neurodynamic test
<b>PPB:</b> Purdue Pegboard	<b>VAS:</b> visual analog scale
<b>PPV:</b> positive predictive value	

## Introduction

### AIM OF THE GUIDELINES

The Academy of Hand and Upper Extremity Physical Therapy and Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association (APTA) have an ongoing effort to create evidence-based clinical practice guidelines (CPGs) for management of patients with musculoskeletal impairments described in the World Health Organization's *International Classification of Functioning, Disability and Health (ICF)*.<sup>296</sup>

The objectives of these CPGs are as follows:

- Describe evidence-based practice, including diagnosis, prognosis, intervention, and assessments of outcomes for musculoskeletal disorders
- Classify and define common musculoskeletal conditions using the World Health Organization's terminology related to impairments of body function and body structure, activity limitations, and participation restrictions
- Identify interventions supported by current best evidence to address impairments of body function and structure, activity limitations, and participation restrictions associated with common musculoskeletal conditions
- Identify appropriate outcome measures to assess changes resulting from physical therapy interventions in body function and structure as well as in activity and participation of the individual
- Provide a description to policy makers, using internationally accepted terminology, of the practice of orthopaedic

physical therapists and hand rehabilitation

- Provide information for payers and claims reviewers regarding the practice of orthopaedic and hand therapy for common musculoskeletal conditions
- Create a reference publication for clinicians, academic instructors, clinical instructors, students, interns, residents, and fellows regarding the best current practice of orthopaedic physical therapy and hand rehabilitation

### STATEMENT OF INTENT

These guidelines are not intended to be construed or to serve as a standard of medical care. Standards of care are determined on the basis of all clinical data available for an individual patient and are subject to change as scientific knowledge and technology advance and patterns of care evolve. These parameters of practice should be considered guidelines only. Adherence to them will not ensure a successful outcome in every patient, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgment regarding a particular clinical procedure or treatment plan must be made in light of the clinical data presented by the patient, the diagnostic and treatment options available, and the patient's values, expectations, and preferences. However, we suggest that significant departures from accepted guidelines should be documented in the patient's medical records at the time the relevant clinical decision is made.

## Methods

The Academy of Hand and Upper Extremity Physical Therapy and the Academy of Orthopaedic Physical Therapy, APTA, Inc appointed content experts to develop CPGs for musculoskeletal conditions of the elbow, forearm, wrist, and hand. These content experts were given the task to identify impairments of body function and structure, activity limitations, and participation restrictions, described using ICF terminology, that could (1) categorize patients into mutually exclusive impairment patterns upon which to base intervention strategies, and (2) serve as measures of changes in function over the course of an episode of care. The second task given to the content experts was to describe the supporting evidence for the identified impairment pattern classification, as well as interventions for patients with activity limitations and impairments of body function and structure consistent with the identified impairment pattern classification. It was also acknowledged by the Academy of Orthopaedic Physical Therapy content experts that only performing a systematic search and review of the evidence related to diagnostic categories based on *International Statistical Classification of Diseases and Related Health Problems (ICD)*<sup>297</sup> terminology would not be sufficient for these ICF-based CPGs, as most of the evidence associated with changes in levels of impairment or function in homogeneous populations is not readily searchable using the ICD terminology. Thus, the authors of this guideline independently performed a systematic search of MEDLINE, CINAHL, and the Cochrane Database of Systematic Reviews (1967 through November 2018) for any relevant articles related to classification, examination, and intervention strategies for carpal tunnel syndrome (CTS). Additionally, when relevant articles were identified, their reference lists were hand searched in an attempt to identify other relevant articles. Articles from the searches were compiled and reviewed for accuracy by the authors (see **APPENDIX A** for full search strategies and **APPENDIX B** for search results, available at [www.jospt.org](http://www.jospt.org)).

The authors declared relationships and developed a conflict management plan, which included submitting a Conflict of Interest form to the Academy of Orthopaedic Physical Therapy, APTA, Inc. Articles that were authored by a reviewer were assigned to an alternate reviewer. Funding was provided by the APTA to the CPG development team for travel and expenses to the CPG development workshop. The CPG development team maintained editorial independence.

Articles contributing to recommendations were reviewed based on specified inclusion and exclusion criteria, with the goal of identifying evidence relevant to physical therapist clinical decision making for adults with CTS. The title and abstract

of each article were reviewed independently by 2 members of the CPG development team for inclusion (see **APPENDIX C** for inclusion and exclusion criteria, available at [www.jospt.org](http://www.jospt.org)). Full-text review was then similarly conducted to obtain the final set of articles for contribution to recommendations. Additional CPG team members provided the final decision for discrepancies that were not resolved by the review team (see **APPENDIX B** for flow chart of articles and **APPENDIX E** for articles included in recommendations by topic, available at [www.jospt.org](http://www.jospt.org)). For selected relevant topics that were not appropriate for the development of recommendations, such as incidence and imaging, articles were not subject to the systematic review process and were not included in the flow charts. Evidence tables for this CPG are available on the Clinical Practice Guidelines page of the Academy of Orthopaedic Physical Therapy of the APTA website: [www.orthopt.org](http://www.orthopt.org).

This guideline was issued in 2019 based on publications in the scientific literature prior to November 2018. This guideline will be considered for review in 2023, or sooner if clinically significant new evidence becomes available. Surveillance will include monitoring MEDLINE and CINAHL additions using feeds related to the search terms. Any updates to the guideline in the interim period will be noted on the Academy of Orthopaedic Physical Therapy of the APTA website ([www.orthopt.org](http://www.orthopt.org)).

### LEVELS OF EVIDENCE

Individual clinical research articles were graded according to criteria adapted from the Centre for Evidence-Based Medicine, Oxford, United Kingdom ([www.cebm.net](http://www.cebm.net)) for diagnostic, prospective, and therapeutic studies.<sup>226</sup> If the 2 content experts did not agree on a grade of evidence for a particular article, a third content expert was used to resolve the issue (see **APPENDICES F** and **G** for levels of evidence and details on procedures used for assigning levels of evidence, available at [www.orthopt.org](http://www.orthopt.org)). The evidence update was organized from highest level of evidence to lowest level. An abbreviated version of the grading system is provided below.

I	Evidence obtained from systematic reviews, high-quality diagnostic studies, prospective studies, or randomized controlled trials
II	Evidence obtained from lesser-quality diagnostic studies, systematic reviews, prospective studies, or randomized controlled trials (eg, weaker diagnostic criteria and reference standards, improper randomization, no blinding, less than 80% follow-up)
III	Case-control studies or retrospective studies
IV	Case series
V	Expert opinion

## Methods (continued)

### STRENGTH OF EVIDENCE AND GRADES OF RECOMMENDATIONS

The overall strength of the evidence supporting recommendations made in these guidelines was graded according to guidelines described by Guyatt et al,<sup>122</sup> as modified by MacDermid et al<sup>172</sup> and adopted by the coordinator and reviewers of this project. In this modified system, the typical A, B, C, and D grades of evidence have been modified to include the role of consensus expert opinion and basic science research to demonstrate biological or biomechanical plausibility.

The strength of the evidence supporting the recommendations was graded according to the information provided below. Each team developed recommendations based on the strength of evidence, including how directly the studies addressed the question on hand pain and sensory deficits: CTS. In developing their recommendations, the authors considered the strengths and limitations of the body of evidence and the health benefits, side effects, and risks of tests and interventions.

GRADES OF RECOMMENDATION	STRENGTH OF EVIDENCE	
A	Strong evidence	A preponderance of level I and/or level II studies support the recommendation. This must include at least 1 level I study
B	Moderate evidence	A single high-quality randomized controlled trial or a preponderance of level II studies support the recommendation
C	Weak evidence	A single level II study or a preponderance of level III and IV studies, including statements of consensus by content experts, support the recommendation
D	Conflicting evidence	Higher-quality studies conducted on this topic disagree with respect to their conclusions. The recommendation is based on these conflicting studies
E	Theoretical/foundational evidence	A preponderance of evidence from animal or cadaver studies, from conceptual models/principles, or from basic science/bench research support this conclusion
F	Expert opinion	Best practice based on the clinical experience of the guidelines development team

### GUIDELINE REVIEW PROCESS AND VALIDATION

Identified reviewers who are experts in management and rehabilitation reviewed this CPG content and methods for integrity, accuracy, and that it fully represents the condition. Any comments, suggestions, or feedback from the expert reviewers were delivered to the author and editors to consider and make appropriate revisions. These guidelines were also posted for public comment and review on the Academy of Orthopaedic Physical Therapy website ([www.orthopt.org](http://www.orthopt.org)),

and a notification of this posting was sent to the members of the Academy of Orthopaedic Physical Therapy, APTA, Inc. Any comments, suggestions, and feedback gathered from public commentary were sent to the authors and editors to consider and make appropriate revisions in the guideline. In addition, a panel of consumer/patient representatives and external stakeholders, such as claims reviewers, medical coding experts, academic educators, clinical educators, physician specialists, and researchers, also reviewed the guideline and provided feedback and recommendations that were given to the authors and editors for further consideration and revisions. Last, a panel of consumer/patient representatives and external stakeholders and a panel of experts in physical therapy CPG methodology annually review the Academy of Orthopaedic Physical Therapy's ICF-based CPG policies and provide feedback and comments to the CPG coordinator and editors to improve the APTA guideline development and implementation processes.

### DISSEMINATION AND IMPLEMENTATION TOOLS

In addition to publishing these guidelines in the *Journal of Orthopaedic & Sports Physical Therapy (JOSPT)*, these guidelines will be posted in the CPG areas of both the *JOSPT* and the Academy of Orthopaedic Physical Therapy, APTA, Inc websites, and will be submitted for posting on ECRI Guidelines Trust ([guidelines.ecri.org](http://guidelines.ecri.org)). The implementation tools planned to be available for patients, clinicians, educators, payers, policy makers, and researchers, and the associated implementation strategies, are listed in **TABLE 1**.

### CLASSIFICATION

The International Classification of Diseases-10th Revision-Clinical Modification (ICD-10-CM) and ICF codes that could be used when managing individuals with CTS are provided below.

#### ICD-10-CM

Carpal tunnel syndrome unspecified upper limb	G56.00
Carpal tunnel syndrome right upper limb	G56.01
Carpal tunnel syndrome left upper limb	G56.02
Pain in the right hand	M79.641
Pain in the left hand	M79.642
Pain in unspecified hand	M79.643
Pain in right fingers	M79.644
Pain in left fingers	M79.645
Pain in unspecified fingers	M79.646
Hypoesthesia of skin	R20.1
Paresthesia of skin	R20.2
Unspecified disturbances of skin sensation (includes temperature, localization, tactile discrimination, texture, vibration)	R20.9

Methods (continued)

<b>ICF body structure code</b>		Grasping	d4401
Structure of the nervous system other specified	s198	Manipulating	d4402
Structure of hand	s7302	Fine hand use other specified	d4408
Muscles of the hand	s73022	Driving	d475
<b>ICF body function codes</b>		Toileting	d530
Sleep functions	b134	Dressing	d540
Maintenance of sleep cycle	b1342	Eating	d550
Proprioceptive function	b260	Drinking	d560
Touch function	b265	Preparing meals	d630
Sensory functions related to temperature and other stimuli	b270	Doing housework	d640
Sensitivity to vibration	b2701	Remunerative employment	d850
Sensitivity to pressure	b2702		
Sensation of pain	b280		
Radiating pain in a segment or region	b2804		
Pain in upper limb	b28014		
Power of isolated muscles and muscle groups	b7300		
Control of simple voluntary movements	b7600		
Coordination of voluntary movements	b7602		
Protective functions of the skin	b810		
<b>ICF activities and participation codes</b>			
Writing	d170		
Carrying out daily routine	d230		
Using telecommunication devices and techniques	d3600		
Fine hand use	d440		
Picking up	d4400		

**SCOPE AND ORGANIZATION OF THE GUIDELINE**

This guideline includes information related to incidence, prevalence, anatomy, pathoanatomy, clinical course, risk factors, diagnosis, outcomes assessments, and interventions for CTS. Where appropriate, sections contain a summary or evidence synthesis and a statement describing gaps in knowledge. Grades of recommendation have been provided for areas related to clinical practice, including diagnosis, outcomes assessment, and interventions. The use of and recommendations for specific diagnostic tests, such as nerve conduction studies, electromyography, magnetic resonance imaging, and ultrasonography, are beyond the scope of this guideline and could serve as future CPG topics.

**TABLE 1**

PLANNED STRATEGIES AND TOOLS TO SUPPORT THE DISSEMINATION AND IMPLEMENTATION OF THIS CLINICAL PRACTICE GUIDELINE

Tool	Strategy
JOSPT's "Perspectives for Patients" and/or "Perspectives for Practice" articles	Patient-oriented and clinician-oriented guideline summaries available on <a href="http://www.jospt.org">www.jospt.org</a>
Mobile app of guideline-based exercises for patient/clients and health care practitioners	Marketing and distribution of app using <a href="http://www.orthopt.org">www.orthopt.org</a>
Clinician's Quick-Reference Guide	Summary or guideline recommendations available on <a href="http://www.orthopt.org">www.orthopt.org</a>
JOSPT's Read for Credit <sup>SM</sup> continuing education units	Continuing Education Units available for physical therapists and athletic trainers
Webinars: educational offering for health care practitioners	Guideline-based instruction available for practitioners on <a href="http://www.orthopt.org">www.orthopt.org</a>
Mobile and web-based app of guideline for training of health care practitioners	Marketing and distribution of app using <a href="http://www.orthopt.org">www.orthopt.org</a>
Physical Therapy National Outcomes Data Registry	Support the ongoing usage of data registry for common musculoskeletal conditions ( <a href="http://www.ptoutcomes.com">www.ptoutcomes.com</a> )
Logical Observation Identifiers Names and Codes mapping	Publication of minimal data sets and their corresponding Logical Observation Identifiers Names and Codes for the wrist/hand region on <a href="http://www.orthopt.org">www.orthopt.org</a>
Non-English versions of the guidelines and guideline implementation tools	Development and distribution of translated guidelines and tools to JOSPT's international partners and global audience

## CLINICAL PRACTICE GUIDELINES

# Impairment/Function-Based Diagnosis

## PREVALENCE AND INCIDENCE

**I** The overall lifetime prevalence of self-reported and physician-diagnosed carpal tunnel syndrome (CTS), regardless of work status, is 8.0%.<sup>164</sup> Prevalence in the United States working population, when confirmed by both electrodiagnostic testing and clinical examination, is 7.8%.<sup>77</sup> For women, the prevalence is nearly twice that for men (10% compared to 5.8%). There is a marked increase in prevalence with increasing age: 3.7% in those younger than 30 years of age compared to 11.9% in those over 50 years of age.<sup>77</sup>

Incidence data have been reported for some geographic areas. Data reported as part of the Rochester Epidemiology Project, which included individuals from Olmstead County, MN dating from 1981 to 2005, show an incidence rate of 3.76 per 1000 person-years (4.91 for women and 2.58 for men).<sup>105</sup> Incidence data collected from France show a lower incidence rate (1.4 per 1000 person-years in women and 0.6 per 1000 person-years in men).<sup>248</sup>

When comparing data from 1981 to 1985 to data from 2001 to 2005, the incidence of CTS increased from 2.58 per 1000 person-years to 4.24 per 1000 person-years.<sup>105</sup> Data from 2007 to 2011 also show an increase in occupational-related CTS.<sup>247</sup> The increase may be due to greater awareness and more patients presenting for care.<sup>105</sup>

Incidence rates derived from the working population are reportedly higher than those for the general population.<sup>77,248</sup> The overall incidence in this group is 23 per 1000 person-years when CTS was confirmed through both clinical exam and electrodiagnostic studies.<sup>77</sup> When the diagnosis was confirmed by symptoms alone, the incidence was much higher (93 per 1000 person-years). When electrodiagnostic tests alone were used to confirm the diagnosis, the incidence was 40 per 1000 person-years.<sup>77</sup> These large differences in incidence rates found when using different diagnostic criteria support the need for a better gold standard to confirm the CTS diagnosis.

## ANATOMICAL AND PATHOANATOMICAL FEATURES

### Anatomical Features

The carpal tunnel is formed by the carpal bones and the transverse carpal ligament. The tunnel circumference is rigid

with bony dorsal boundaries and the stiff palmar boundary formed by the transverse carpal ligament. The ligament spans from the pisiform bone and hook of hamate on the ulnar side to the scaphoid and trapezium tubercles on the radial side. Nine flexor tendons pass through the carpal tunnel: 4 tendons from the flexor digitorum superficialis (FDS) muscle, 4 from the flexor digitorum profundus (FDP) muscle, and a single tendon from the flexor pollicis longus (FPL) muscle. The tendons of the FDS and FDP are arranged in 2 rows, with the FDS tendons more palmar and the FDP tendons deeper, dorsal to the FDS tendons. The carpal tunnel contains 2 bursae: the radial bursa, which encases the FPL, and the ulnar bursa, which surrounds the tendons of the FDS and FDP.<sup>90</sup> The median nerve is vulnerable to compression from external or internal forces, because it is the most superficial structure in the carpal tunnel, lying between the transverse carpal ligament and the ulnar bursa.

Classic sensory and motor innervation of the median nerve in the hand (affected in patients with CTS) includes the sensory branches of the thumb, index, middle, and radial half of the ring fingers, while the motor branches innervate the first and second lumbrical muscles, opponens pollicis, abductor pollicis brevis (APB), and the superficial portion of the flexor pollicis brevis muscles. The sensation to the skin directly over the carpal tunnel and the thenar eminence is typically not affected, because these areas are supplied by the palmar cutaneous branch, which branches off the median nerve approximately 5 cm proximal to the wrist crease.<sup>149</sup> The area over the scaphoid tubercle is also spared in CTS because its innervation comes from the lower antebrachial cutaneous nerve.

Mackinnon<sup>174</sup> described the blood supply to the median nerve as being from the radial and ulnar arteries and running to the nerve from the superficial palmar arch. The vessels coil the nerve, which ensures an adequate blood supply during nerve gliding. Blood flows from these vessels into the vasconeurium and then into the epineurial space. Vessels run in a plexus formation in the epineurium and perineurium, reaching the endoneurium as only a fine network of capillaries.<sup>174</sup> Changes in the blood supply have been implicated in the development of CTS and are described below.



### Pathoanatomical Features

Classic CTS symptoms include numbness and tingling in the median nerve distribution of the hand, and, in more severe cases, loss of strength of muscles innervated distally by the median nerve. Median nerve pathology impacts all nerve functions distal to the site of lesion, with some possible pain being felt proximally to the shoulder. Even though the definition seems straightforward, controversy abounds regarding its etiology. A variety of pathoanatomical factors have been implicated in the development of CTS, including elevated carpal tunnel pressure, ischemic changes within the nerve, and compression from adjacent structures.

### Elevated Carpal Tunnel Pressure

**II** Chen et al<sup>61</sup> studied the validity of carpal tunnel pressure as a source for median nerve compression. Tunnel pressure was measured at various points in patients undergoing carpal tunnel release (CTR) surgery. The highest mean  $\pm$  SD tunnel pressure before surgery was  $58.9 \pm 3.4$  mmHg and following surgery was  $7.7 \pm 0.9$  mmHg, confirming preoperative elevated tunnel pressure and confirming the usefulness of CTR surgery to lower pressure.

Chen et al<sup>61</sup> reported moderate association between elevated tunnel pressure and loss of some aspects of median nerve function as measured by correlations between tunnel pressure and findings from nerve conduction studies (NCS) ( $r = 0.53$  for distal motor latency [DML],  $r = 0.47$  for sensory nerve action potential [SNAP],  $r = -0.54$  for sensory nerve conduction velocity [SNCV]). However, preoperative pressure was not related to 3-month postoperative outcomes as measured by the Boston Carpal Tunnel Questionnaire-symptom severity scale (CTQ-SSS). Instead, Chen et al<sup>61</sup> concluded that NCS results better predicted 3-month outcome.

**III** Ahn et al<sup>2</sup> evaluated carpal tunnel pressures in patients with CTS and recorded structural findings from ultrasound imaging and nerve conduction measures. Elevated pressure was confirmed preoperatively, with the mean tunnel pressure being 56.7 mmHg distal to the incision site and 18.2 mmHg proximal to the incision site. After CTR surgery, pressure decreased to 7.4 mmHg distally and 7.5 mmHg proximally ( $P < .05$ ).

Ahn et al<sup>2</sup> reported that maximum tunnel pressure was not different between patients with moderate, severe, or extreme pathology classified based on the NCS results, even though median nerve cross-sectional area differed between individuals with different NCS severities. Ahn et al<sup>2</sup> suggested that intraneural pressure may be more relevant than tunnel pressure. Due to the conflicting findings between the aforementioned studies,<sup>2,61</sup> Chen et al<sup>61</sup> concluded that there may be another mechanism of median nerve damage besides those attributed to pressure.

**III** Gelberman et al<sup>103</sup> compared carpal tunnel pressure between those with and without CTS. They reported a statistically significant higher carpal tunnel pressure in the patient group when compared to the controls with the wrist in a neutral position ( $P < .001$ ), a flexed position ( $P < .005$ ), and an extended position ( $P < .010$ ). Wrist position affected pressure for patients and controls, with the lowest pressure in neutral and higher pressures in flexion and extension. Immediately following CTR surgery, pressure decreased in the patient group to 5.0 mmHg.

### Ischemia and Nerve Fibrosis

**V** In a narrative review of basic science literature including animal and human studies, Gelberman et al<sup>104</sup> described a gradual decrease in intraneural blood flow with experimental compression from 50 to 80 mmHg and complete ischemia at 80 mmHg. Findings from both animal and human studies show increased epineural edema and endoneurial fluid pressure related to the magnitude and duration of the compression.

**V** In a subsequent narrative review, Mackinnon<sup>174</sup> described the mechanism between ischemia, neural edema, and fibrosis based on animal models. She indicated that nerve compression leads to breakdown in the blood nerve barrier at the endoneurial vessels, causing a leakage of fluid into the endoneurium. If the barrier in the inner layers of the perineurium remains intact, the endoneurial fluid pressure will increase and result in a mini-compartment syndrome within the fascicle. She described this breakdown and leakage of fluid as causes that lead to the accumulation of proteins, lymphocytes, fibroblasts, macrophages, and eventually scar formation, or nerve fibrosis.

### Compression From Adjacent Structures

**III** Freeland et al<sup>100</sup> studied the presence of prostaglandins (PGE<sub>2</sub>) and interleukins (IL-1 and IL-6) in serum and the tenosynovium in those with CTS and a control group. These authors found elevated IL-6 and PGE<sub>2</sub> levels in the tenosynovium in those with CTS compared to the control group. These chemicals have been associated with stimulating tissue fibrogenesis.<sup>100</sup> There was no significant difference in IL-1 levels between the 2 groups. This latter finding supports the lack of acute inflammation in the tendon sheath when assessed at the time of surgery.<sup>100</sup>

**III** The subsynovial connective tissue (SSCT) is a highly vascular layer between the flexor tendons and ulnar bursa. Ettema et al<sup>90</sup> examined the histology and immunohistochemistry of the SSCT of individuals undergoing CTR surgery for idiopathic CTS. There was a marked increase in fibroblast density, collagen fiber size, vascular proliferation, and collagen type III in the patient

group compared to the control group. The presence of collagen type III is important because it is inherently weak and could possibly predispose an individual to a cycle of further injury.<sup>90</sup> There was also a significantly greater amount of transforming growth factor- $\beta$  in the patient group compared to the control group. Transforming growth factor- $\beta$  is a profibrotic cytokine present during wound healing and plays a role in fibrosis and scarring. Authors of other level 3 studies have identified similar changes in the tenosynovium in individuals with CTS.<sup>132,271</sup>

### Summary

Elevated carpal tunnel pressure has been implicated in the development of CTS, and studies support elevated pressure in patients just prior to surgery that decreases postoperatively. The etiology behind the elevation in pressure is unknown. Bench research suggests there is a disruption in intraneural blood flow that contributes to intraneural edema and fibrosis. Enlargement of the flexor tendon synovial sheaths, such as in flexor tenosynovitis, has been implicated as the source contributing to median nerve compression. However, models suggesting acute inflammation within the sheath are not well supported.<sup>100,198</sup> Instead, there is evidence to support fibrous synovial hypertrophy in individuals undergoing surgical release for idiopathic CTS.<sup>90,100,132,271</sup>

### CLINICAL COURSE WITH AND WITHOUT TREATMENT

**II** In a systematic review, Burton et al<sup>49</sup> reported that some patients (28%-62%) recover without intervention, while others (32%-58%) deteriorate in the absence of intervention. In patients who undergo nonsurgical management, authors reported that 57% progress to surgery within 6 months, 58% progress to surgery in 1 year, and 62% to 66% progress to surgery in 3 years.<sup>49</sup>

**II** Three studies not included in the systematic review by Burton et al<sup>49</sup> reported outcomes following nonsurgical management in patients with CTS who did not have thenar muscle atrophy.<sup>271,109,229</sup> Povlson et al<sup>229</sup> enrolled 75 patients who were treated with a night orthosis for 3 months. At the end of 3 months, 52 (69%) were satisfied with their outcome, while 17 (23%) progressed to surgery. Of the 52 who were satisfied at 3 months, 30 responded to a follow-up questionnaire presented 33 months after concluding the original treatment. Of the 30 (63% female) who responded, 13 were still satisfied with the wrist orthosis, 14 had undergone surgery, and 3 were not satisfied and were contemplating surgery. Baker and Livengood<sup>27</sup> analyzed baseline, 3-month, and 6-month data from patients who had participated in a randomized clinical trial (RCT) using a wrist orthosis. Their results indicated that 21 (22%) of 96 individuals who completed their study went on to have surgery. Gerritsen

et al<sup>109</sup> reported a 12-month success rate of 31% for use of a neutral night wrist orthosis for 6 weeks.

**II** Ollivere et al<sup>212</sup> found that 14 (16%) of 89 hands of 58 individuals with CTS of all levels of severity (mean  $\pm$  SD symptom duration, 24  $\pm$  29 months [range, 1-144 months]) improved with nonsurgical treatment alone, while 75 (84%) of the 89 hands underwent CTR surgery during or after 3 months of nonsurgical management consisting of a steroid injection, night wrist orthosis, tendon gliding exercises, and simple analgesia.

**II** Researchers have examined factors that predict progression to surgery. Burton et al<sup>49</sup> found that symptom duration, a positive Phalen test, and thenar eminence muscle wasting were associated with poor outcomes with nonsurgical management. Gerritsen et al<sup>109</sup> reported that shorter symptom duration (less than 1 year) and lower severity of nighttime symptoms (score of less than 6/10) were the best predictors of success with nonsurgical management. Baker and Livengood<sup>27</sup> reported that having more than 1 nonsurgical intervention was a predictor of progression to surgery (odds ratio [OR] = 24.3; 95% confidence interval [CI]: 4.3, 138.2). Four studies examined the use of the CTQ-SSS<sup>162</sup> as a prognostic indicator for progression to surgery, with conflicting results that will be discussed in the Outcome Measures section.<sup>43,109,147,212</sup>

**IV** Capasso et al<sup>53</sup> followed 24 individuals classified as having severe idiopathic CTS based on electrodiagnostic and clinical findings. Long-term outcomes for untreated patients (n = 9) and those receiving nonsurgical management (n = 3) were poor. At the time of the re-evaluation, which ranged from 1 to 9 years after diagnosis, 90% of the untreated patients continued to have pain and/or paresthesia, and all patients showed thenar eminence muscle atrophy, loss of strength ("plegia") of the APB muscle, hyperesthesia, and absence of median nerve conduction responses. The 12 individuals who had CTR surgery showed signs of electrophysiological reinnervation in all but 1 case. When comparing groups, those who underwent CTR surgery showed better resolution of pain and paresthesia, lower CTQ scores, improvement in APB muscle strength, and reappearance of compound muscle action potential (CMAP) and SNAP. Hyperesthesia remained unchanged in both groups.

### Evidence Synthesis and Clinical Rationale

The likelihood of patient successful response to nonsurgical management is unknown. There is evidence that the clinical course of some patients managed nonsurgically is positive, and for some patients, nonsurgical management is curative. In contrast, evidence on the percentage of individuals who progress to surgery after failed nonsurgical management

ranges from 23%<sup>229</sup> to 84%<sup>212</sup> after 3 months and 57% to 58% at 6 months and 1 year, respectively.<sup>49</sup> There are some single studies that have identified factors that predict progression to surgery, but these need to be validated in larger studies. More research is needed to identify the characteristics of patients who benefit from nonsurgical management versus those who can achieve positive outcomes only through surgical management. In light of a preponderance of studies reporting fairly high rates of progression to surgery, clinicians must measure progress carefully and refer patients for surgical consultation if improvement with nonsurgical management is not observed.

### Summary

Clinicians should assess symptom duration, severity of nighttime symptoms, presence of a positive Phalen test, presence of thenar eminence muscle wasting, and prior nonsurgical interventions in individuals with CTS because these factors have been shown to influence results with nonsurgical management. There is a need for more research that helps in confirming factors that suggest the need for surgery versus a trial of nonsurgical intervention, especially in those with mild to moderate CTS.

### CLASSIFICATION

Carpal tunnel syndrome can be acute or chronic. Acute CTS is relatively rare and has various causes, such as spontaneous bleeding, thrombosis, dislocation of a metacarpal base, infection, pregnancy, and fractures, with distal radius fractures being the leading cause.<sup>104</sup> Chronic CTS has a gradual onset, sometimes presenting in an individual finger and later spreading to the remaining median nerve distribution.<sup>270</sup> The initial onset of symptoms is usually at night, but as symptoms worsen, individuals may complain of symptoms throughout the day along with clumsiness and difficulty with grip and pinch.<sup>270</sup>

Carpal tunnel syndrome is most commonly classified by severity (mild, moderate, severe, or extreme). Classification systems reported in the literature are largely based on data from electrophysiological studies.<sup>39,56,117,137,220,286</sup> Rempel et al<sup>238</sup> provided consensus criteria for classifying CTS in epidemiologic studies; however, these criteria were not intended for clinical diagnosis or management.

**III** In a recent study, Roll et al<sup>246</sup> reported on an 8-point scoring system (range, 0-7, with 0 as least severe and 7 as most severe) that combined clinical criteria (Phalen test, Tinel sign, Durkan test, the CTQ-SSS and Boston Carpal Tunnel Questionnaire-functional scale [CTQ-FS]) with ultrasound findings to determine severity of CTS. Authors concluded that the system accurately classified 79.8% of participants into the correct severity based on electrodiagnostic studies.

**III** Caliandro et al<sup>51</sup> examined severity based on the patient's distribution of symptoms. They found that the likelihood of having a median-distribution presentation increased with increasing severity (OR = 2.07; 95% CI: 1.51, 2.83) as measured with NCS. Also, patients with mild and moderate severities of CTS were more likely to present with a stocking-glove paresthesia distribution.

**V** There were 2 classification systems published by Gelberman et al<sup>104</sup> and Szabo and Madison,<sup>270</sup> similarly based on a combination of clinical and electrodiagnostic findings. According to Gelberman et al,<sup>104</sup> mild CTS included a symptom duration of less than 1 year; diffuse complaints; intermittent numbness; normal 2-point discrimination (2PD), and absence of weakness or atrophy. Nerve conduction velocities (NCVs) were increased only by 1 to 2 m/s, and there were no fibrillations on electromyographic testing. Intermediate CTS included constant paresthesia and numbness, elevated threshold values, and increased DMLs. Advanced CTS was characterized by permanent sensory and motor loss and thenar muscle atrophy. The classification outlined by Szabo and Madison<sup>270</sup> was similar in terms of electrodiagnostic findings. In early CTS, sensory latencies are more likely to be prolonged than motor latencies; intermediate CTS included constant sensory deficits and possible motor impairment, and advanced CTS included severe loss of sensory and motor function, as well as thenar muscle atrophy.

**V** Maggard et al<sup>177</sup> also outlined a severity scale based on a literature review. In their classification, mild disease included all 3 of the following: (1) symptom pattern at least characteristic of CTS, (2) intermittent symptoms, and (3) no abnormalities of physical exam. Moderate CTS included (1) symptom pattern at least characteristic of CTS, (2) no thenar atrophy, and (3) at least 1 of the following: constant symptoms, thenar musculature weakness, or loss of sensory function in fingers 1, 2, or 3. Severe disease included (1) symptom pattern at least characteristic of CTS and (2) thenar muscle atrophy. In a Delphi consensus study, Graham et al<sup>116</sup> indicated that thenar muscle atrophy, location/presence of sensory symptoms, nocturnal symptoms, and APB muscle weakness were among the top 5 diagnostic criteria identified by participating physicians.

**V** Mackinnon<sup>174</sup> provided a classification based on the Sunderland stages of nerve injury that included pathophysiological changes and electrodiagnostic findings. It was later expanded upon by MacDermid and Doherty<sup>169</sup> to include clinical exam findings based on pathophysiology. In a grade 1 injury (neuropraxia), there is conduction block, and there may be some areas of segmental demyelination. The axon is uninjured and does not need to

undergo regeneration. Provocative testing that increases pressure on the nerve is likely to result in increased paresthesia. Sensory changes should be evident in the largest nerve fibers, and thus the patient would have diminished light touch and vibration threshold sensations. A grade 2 injury (axonotmesis) involves axonal injury and may show signs of remyelination; therefore, one may suspect a positive Tinel sign and 2PD changes. Patients may no longer experience paresthesia but numbness instead, and there may be a noticeable loss of strength. A grade 3 injury has axonal loss and scarring in the endoneurium, and patients have constant numbness and observable thenar muscle atrophy.<sup>169,174</sup>

**Summary**

There is a lack of consensus on clinical classification of CTS, especially in the absence of electrodiagnostic studies. Classifications based on clinical signs and symptoms alone or combined with electrodiagnostic studies are largely based on anecdotal evidence, expert consensus, or the pathophysiology of nerve compression and lack independent validation. According to evidence presented, the frequency of symptoms (mild demonstrating more intermittent symptoms and moderate demonstrating more constant symptoms) seems to be a factor that distinguishes mild from moderate CTS, and thenar muscle atrophy is the clinical sign that distinguishes patients with severe CTS from those with mild or moderate disease.

**RISK FACTORS**

**Intrinsic Risk Factors**

**Obesity**

Several authors suggest that obesity increases fatty tissue and/or hydrostatic pressure within the carpal tunnel producing compression on the median nerve.<sup>289</sup> Others theorize that metabolic changes occur in obesity causing endoneurial edema and intrafascicular swelling of the median nerve.<sup>120,260</sup> Obesity is one component of metabolic syndrome that has been associated with nerve injury possibly through extracellular protein glycation, mitochondrial dysfunction, and/or oxidative stress.<sup>260</sup>

**I** In a study of 3515 participants followed prospectively for up to 7 years, the risk of developing CTS in the right dominant hand was noted to increase linearly as body mass index (BMI) rose.<sup>127</sup> Having a BMI greater than 30 kg/m<sup>2</sup> nearly doubled the risk of developing CTS (hazard ratio [HR] = 1.67; 95% CI: 1.26, 2.21).

**II** The majority of prospective studies<sup>18,36,40,73</sup> and 1 meta-analysis<sup>260</sup> demonstrated that the risk of developing CTS increases linearly with increasing BMI, and the risk at least doubles for those individuals with a BMI greater than 30 kg/m<sup>2</sup>. The sole study that did not find

an association suggested the reason for this was the low power of the study (109 individuals with obesity in a sample of 1611 workers).<sup>225</sup> Additionally, BMI was strongly and positively correlated with slowing of median nerve conduction found in a 5-year follow-up of industrial workers.<sup>36</sup>

**III** A significant number of additional studies support obesity as a risk factor for CTS<sup>18,36,40,65,73,74,84,92,133,140,152,158,185,186,193,197,201,244,272</sup> and higher BMI has been associated with increased risk for more severe forms of CTS.<sup>74</sup> The ability to diagnose CTS using BMI and other measures used to quantify abdominal adiposity, which have been shown to be better predictors of cardiovascular and other diseases, was assessed by Mondelli et al.<sup>195</sup> Although a high BMI, waist-to-hip height ratio (waist circumference/hip circumference/height greater than 0.53 for women and greater than 0.54 for men) and waist-stature ratio (waist circumference/individual's height greater than 0.54 for women and greater than 0.57 for men) predicted those with severe CTS with sensitivity ranging from 72% to 92% (values varied by sex and whether compared to electrodiagnosis or clinical diagnosis), specificity did not reach levels for acceptable diagnostic accuracy (57%-66%).

**Age and Female Sex**

The physiologic changes associated with aging have been suggested to predispose individuals to CTS, specifically vascular abnormalities and age-associated decreased axon number and conduction velocity.<sup>18</sup> The reason for a potential higher incidence of CTS in women is less clear. A hormonal mechanism is often proposed, as well as, the smaller cross-sectional area of the carpal tunnel in women compared to men.<sup>79,269</sup> Other hypotheses related to female sex include more common reporting of symptoms; lower strength that necessitates a greater percentage of maximum voluntary contraction to complete the same tasks; and smaller stature leading to greater wrist deviations required at work stations.

**I** **II** Results from level I<sup>27</sup> and II studies<sup>205,248,282</sup> concur that increasing age and the female sex are risk factors for CTS. Specifically, the risk for CTS appears to increase linearly with age and more than doubles in those over the age of 50. Female sex increases the risk between 1.5 and 4 times compared to male counterparts.

**III** Additional level III studies also support increasing age<sup>21,36,40,74,87,92,130,152,158,186,197,201,204,242-244,269,272,289</sup> and female sex as risk factors.<sup>21,36,87,92,158,186,197,265,272,289</sup>

**Diabetes Mellitus**

Diabetes mellitus (DM) has been proposed as a risk factor for CTS. The mechanism by which this syndrome may influ-

Journal of Orthopaedic & Sports Physical Therapy®  
Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

ence the development of CTS is not completely understood. Diabetes mellitus is known to cause peripheral neuropathy by glycosylation of protein end products increasing circulating inflammatory cytokines and vascular endothelial growth factor. These mediators may sensitize the median nerve to alterations within the carpal tunnel.<sup>227,265,278</sup> Oktayoglu et al<sup>211</sup> hypothesize that the increased osmotic pressure arising from intracellular sorbitol accumulation in diabetes may result in edema and hydropic degeneration. DM may also produce vascular changes and tendinopathy leading to CTS.<sup>265</sup> In fact, Taser et al<sup>273</sup> have found an increased number of fibroblasts, increased collagen fiber diameter and lengths, as well as, neo-vascularization in the SSCT of patients with DM undergoing CTR surgery compared to those with idiopathic CTS or patients with hypothyroidism.

**I** Harris-Adamson et al,<sup>127</sup> did not find DM to be a significant independent predictor for the development of CTS when the data was adjusted for sex, age, and BMI.

**II** A random-effects meta-analysis<sup>227</sup> and a large prospective study<sup>60</sup> both found significantly higher risk of CTS in those with DM (OR = 1.69; 95% CI: 1.45, 1.96 and HR = 1.31; 95% CI: 1.28, 1.34, respectively). The risk was similar for individuals with type 1 and 2 diabetes.<sup>227</sup>

**III** Authors of 6 studies<sup>36,119,130,197,211,278</sup> found significant associations and 1 found no association between DM and CTS.<sup>87</sup> Those reporting an OR found increased risk of CTS in the presence of DM to be in the range of 1.24 to 2.2. Oktayoglu et al<sup>211</sup> demonstrated that patients with type 2 diabetes had significantly higher incidence of CTS than even individuals with hypothyroidism or acromegaly. In the one study, where authors found no association between CTS and DM, the relative risk was 1.26 (95% CI: 0.65, 2.44), and it did not reach statistical significance.<sup>87</sup>

**Rheumatoid Arthritis**

Synovial expansion, joint erosion, and ligament laxity that occurs with rheumatoid arthritis (RA) may result in loss of carpal tunnel height and increased pressure on the median nerve.<sup>250</sup>

**I** Rheumatoid arthritis was not found to be a significant, independent predictor for the development of CTS when the data were adjusted for sex, age, and BMI in a study by Harris-Adamson et al.<sup>127</sup>

**II** In contrast, even after adjusting for age and sex, Shiri's<sup>255</sup> meta-analysis of studies examining risk of CTS in individuals with RA showed increased risk (pooled OR = 1.96; 95% CI: 1.57, 2.44; I<sup>2</sup> = 32.2%).

**III** Two systematic reviews provided conflicting findings,<sup>250,278</sup> and 1 primary study<sup>87</sup> found no association between RA and CTS. Specifically, the pooled data from 8 studies in Sakthiswary and Singh's<sup>250</sup> meta-analysis revealed that 5.5% of patients with RA had CTS, which is similar to the prevalence of CTS in the general population (2.7%-5.8%).

**Cardiovascular Risk Factors**

Common cardiovascular risk factors include hypercholesterolemia, hypertension, high triglycerides, increasing age, diabetes, obesity and smoking. The theory on how the latter 4 risk factors may predispose to CTS are described in other sections of this CPG. Hypercholesterolemia has been associated with upregulating growth factors responsible for fibrogenesis in various organs and peripheral nerves. Nakamichi and Tachibana<sup>199</sup> hypothesize that this may increase connective tissue within the median nerve leading to increased risk of CTS. The mechanism by which other cardiovascular risk factors (hypertension, high triglycerides, etc) may lead to CTS has not been described.

**III** One study found that the prevalence of CTS and median nerve cross-sectional area within the carpal tunnel increased significantly as low-density lipoprotein (LDL) levels increased.<sup>199</sup> Although obesity was more prevalent in the CTS group, obesity was not found to be a significant factor in the logistic regression model.

**III** Shiri et al<sup>259</sup> found cardiovascular risk factors to be associated with CTS in a large cross-sectional study. The specific risk factors varied based on age. In the younger age group (30-44 years), the following risk factors were associated with CTS: obesity, high LDL cholesterol, high triglycerides, hypertension, and cardiac arrhythmia. In the older age group (older than 60 years), coronary artery disease, valvular heart disease, and carotid artery intima-media thickness were associated with higher risks of CTS. Hegmann et al<sup>130</sup> found an association between CTS and the cardiovascular disease risk factor score which included: age, hypertension, tobacco use, and DM.

**Osteoarthritis and Previous Musculoskeletal Disorders**

One theory for how osteoarthritis(OA) may predispose people to CTS is that hypertrophy of carpal bones narrows the tunnel and thereby produces compression of the median nerve. The reason for previous musculoskeletal disorders leading to CTS is less clear. Werner et al<sup>290</sup> suggests (1) that individuals with pain in other parts of the upper extremity may develop compensatory strategies that place higher loads and awkward positioning of the hand and wrist or (2) because CTS can refer pain to the elbow or shoulder, patients with CTS may be misdiagnosed as having various tendinopathies. Ferry et

al<sup>96</sup> also propose that mechanical problems in the cervical area may contribute to multiple disorders of the upper limbs.

**II** Individuals with a history of wrist or hand tendinopathies had increased odds of developing CTS in a prospective study of employees in an automotive assembly plant (OR = 4.74; 95% CI: 1.09, 20.43).<sup>289</sup> In Shiri's<sup>255</sup> meta-analysis of individuals with OA, 2 studies consisting of 19 480 participants were pooled and data were adjusted for age and sex. The OR for development of CTS was 1.87 (95% CI: 1.64, 2.13; I<sup>2</sup> = 0%) in individuals with OA.

**III** Level III studies have found the following musculoskeletal disorders are associated with occurrence of CTS: (1) prior distal upper extremity disorders (OR = 3.48; 95% CI: 2.56, 4.73)<sup>92</sup>; (2) arm fracture, OA of the spine, tennis elbow, and joint pain (OR = 1.98; 95% CI: 1.61, 2.42)<sup>96</sup>; (3) lupus, disc disease, OA, or RA (OR = 2.4; 95% CI: 1.24, 4.67)<sup>208</sup>; (4) cervical spine complaints or previous upper limb trauma (OR = 4.57; 95% CI: 2.28, 9.14 and OR = 8.09; 95% CI: 2.35, 27.91, respectively)<sup>242</sup>; and (5) rotator cuff syndrome (OR = 1.84; CI not reported).<sup>55</sup>

### Hypothyroidism

Several mechanisms have been proposed to explain how hypothyroidism may contribute to the development of CTS including: synovial thickening surrounding flexor tendons, deposition of pseudomucinous material on the median nerve, alterations in fluid balance, and increased peripheral edema.<sup>143,211,256,273</sup>

**III** Two meta-analyses assessed the association between hypothyroidism and CTS. Shiri<sup>256</sup> analyzed the 4 studies that controlled for potential confounders and found a significant association (effect size [ES], 1.44; 95% CI: 1.27, 1.63; I<sup>2</sup> = 50%). van Dijk et al<sup>278</sup> found a pooled OR of 1.4 (95% CI: 1.0, 2.0) in their analysis of 9 articles. Two of 3 other studies<sup>157,197,211,243</sup> not included in the above meta-analyses concurred that hypothyroidism is a risk factor for CTS.

### Genetic Predisposition

**III** Hemminki et al<sup>131</sup> compared hospitalized sibling pairs affected with a nerve, nerve root, or plexus disorder to hospitalized sibling pairs without any such neurological disorder. The calculated sibling risk for a nerve, nerve root, or plexus disorder when one sibling had CTS was 4.08. Sibling risk for CTS when one sibling had CTS increased to 6.18 (95% CI: 2.88, 12.73). In a multi-center population-based case-control study, Mattioli et al<sup>185</sup> found that the odds of CTS development increased 7-fold in those whose sibling had a history of CTS (OR = 8.1; 95% CI: 2.3, 29.2), whereas Nordstrom et al<sup>208</sup> found twice the odds

for development of the syndrome (OR = 2.09; 95% CI: 1.28, 3.4) in individuals with a parent, sibling, or child with history of CTS. Bland<sup>40</sup> found that those with a family history of CTS were at increased odds for development of CTS only when under the age of 63 (OR = 1.42; 95% CI: 1.14, 1.77). In a twin study, Hakim et al<sup>124</sup> calculated the case-wise concordance (the probability that a twin is affected, given that the cotwin is affected) was 0.35 in monozygotic twins compared to 0.24 in dizygotic. There was a significantly increased monozygotic to dizygotic ratio of 1.48 with an estimated genetic inheritance of 46%. When adjusting for other potential confounders, no other risk factor was significant. Radecki<sup>233</sup> noted significantly more individuals with CTS (27.3 %) also had positive family history compared to only 13.3% of those without confirmed CTS. A positive family history was predictive ( $\chi^2 = 20.48$ ) of positive NCS with a relative risk of 1.35.

### Wrist/Hand Anthropometrics

It has been proposed that individuals with a square-shaped wrist (proportionally thicker in anterior/posterior plane when compared to mediolateral plane) and those with shorter fingers or palm may be at increased risk for CTS because of a greater need for flexion and extension range of motion, and therefore, more force required to perform tasks.<sup>18,140</sup> Over time this may increase carpal tunnel pressure.

Commonly measured using a sliding digital caliper, wrist and hand anthropometrics, include: (1) wrist width: maximum distance at the level of the distal flexor wrist crease; (2) wrist depth: anteroposterior depth at the level of the distal flexor wrist crease; (3) palm length: distance between the distal flexor crease of the wrist to the proximal crease of the middle finger; (4) middle finger length: distance of the proximal flexor crease of the middle finger to the tip of the same finger; (5) hand length: distance between the distal flexor crease of the wrist to the tip of the middle finger; and (6) palm width: maximum distance between the heads of the second and fifth metacarpals. Commonly calculated indices include (1) wrist ratio: wrist depth divided by wrist width, (2) wrist-palm ratio: wrist depth divided by palm length, (3) hand ratio: hand length divided by palm width, and (4) shape index: palm width multiplied by 100 and divided by hand length.

### Wrist Ratio (Square Wrist)

**II** In the study by Nathan et al,<sup>203</sup> a higher wrist ratio (more square wrist) was the third most predictive factor (after BMI and increasing age) for maximum latency difference in sensory nerve conduction.

**III** Shiri<sup>257</sup> completed a meta-analysis of 16 papers that studied the association between CTS and wrist ratio. The mean wrist ratio was higher in individuals

with CTS compared with those without CTS (pooled mean difference [MD], 0.036). A square-shaped wrist was associated with CTS with a pooled OR of 4.56 (95% CI: 2.97, 6.99) and for those with a wrist ratio greater than 0.70 the OR was 2.73 (95% CI: 1.49, 5.01). This trend was true for both men and women. One of the studies in this review, Hlebs et al,<sup>133</sup> found the sensitivity and specificity using the greater than 0.70 wrist ratio in determining those with and without CTS to be excellent (90% and 82%, respectively). In a more recent study, authors reported that a wrist ratio greater than 0.69 increased the odds of having CTS (OR = 8.2; 95% CI: 1.2, 53.2).<sup>215</sup>

Authors of 3 other studies (not reviewed in Shiri's meta-analysis<sup>257</sup>) found that a higher wrist ratio increases an individual's risk for CTS.<sup>74,193,233</sup> The mean  $\pm$  SD wrist ratio from these studies ranged from 0.68  $\pm$  0.04 to 0.75  $\pm$  0.05 for patients with CTS and 0.65  $\pm$  0.04 to 0.69  $\pm$  0.02 for those without. The cutoff value for the wrist ratio was set at greater than 0.70 in the former 2 studies. Keeping the same cutoff value for men but setting the cut-off value for women at greater than 0.71, Mondelli et al<sup>193</sup> found the sensitivity ranged from 59% to 70% and specificity 48% to 59%. Positive and negative likelihood ratios were 1.35 to 1.44 and 0.62 to 0.69, respectively.

In a later study using the same subject population, Mondelli et al<sup>195</sup> noted that the wrist ratio was better at predicting those with severe CTS than CTS in general, especially for men. Values were calculated separately for men and women and clinical versus electrophysiologic diagnoses ranged from 69% to 79% for sensitivity, 48% to 59% for specificity, 1.32 to 1.76 for positive likelihood ratios (+LRs), and 0.43 to 0.65 for negative likelihood ratios (-LRs).

#### Hand Ratio/Shape Index (Short, Wide Hand)

Authors of 8 studies found that those with CTS had significantly shorter and wider hands than those without CTS. Three studies reported hand ratios,<sup>65,66,140</sup> 2 reported shape index,<sup>44,133</sup> 1 assessed both values,<sup>193</sup> and 2 palm length/palm width.<sup>18,206</sup> The mean  $\pm$  SD hand ratio ranged from 2.00  $\pm$  0.10 to 2.29  $\pm$  0.12 for CTS cases and 2.20  $\pm$  0.1 to 2.35  $\pm$  0.11 for controls. Shape index ranged from 44.85  $\pm$  3.19 to 46.8  $\pm$  2.4 for CTS cases and 42.31  $\pm$  2.7 to 45.0  $\pm$  2.1 for controls.

Of the 2 studies that calculated sensitivities and specificities,<sup>193,206</sup> the best sensitivity (70.8%) was obtained for using the cutoff value of less than 1.17 in palm length/width measure. The best specificity (71.1%) was found in using greater than 46.1 for shape index and less than 2.17 for hand ratio in men.

#### Wrist-Palm Ratio

Mondelli et al<sup>193-195</sup> found that the wrist-palm ratio was one of the best anthropometric indexes for predicting those at risk for CTS development. When controlling for age and sex, the relative risk ratio was 1.52 for mild, 1.85 for moderate, and 2.39 for severe CTS. The wrist-palm ratio was better than the wrist ratio in its diagnostic characteristics. With a cut off value of greater than 0.39 for women and greater than 0.40 for men; values obtained for identifying those with severe CTS ranged between 81% to 96% for sensitivity, 59% to 75% for specificity, 2.09 to 3.85 for +LR, and 0.06 to 0.25 for -LR. Identification of other severity levels of CTS was not as successful. Predictive value of the wrist-palm ratio was generally more accurate for men than women and when using clinical diagnosis versus electrophysiological data. The authors concluded that the wrist-palm ratio could be used to support a diagnosis of severe CTS.

Kouyoumdjian et al<sup>155</sup> found a significant positive correlation between the wrist-palm ratio and severity of CTS ( $P < .001$ ) for those with moderate to severe CTS. Wrist-palm ratios in these patients ranged from 0.38 to 0.40. No correlation was found between wrist-palm ratio and mild CTS.

#### Height

Six studies<sup>65,80,84,185,193,200</sup> found that individuals with CTS were significantly shorter in stature ( $P < .05$ ). Height of patients with CTS ranged from a mean  $\pm$  standard deviation of 152.8  $\pm$  4.4 cm in the study by Nakamichi and Tachibana<sup>199</sup> conducted in Japan to 174  $\pm$  7 cm for Danish men in the de Krom et al<sup>80</sup> study. Mondelli et al<sup>193</sup> calculated the sensitivity, specificity, +LR, and -LR using the cut-off height of less than 160.5 cm for females and less than 171.5 cm for males to differentiate those with CTS from those without CTS. The results for the Italian women and men, respectively, were a sensitivity of 65.5% and 56.7%; specificity of 46% and 62.3%; +LR of 1.21 and 1.5; and -LR of 0.76 and 0.70, demonstrating poor diagnostic accuracy.

#### Alcohol Use

In all 3 studies that investigated alcohol use, light to moderate drinking (fewer than 3 drinks per day) either did not increase the risk or decreased the risk of CTS.<sup>185,202,259</sup> The results were conflicting for individuals who reported consuming more than 3 drinks per day on average or drinking more than 6 drinks on 1 day per week.

#### Smoking

Studies<sup>40,69,110,242,282</sup> including random effects meta-analyses,<sup>228</sup> assessing whether there is an association between CTS and smoking provide conflicting results.

**Physical Activity Level**

**III** Five of the 6 studies<sup>87,110,115,201,208,259</sup> analyzing the effect of increased physical activity demonstrated a protective effect with ORs or RRs ranging from 0.40 to 0.97 in decreasing the risk for CTS.

**Oral Contraceptive and Estrogen Use**

**II** **III** Determining whether oral contraceptive use or estrogen replacement therapy increase the risk for CTS is complicated by the fact that more recent studies<sup>242,243</sup> did not look at these medications in isolation, and results of studies that separated oral contraceptives provide conflicting results.<sup>69,80,96,110,155,228,248,249,255,282</sup>

**III** Studies that evaluated estrogen replacement therapy alone demonstrated that women who underwent therapy were twice as likely to require CTR surgery than controls.<sup>84,265</sup>

**Women's Health Factors (Hysterectomy, Menopause, Oophorectomy, Parity)**

Hormonal imbalance has been hypothesized as a reason for various women's factors increasing the risk of CTS. More specifically, estrogen withdrawal may have a vasodilatory action explaining menopausal hot flashes and raised pressure within the carpal tunnel.<sup>224</sup>

**II** **III** The studies that assessed the association between CTS and hysterectomy, menopause, oophorectomy and the number of births or pregnancies report conflicting results.<sup>80,84,91,100,111,185,190,224,243,249,269,298</sup>

**Summary**

The intrinsic risk factors with the strongest link to CTS are obesity, age, and female sex. The risk increases linearly with BMI and age. The risk doubles in individuals with a BMI greater than 30 kg/m<sup>2</sup> and in those over the age of 50. Female sex increases the risk by 1.5 to 4 times.

Intrinsic risk factors linked to CTS, but to a lesser extent include DM, OA, previous musculoskeletal disorders, estrogen replacement therapy, cardiovascular disease risk factors, hypothyroidism, family history of CTS, lack of physical activity, wrist ratio greater than 0.70, wrist-palm ratio greater than 0.39, a short, wide hand, and short stature.

No conclusion can be made on the following factors because the evidence is conflicting: RA, smoking, alcohol abuse, oral contraceptive use, menopause, parity, hysterectomy, or oophorectomy.

**Occupational Risk Factors**

**Forceful Exertions, Repetitive Use, Vibration Exposure, and Wrist Position**

**I** In their prospective study to identify potential biomechanical risk factors, Harris-Adamson et al<sup>128</sup> found that for those with exposure to hand forces between 2.1 and 4 on the Borg CR10 scale (10-category scale with ratio properties), the risk of CTS increased 60%, and in those who rated their exposure as greater than 4, the risk increased 117%. The risk of CTS increased linearly with forceful hand repetition rates between rates of 2.6 and 30 per minute. However, there was no association between CTS and total hand repetition, vibration, or wrist flexed or extended posture greater than 30°. The authors cautioned against making conclusions about vibration and wrist posture because vibration levels were not measured (simply noted to be present or absent), and the time workers were in extreme wrist postures averaged only 5.6% for flexion and 0.6% for extension. In a later analysis of this same cohort, Harris-Adamson et al<sup>129</sup> noted that these biomechanical risk factors were not confounded by psychosocial risk factors or vice versa.

**II** All the level II studies which examined forceful exertions<sup>48,76,78,91,141</sup> found them to be a substantial risk factor for the development of CTS, with OR or HR between 1.14 and 19.57. The risk of CTS increased linearly with increasing number of forceful exertions, with the highest HR found when exertions exceeded 60% of work time.<sup>124</sup> Vibration was a risk factor in 2 studies, with an OR of 2.02 (95% CI: 1.04, 3.9)<sup>91</sup> and 2.74 (95% CI: 1.13, 6.65)<sup>76</sup> respectively. The 2 studies on extreme wrist flexion/extension positions reported conflicting results.<sup>76,225</sup>

**III** In a meta-analysis of 9 studies of work involving nonneutral wrist posture, You et al<sup>302</sup> found a positive association with the development of CTS (relative risk [RR] = 2.01; 95% CI: 1.65, 2.43). Studies using self-report of wrist postures had a higher relative risk than studies where wrist position was observed (RR = 2.95 versus 1.44).

**III** Barcenilla et al<sup>32</sup> performed a meta-analysis of studies published between January 1980 to December 2009 relating to occupational risk factors. Based on the 37 studies, the strongest associations between CTS and occupational factors were (1) use of vibratory tools (OR = 5.4; 95% CI: 3.14, 9.31); (2) hand force (OR = 4.23; 95% CI: 1.53, 11.68); and (3) repetition (OR = 2.26; 95% CI: 1.73, 2.94).

Other level III systematic reviews, case-control, and cross-sectional studies concur that use of vibratory tools,<sup>92,110,123,223,244,279</sup> forceful work,<sup>92,111,123,223,243,262,279</sup> repetitive work,<sup>110,111,115,123,243,244,27</sup>

Journal of Orthopaedic & Sports Physical Therapy®  
Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.



<sup>9</sup> and nonneutral wrist postures,<sup>110,123,163,207,223,243,262,279</sup> are associated with CTS. Odds ratios were (1) 1.71 to 14.0 for use of vibratory tools, (2) 1.5 to 9.0 for forceful work, (3) 0.50 to 9.39 for repetitive work, and (4) 1.2 to 8.7 for nonneutral wrist postures.

**Computer Use**

**II** Two prospective studies<sup>188,225</sup> with large numbers of participants failed to show increased risk of CTS in those performing computer work.

**II** Andersen et al<sup>15</sup> performed a systematic review of systematic reviews on the causal relationship between CTS and computer use. The authors concluded that epidemiological evidence for computer use and the occurrence of CTS is insufficient.

**III** In their meta-analysis of studies on computer use, Shiri and Falah-Hassani<sup>258</sup> noted different results based on whether the control group used was composed of office workers versus individuals from the general population or other types of workers. The meta-analysis of 6 studies of office workers demonstrated a positive association between CTS and frequent computer or typewriter use (OR = 1.34; 95% CI: 1.09, 1.65), frequent mouse use (pooled OR = 1.84; 95% CI: 1.18, 2.8), and longer duration of computer use (OR = 1.92; 95% CI: 1.17, 3.17). In contrast, the meta-analysis of 6 studies that compared computer workers to the general population or other types of workers, showed an inverse relationship between computer use and CTS (OR = 0.72; 95% CI: 0.58, 0.90).

**III** Mediouni et al<sup>189</sup> did not find a significant association between computer use and CTS in their meta-analysis of 6 studies, however they did not provide detail of control group composition. Mediouni et al's<sup>189</sup> review included only 1 study<sup>24</sup> that was also reviewed in the Shiri and Falah-Hassani<sup>258</sup> meta-analysis.

**III** Al-Hashem and Khalid<sup>5</sup> found a significant negative correlation ( $r = 0.48$ ) between the terminal latency index of the median nerve and hours of weekly mouse use. No significant association was noted between weekly keyboard use and terminal latency index ( $r = 0.05$ ).

**V** Rempel et al<sup>241</sup> found significant increases in carpal tunnel pressure with typing and with wrist deviation in extension and radial deviation positioning on a keyboard when compared to static and neutral wrist positioning.

**Psychosocial Factors at Work**

**I** One systematic review<sup>181</sup> and 1 cohort study<sup>127</sup> found high decision latitude and high social support to be protective of CTS development whereas, high psy-

chological demand increased the risk. When combining high psychological demand and low decision latitude (high job strain), the chance of developing CTS was even higher (HR = 1.86; 95% CI: 1.11, 3.14) compared to workers with low demand and high control at work.<sup>127</sup>

**I** However, Leclerc et al<sup>161</sup> did not find an association between psychological demand or social support. Additionally, the presence of somatic complaints and depression were not predictive of those with CTS. Low job satisfaction was considered a potential risk factor for women (OR = 2.87; 95% CI: 1.13, 7.29) but not for men.

**II** Burt et al<sup>48</sup> concurred with level I studies that noted high job strain was associated with CTS (HR = 2.13; 95% CI: 1.00, 4.54) in their 2-year prospective study. Other level II studies<sup>46,106,225</sup> were contradictory on whether high psychological demand and low decision authority individually were associated with CTS. Two studies supported these as risk factors and 1 found no association. No association was found in level II studies between CTS and the variables of social support at work<sup>46,106,225</sup> and job security.<sup>46,106</sup> Likewise, no association was found in 1 study assessing job satisfaction.<sup>106</sup>

**III** Studies<sup>92,110,160,207,244,262,279</sup> are conflicting as to whether job dissatisfaction, job demand, job strain, and decision latitude are linked to CTS. Three studies<sup>92,262,279</sup> found no association between social support at work and CTS.

**Summary**

The occupational risk factor with the strongest association with CTS is forceful hand exertions. Weaker associations are present between CTS and the following factors: high psychological demand at work when paired with low decision authority, vibration, prolonged off neutral wrist positioning, and repetitive work.

Computer users do not have an increased risk of CTS when compared to the general population or industrial workers. However, when comparing office workers with short versus longer duration of computer use, the odds of CTS are slightly increased ( $1 < ORs < 2$ ).

**DIFFERENTIAL DIAGNOSIS**

Common differential diagnoses include cervical radiculopathy, thoracic outlet syndrome, diabetic or polyneuropathy, and other median neuropathies such as pronator teres syndrome. Others include ulnar and radial tunnel syndrome. Serious conditions such as amyotrophic lateral sclerosis and multiple sclerosis can begin with distal symptoms that mimic CTS. The

patient history, presence of risk factors, and the location and characteristics of symptoms are key aspects in differentiating CTS from other conditions. An upper quarter screening examination is warranted to rule out proximal nerve lesions and serious medical conditions, as is a clearing exam for the cervical spine.

Advanced imaging and electrodiagnostic studies have been used in the differential diagnosis of CTS. According to the CPG published in 2016 by the American Academy of Orthopaedic Surgeons,<sup>7</sup> there is limited evidence for the use of a handheld NCS device in the diagnosis of CTS and moderate evidence to support the use of electrodiagnostic studies. In the guideline, there were recommendations discouraging the routine use of diagnostic ultrasound (based on limited evidence) and MRI (based on moderate evidence) in CTS. While diagnostic ultrasound may have some value in identifying anatomical variations, more research is needed on its use in individuals with CTS.

## DIAGNOSIS

Tests and measures used to assess individuals with complaints consistent with CTS include symptom assessment, provocative tests, and sensory measures. An overview of each will be reported here. Both kappa values and ICCs have been used to report reliability data. The scale for interpreting kappa values is 0 to 0.20, poor; 0.21 to 0.40, fair; 0.41 to 0.60, good; 0.61 to 0.80, substantial; and 0.81 or greater, almost perfect.<sup>159</sup> The scale for interpreting ICCs is less than 0.40, poor; 0.41 to 0.75, fair to good; greater than 0.75, excellent.<sup>261</sup>

### Symptom Assessment

#### Katz Hand Diagram

The Katz hand diagram is used to assess the presence and characteristics of symptoms. Patients are asked to indicate the location of their symptoms of pain, tingling, numbness, and/or decreased sensation on a picture of right and left hands.<sup>146</sup> The likelihood of CTS based on the diagram is rated as follows: (1) classic CTS: symptoms in at least 2 of 3 fingers completely innervated by the median nerve (thumb, index, or middle fingers) but no symptoms in the palm or dorsal hand; (2) probable CTS: same as classic except palmar symptoms allowed, unless only on ulnar side of the hand; (3) possible CTS: symptoms in at least one of either the thumb, index, or middle fingers; or (4) unlikely CTS: no symptoms in any of these fingers.

Priganc and Henry<sup>232</sup> found nearly perfect intrarater reliability for the traditional scoring method of the Katz hand diagram ( $\kappa = 0.95$ ). Calfee et al<sup>50</sup> analyzed 3 methods for scoring the hand diagram: (1) the traditional method as described above: using classic or probable as a posi-

tive test; (2) shading 2 or more of the volar distal surfaces of the median innervated fingers; or (3) shading the volar distal aspect of a specific median innervated finger (thumb, index, or middle). For intrarater reliability, mean kappa values were 0.86 for traditional scoring, 0.97 for using 2 or more shaded fingers, and 0.97 for the middle finger score. Interrater reliability improved slightly when using the middle finger score (ICC = 0.98) or when using 2 or more shaded fingers (ICC = 0.96) versus the traditional method (ICC = 0.87).

Calfee et al<sup>50</sup> prospectively examined 1107 newly hired workers from 11 companies and compared results from the Katz hand diagram (using the 3 scoring systems described above), NCS, Phalen test, and Tinel sign. The best sensitivity (67%) in comparison to the gold standard of abnormal nerve conduction was obtained using the middle finger score. Specificity, positive predictive value (PPV), and negative predictive value (NPV) were similar for all methods and ranged from 65% to 81% for specificity, 29% to 59% for PPV, and 65% to 87% for NPV. All scoring methods were significantly associated with Phalen test ( $P < .05$ ) but not Tinel sign. Additionally, all methods (except using the thumb alone) were good predictors of abnormal NCV. The best OR occurred when using the middle finger (OR = 5.3; 95% CI: 2.9, 9.7). When using the traditional method, scoring the diagram as possible, probable, or classic did not change the odds of predicting those with abnormal NCV (OR = 3.3-5.5).

In a systematic review, MacDermid and Wessel<sup>173</sup> pooled data from 6 studies with 293 cases and 226 controls and showed sensitivity and specificity for the Katz hand diagram for diagnosing CTS were equal to 75% and 72%, respectively. Specificity increased to 90% when comparing to data from asymptomatic individuals but decreased to 60% when using data from symptomatic individuals with negative electrodiagnostic testing.

### Provocative Tests

Reliability values for provocative tests are provided in **TABLE 2**. Intrarater reliability values show good reliability for the Phalen test,<sup>183,232</sup> good to substantial reliability for the Tinel sign,<sup>183,232</sup> and substantial to excellent reliability for the carpal compression test.<sup>232,292</sup> There was more variability in interrater reliability for these measures with kappa values between 0.27 and 0.88.<sup>170,183,251,283</sup> The reverse Phalen test,<sup>170</sup> upper-limb neurodynamic test (ULNT),<sup>283</sup> and the scratch-collapse test<sup>41,62</sup> show good to almost perfect interrater reliability with kappa values between 0.63 and 0.98, but these have no intrarater values available (**TABLE 2**). Sensitivity, specificity, PPVs, and NPVs are reported in **TABLE 3**.<sup>2,3,8,9,42,45,62,89,113,144,157,168,173,178,184,196,274,280,281,283,292</sup> Likelihood ratios were available for 4 provocative tests including Phalen,<sup>42,283</sup> Tinel,<sup>283</sup> carpal compression,<sup>283</sup> and ULNT (**TABLE 4**).<sup>45,280,281,283</sup>

The following represents a brief summary of the best available evidence for Phalen test, Tinel sign, carpal compression test, reverse Phalen, ULNT, and the scratch-collapse test.

**Phalen Test**

**I** In a systematic review of literature, MacDermid and Wessel<sup>173</sup> pooled data from 29 studies with more than 3000 cases and 1600 controls and showed sensitivity and specificity equal to 68% and 73%, respectively, for confirming the presence of CTS. Specificity increased to 86% when comparing to data from asymptomatic individuals but decreased to 65% when using data from symptomatic individuals with negative electrodiagnostic testing.

**II** Thüngen et al<sup>274</sup> calculated sensitivity and specificity values using 4 different standards to confirm the CTS diagnosis (electrodiagnostics, clinical presentation, ultrasonography, and postoperative resolution of symptoms). In all circumstances, sensitivity was high (83%-96%) and specificity was much lower (0%-33%) than that reported by MacDermid and Wessel.<sup>173</sup>

**II** Other studies<sup>144,178,283</sup> have also shown sensitivity ranging from 59.7% to 77% for the Phalen test but variable specificity (33%-73.9%). Wainner et al<sup>283</sup> examined the diagnostic accuracy of the Phalen test in 82 consecutive patients referred for an electrophysiologic examination with suspected cervical radiculopathy or CTS, and likelihood ratios (+LR = 1.30; -LR = 0.58) showed the Phalen test was not persuasive in changing an initial hypothesis regarding the presence of a CTS diagnosis (TABLE 4).

**II** Priganc and Henry<sup>232</sup> compared results on provocative tests to CTS severity measured by NCS. There was a significant positive trend for the Phalen test ( $P < .05$ ) but not for the Tinel sign or carpal compression test, suggesting patients with more severe CTS are more likely to have a positive Phalen test.

**IV** LaJoie et al<sup>157</sup> showed substantial agreement when comparing the results from NCS with results of the Phalen test ( $\kappa = 0.64$ ).

**Tinel Sign**

**I** MacDermid and Wessel<sup>173</sup> reported sensitivity and specificity for the Tinel sign of 50% and 77%, respectively, to confirm the presence of CTS. This conclusion was drawn based on results pooled from 27 studies including 2640 CTS cases and 1614 control subjects. Specificity decreased when using data from symptomatic individuals who had negative electrodiagnostic tests (65%) but remained higher than sensitivity.

**II** Thüngen et al<sup>274</sup> also reported higher specificity than sensitivity (sensitivity, 39%-50%; specificity, 65%-100%). Additional studies reported sensitivity and specificity values.<sup>144,178,283</sup> Wainner et al<sup>283</sup> studied 2 variations of the Tinel test. In the first (Tinel A), a reflex hammer, held 15 cm above the patient's wrist crease, was allowed to fall and strike the patient between the tendons of the flexor carpi radialis and palmaris longus, with a positive test being non-painful tingling sensation radiating distally along the path of the median nerve. In the second test (Tinel B), the examiner tapped the patient with reflex hammer using mild-to-moderate force in the same location, attempting to reproduce symptoms. In Tinel B, positive test criteria included discomfort or pain at the wrist or radiating distally along the nerve's course. Likelihood ratios indicated the Tinel test results would provide negligible change from pretest to posttest probability (Tinel A: +LR = 0.98; 95% CI: 0.56, 1.7; -LR = 1.0; 95% CI: 0.69, 1.5; Tinel B: +LR = 1.4; 95% CI: 0.84, 2.5; -LR = 0.78; 95% CI: 0.52, 1.2) (TABLE 4).

**IV** LaJoie et al<sup>157</sup> showed substantial agreement when comparing the results from NCS with results from the Tinel sign ( $\kappa = 0.71$ ).

**Carpal Compression Test**

**II** Sensitivity and specificity values reported for the carpal compression test are shown in TABLE 3.<sup>8,89,113,144,168,173,178,184,196,274,283,292</sup> The review by MacDermid and Wessel<sup>173</sup> (classified as a level II based on the quality of 17 studies reviewed for the carpal compression test) showed higher specificity than sensitivity (specificity, 83%; sensitivity, 64%) when using data from asymptomatic controls. When using data from symptomatic individuals with negative electrodiagnostic tests, specificity decreased to 64%.<sup>173</sup> Likelihood ratios show negligible changes in pretest to posttest probability for the carpal compression test.<sup>283</sup>

**Reverse Phalen Test**

**II** According to the MacDermid and Wessel<sup>173</sup> systematic review, the reverse Phalen test has higher specificity (78%) than sensitivity (57%) values suggesting that it might be useful for ruling in CTS but not for screening for the presence of CTS.

**IV** Goloborod'ko<sup>113</sup> also reported very high values for both sensitivity (88%) and specificity (98%) after examining 34 patients (41 hands).

**Upper-Limb Neurodynamic Testing**

**I** **II** Studies on the sensitivity, specificity, PPVs, NPVs, and likelihood ratios of ULNT1 are reported in TABLES 3 and 4.<sup>45,280,281,283</sup> In these studies, +LRs range from 0.86 to 3.67 for ULNT1 and

-LRs range from 0.75 to 1.90. Studies used different criteria for what was considered a positive test (TABLE 4).

**II** Baselgia et al<sup>33</sup> examined the ULNT1 and ULNT2a to determine the presence of a positive test in those with and without CTS using electrodiagnostic testing as the reference standard. Authors also compared results of ULNT to quantitative sensory testing. In individuals with electrodiagnostically confirmed CTS, only 46% had a positive ULNT. Those with negative ULNT demonstrated greater dysfunction in the unmyelinated nerve fibers according to findings on the quantitative sensory testing.

**Scratch-Collapse Test**

**II** There were 2 level II studies documenting sensitivity and specificity for the scratch collapse test, providing conflicting results (TABLE 3).<sup>62,178</sup>

**Sensory Measures**

Sensory testing has been advocated in the diagnosis of CTS to determine the extent of nerve injury. Hypoxia (as thought to occur in CTS) is proposed to affect large diameter nerve fibers earlier than small diameter fibers, so sensory tests, which stimulate large A-beta fibers would, theoretically, be able to detect CTS in the early stages.

Results from studies on reliability and diagnostic accuracy of sensory instruments are reported in TABLES 5 through 7.<sup>59,67,107,126,139,170,171,173,182,183,274,291,300</sup> Testing with the PCV50 computerized vibrometer (Z tech Medical, Salt Lake City, UT) demonstrated excellent intrarater reliability (TABLE 5). However, this instrument may not be available for clinicians. There were no studies on the reliability of current perception threshold testing, and, therefore, it is not included in the discussion. Main findings from studies are summarized below.

**Semmes-Weinstein Monofilament Test**

**I** Following a systematic review, average sensitivity was 72% (86% when comparing to asymptomatic controls and 70% when comparing to those with symptoms and negative electrodiagnostic findings) with specificity 62% for confirming the diagnosis of CTS.<sup>173</sup>

**II** Yildirim and Gunduz<sup>300</sup> reported the greatest sensitivity (98%) occurred when any radial finger tested higher than the 2.83 filament, but the greatest specificity (97%) occurred when using the 3.22 filament as the threshold for normal and comparing middle finger sensation to that of the small finger. However, the highest diagnostic accuracy (76%) occurred when any radial finger tested higher than 3.22. In patients with moderate to severe CTS, the best diagnostic accuracy (90%) for those with CTS resulted when any radial finger tested higher than 3.22.

**IV** Studies on the correlation between Semmes-Weinstein monofilament testing (SWMT) and NCS results are conflicting. Raji et al<sup>235</sup> found moderate correlations using the monofilament values taken from the thumb ( $r = -0.42, 0.44, \text{ and } 0.44$  for distal sensory latency [DSL], SDL, sensory amplitude, and NCV, respectively). Correlation coefficients using data from other fingers did not exceed 0.33, and only 52% of patients with positive NCS also had abnormal SWMT findings when the 2.83 monofilament was used as the threshold for normal. Elfar et al<sup>88</sup> found no significant correlation between SWMT and electrodiagnostic studies (correlation values not provided,  $P > .05$ ) using data from the middle finger.

**Static 2PD**

**I** **II** Results from 1 level I and 1 level II study showed that 2PD (using less than 4 or less than 5 mm as the normal value) has higher values for specificity than sensitivity, suggesting it would be more valuable for diagnostic confirmation (TABLE 5).<sup>107,274</sup>

**III** The systematic review by MacDermid and Wessel<sup>173</sup> also showed higher specificity than sensitivity in identifying those with CTS. Wolny et al<sup>295</sup> compared the results of 2PD testing in 100 people with a clinical diagnosis of mild or moderate CTS. Results showed a significant difference in 2PD scores tested at the radial 3 fingers between symptomatic and asymptomatic fingers; however, mean 2PD scores were 6 mm and less, which is the accepted normal value for 2PD.

**IV** Elfar et al<sup>88</sup> showed the middle finger was the most involved finger in CTS when examining 2PD scores. Using data from the middle finger, they compared 2PD results with electrodiagnostic testing and found a moderate correlation ( $r = 0.42, P = .0003$ ). There was no significant correlation between 2PD and electrodiagnostic tests for the other fingers.

**Vibrotactile Testing**

Vibration is perceived via different receptor types (slow versus fast adapting) with varying receptive borders (small and sharp versus ill-defined). Slowly adapting receptors include (1) Merkel cells, which respond to vibration frequencies of 0.4 to 2.0 Hz and have sharp receptive fields; and (2) Ruffini end organs, which respond to frequencies of 100 to 500 Hz and have ill-defined receptive fields. The fast-adapting receptors with sharp receptive fields are Meissner's corpuscles, which are stimulated by vibration frequencies of 2 to 40 Hz. Pacinian corpuscles are also fast adapting, responding to frequencies of 40 to more than 500 Hz, but have ill-defined receptive fields.<sup>59,166</sup> Based on this physiology, vibration testing at different frequencies could provide different informa-

Journal of Orthopaedic & Sports Physical Therapy © Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission. Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

tion in the diagnosis of CTS. Findings from studies on the reliability, diagnostic accuracy, and known-group validity of vibrometry in CTS are reported in **TABLES 6** and **7**. Results of studies on concurrent validity are described below. There is a lack of consistent findings in the relationship between vibration sense and NCS because authors have compared various frequencies and various aspects of nerve conduction.

**I** Werner et al<sup>291</sup> compared testing frequencies of 8, 16, 32, 63, 125, 256, and 500 Hz to results of electrodiagnostic testing and physical exam results in 167 manufacturing workers (15 had CTS symptoms and positive findings on electrodiagnostic studies and were considered confirmed cases). Authors reported statistically significant relationships between vibration sense and median sensory peak latency and amplitude, but the magnitude of the correlation coefficients were weak ( $r = 0.02-0.32$ ). In addition, these authors did not find any significant differences in vibration sense in those with CTS compared to a control group at 16, 32, 125, 250, or 500 Hz. There were differences at 8 and 63 Hz, but in another level I study, Checkosky et al<sup>59</sup> found a difference in CTS cases and controls at 10 Hz but no differences at 1 or 300 Hz.

**III** In a systematic review, MacDermid and Wessel<sup>173</sup> found the sensitivity and specificity for the 256 Hz tuning fork were 55% and 81%, respectively, for confirming the CTS diagnosis.

### Combining Individual Tests Into Test Batteries

**II** Wainner et al<sup>283</sup> showed a balance between sensitivity (0.98) and specificity (0.54) with more than 3 positive tests from the following: shaking hands relieves symptoms, wrist-ratio index greater than 0.67, CTQ-SSS greater than 1.9, diminished sensation in median nerve distribution, and age greater than 45 years. Requiring all 5 to be positive decreased sensitivity to 0.18 and increased specificity to 0.99. The greatest +LR (4.60; 95% CI: 2.5, 8.7) occurred when 4 or more of these tests were positive (**TABLE 4**).

**III** Ntani et al<sup>209</sup> examined results from 1806 hands in 908 individuals. Sensory NCV was most diminished in hands with (1) extensive numbness or tingling in the median nerve sensory distribution and (2) a positive Tinel sign and Phalen test. The authors recommended combining the Tinel sign and Phalen test to serve as diagnostic filters to determine when NCS were not necessary. Authors concluded that when an individual demonstrated a negative Tinel sign and Phalen test, there was no need to refer the individual for sensory nerve conduction testing. The authors did not report sensitivity and specificity values, based on reasoning that no measures, including electrodiagnostic testing, could be considered a valid gold standard.

**IV** Four studies supported the value of combining singular tests into a test battery to improve diagnostic accuracy. Koris et al<sup>153</sup> included patients with confirmed CTS and individuals without CTS and found that combining results across fingers from SWMT increased sensitivity from 16% to 82%, with specificity equal to 86%. Fertl et al<sup>97</sup> examined 47 patients (63 hands) with CTS confirmed by NCS and 20 healthy controls (39 hands) and found that combining a timed Phalen test (timed to appearance of symptoms) and the manual carpal compression test improved all diagnostic statistics resulting in a PPV of 95% and an NPV of 88%. In a retrospective, unblinded chart review, LaJoie et al<sup>157</sup> reviewed data from 81 patients (162 wrists). Outcome measures were Tinel sign, Phalen test, and NCS findings. When all 3 tests are positive, the probability of having CTS was 99%; when Tinel and Phalen were positive, probability was 92%; when Tinel and NCS were positive, probability was 93%; and when Phalen and NCS were positive, probability was 68%. The authors concluded that when one of the provocative tests is positive and the other negative, there is a large potential gain in probability of disease with positive findings from NCS. When both clinical tests are negative or both are positive, there is little gain from performing NCS. Boland and Kiernan<sup>42</sup> examined 86 hands (74 hands with electrophysiological changes and 12 without) and found that the addition of sensory testing using the pinprick testing tool does not improve the diagnostic accuracy for the Phalen test or modified carpal compression test.

### Evidence Synthesis and Clinical Rationale

There is variability in the methods used in studies examining accuracy of diagnostic tests for CTS. This makes it difficult to compare study results and arrive at a recommendation for one preferred test. Variability can be attributed to differences in research designs, study settings, reference gold standards used for confirming the CTS diagnosis, and test performance and interpretation. Also, the majority of studies used asymptomatic control groups leading to diagnostic results distinguishing patients with CTS from nonpatients, whereas a lesser number of studies used individuals with other upper extremity pathologies, leading to clinically relevant differential diagnosis. While diagnostic accuracy values for some aforementioned tests may be acceptable, there is no evidence to support an isolated test or measure that can confirm the presence of CTS. The greatest likelihood ratios were found when subjective and/or objective data were combined with anthropometric measurements<sup>97,157,283</sup>; however, these data need further validation in separate and larger samples.

### Gaps in Knowledge

Additional research is needed to determine how these tests can help clinicians assess the presence and severity of CTS as well as differentiate CTS from other upper extremity com-

pression neuropathies. There is insufficient evidence available to determine the usefulness of the finger flexion wrist flexion with compression test, flick test, Luthy sign, lunate press test, modified carpal compression (that used oscillations over carpal tunnel) test, modified pneumatic compression test, Tanzer test, tethered median nerve tests, current perception threshold tests, and moving 2PD test.

### Recommendations

**A** When examining a patient with suspected CTS, clinicians should use SWMT using the 2.83 or 3.22 monofilament as the threshold for normal light touch sensation and static 2PD on the middle finger to aid in determining the extent of nerve damage. In those with suspected moderate to severe CTS, clinicians should assess any radial finger using the 3.22 filament as the threshold for normal. The SWMT should be repeated by the same provider.

**B** In those with suspected CTS, clinicians should use the Katz hand diagram, Phalen test, Tinel sign, and carpal compression test to determine the likelihood of CTS and interpret examination results in the context of all clinical exam findings.

Clinicians should assess and document the patient's age (older than 45 years), whether shaking their hands relieves their symptoms, sensory loss in the thumb, wrist-ratio index (greater than 0.67), and scores from the CTQ-SSS (greater than 1.9). The presence of more than 3 of these clinical findings has shown acceptable diagnostic accuracy.

**D** There is conflicting evidence on the diagnostic accuracy and clinical utility of the ULNTs, scratch-collapse test, and tests of vibration sense in the diagnosis of CTS, and therefore no recommendation can be made.

### Decision Tree Model

Carpal tunnel syndrome is a common problem, and it is important that clinicians arrive at an accurate diagnosis so interventions can be aimed appropriately. The proposed

model provides an approach that includes information and test results that should be gleaned during the examination. Clinicians should recognize that data gathered can help in confirming the presence of the condition, aid in hypothesizing the severity, and provide baseline measures for treatment. Components include (1) examination, (2) evaluation, and (3) intervention strategies (**FIGURE**).

#### Component 1

The combination of the history and physical examination findings is crucial in determining the presence of CTS. Clinicians should also use the data gathered to help in determining the severity of the pathology if possible. Determining severity is a key component of patient care. The presence of severe pathology (indicated by thenar muscle atrophy) would indicate a need for referral to a hand surgeon. Clinicians may need to suggest NCS when the clinical examination is inconclusive.

#### Component 2

Evaluation of physical examination findings, as outlined in the **FIGURE**, should be consistent with the diagnosis of CTS and its severity suggesting either nonsurgical or surgical management is indicated. The diagnosis and management of the patient's condition should be appropriately modified if the evaluation of clinical findings related to the musculoskeletal impairments of body functioning (ICF) and associated tissue pathology/disease (ICD) suggest other upper extremity conditions or systemic or medical disease.

#### Component 3

This component includes a list of the evidence-based interventions available. The highest level of evidence supports the use of the neutral wrist orthosis. Clinicians should consider all contraindications as well as costs associated with each intervention. This component also includes the outcomes assessment, or measurement of change over time. The only validated tool for assessing change in individuals undergoing nonsurgical management is the CTQ-SSS. Other tools can be used, such as the CTQ-FS or DASH, but clinically important change scores have not been identified in those undergoing nonsurgical management.

**Component 1: Examination**

**History**

- Medical history
- Risk factor assessment
- Medical or diagnostic testing, including electrodiagnostics
- Social and work history
- Symptom assessment, including duration, frequency, intensity, and type
- Symptom onset (rapid or gradual)
- Presence of nocturnal symptoms
- Location of symptoms (is sensation over scaphoid tubercle spared?)
- Katz hand diagram (B)\*
- Activities that increase/decrease symptoms
- Chief complaint(s), including impairments, activity limitations, and participation restrictions
- Prior treatment and its success
- CTQ-SSS (B)\*
- CTQ-FS or DASH questionnaire (B)

**Medical Screening**

- Cardiovascular and pulmonary system (heart rate, blood pressure, etc)
- Integumentary system (trophic changes, scars, discoloration, swelling)
- Musculoskeletal system (cervical and upper-quarter movement analysis, postural assessment, presence of atrophy, especially thenar)
- Neuromuscular system (upper-quarter screening, including dermatomes and sensation in terminal branch distributions, myotomes, deep tendon reflexes, and pathological reflexes)
- Cognition and communication

**Tests and Measures**

When CTS is suspected:

- Phalen test (B)
- Carpal compression test (B)
- Assess for presence of Tinel sign (B)
- Monofilament threshold testing (A)
- Static 2PD (A)
- Baseline grip and 3-point or tip pinch strength (C)
- Dellon-modified Moberg pick-up test or Purdue Pegboard to assess dexterity (C)
- Test combination looking for 3 or more of the following: age >45 y, shaking hands provides relief, wrist ratio greater than 0.67, CTQ-SSS greater than 1.9, diminished light touch in median nerve distribution (B)

**Component 2: Evaluation**

Following the examination, therapists should choose 1 of the following actions

**Patient/client is appropriate for therapy services and an evidence-based intervention is provided**

- Examination data show findings consistent with mild to moderate CTS, and the patient/client agrees with a trial of nonsurgical management
- Examination data show findings consistent with severe CTS, and (1) the patient/client has seen a surgeon, who has decided the individual is not a surgical candidate due to comorbidities; (2) the patient/client is awaiting surgery; or (3) the patient/client has refused surgery after counseling on the negative effects of long-standing nerve compression

**Patient/client is appropriate for therapy but would also benefit from a referral to a physician**

- Examination data suggest any severity of CTS, with concurrent signs and symptoms of another condition that warrant further medical testing. In these individuals, CTS treatment may commence as long as there would be no contraindications from the suspected concurrent condition
- Examination data suggest signs and symptoms consistent with severe CTS and the patient/client chooses a trial of nonsurgical intervention while awaiting a physician visit

**Patient is not appropriate for therapy and requires referral to another provider**

- Examination data reveal suspected neuromuscular diagnosis other than CTS that is beyond the scope of physical therapy treatment

Figure continues on page CPG24.

**FIGURE.** Decision tree model. \*Letters in parentheses reflect the grade of evidence on which the recommendation for each item is based: (A) strong evidence, (B) moderate evidence, (C) weak evidence, (D) conflicting evidence, (E) theoretical/foundational evidence, and (F) expert opinion.

# CARPAL TUNNEL SYNDROME: CLINICAL PRACTICE GUIDELINES

## Component 3: Intervention Strategies

### Primary Interventions (B)

#### Orthoses

- Patients/clients should be instructed in the use of a neutral-positioned wrist orthosis for night wear. Treatment should also include counseling on pathology, risk identification, symptom self-management, and postures/activities that aggravate symptoms. Duration of orthosis use may be increased to include daytime wear, or the metacarpophalangeal joints may be included if nighttime wrist-neutral positioning alone does not provide sufficient relief

### Secondary Interventions (C)

#### Assistive technology

- May counsel patients/clients on limiting mouse use and finding a keyboard that limits key-strike force

#### Thermotherapy

- May consider a trial of superficial heat when patients/clients are able to understand the possibility of negative effects of superficial heat on sensory-impaired tissue and on acute inflammation

#### Electrotherapy

- May consider a trial of interferential current during supervised therapy sessions for short-term pain relief

#### Phonophoresis

- May consider a trial of phonophoresis during supervised therapy sessions

#### Manual therapy

- May implement based on patient data from the examination

#### Stretching

- May add lumbrical or general stretching to a program that includes an orthosis

### Re-evaluate

Patient goals met

Discharge to self-management

Adjust/modify interventions  
• Patient goals met

Not improving/worsening occurs

Refer  
• Consultation with other providers

**FIGURE (CONTINUED).** Decision tree model. \*Letters in parentheses reflect the grade of evidence on which the recommendation for each item is based: (A) strong evidence, (B) moderate evidence, (C) weak evidence, (D) conflicting evidence, (E) theoretical/foundational evidence, and (F) expert opinion.



TABLE 2

RELIABILITY VALUES FOR PROVOCATIVE TESTS\*

Test/Study	Level of Evidence	Intrater Reliability <sup>†</sup>	Interrater Reliability <sup>†</sup>
<b>Phalen test</b>			
Salerno et al <sup>251</sup>	I		$\kappa = 0.42$ (0.26, 0.58)
Wainner et al <sup>263</sup>	II		$\kappa = 0.79$ (0.59, 1.00)
Priganc and Henry <sup>232</sup>	II	$\kappa = 0.58$ (0.22, 0.94)	
MacDermid et al <sup>170</sup>	II		$\kappa = 0.88$ (0.77, 0.98)
Marx et al <sup>283</sup>	IV	$\kappa = 0.52$	$\kappa = 0.65$
<b>Tinel sign</b>			
Salerno et al <sup>251</sup>	I		$\kappa = 0.27$ (0.06, 0.50)
Wainner et al <sup>263</sup> (Tinel A) <sup>‡</sup>	II		$\kappa = 0.47$ (0.21, 0.72)
Wainner et al <sup>263</sup> (Tinel B) <sup>§</sup>	II		$\kappa = 0.35$ (0.10, 0.60)
Priganc and Henry <sup>232</sup>	II	$\kappa = 0.51$ (0.13, 0.88)	
MacDermid et al <sup>170</sup>	II		$\kappa = 0.81$ (0.66, 0.98)
Marx et al <sup>283</sup>	IV	$\kappa = 0.80$	$\kappa = 0.77$
<b>Carpal compression test</b>			
Salerno et al <sup>251</sup>	I		$\kappa = 0.64$ (0.44, 0.83)
Priganc and Henry <sup>232</sup>	II	$\kappa = 0.63$ (0.33, 0.92)	
Wainner et al <sup>263</sup>	II		$\kappa = 0.77$ (0.58, 0.96)
Williams et al <sup>192</sup>	IV	ICC = 0.81 <sup>¶</sup> , 0.92 <sup>¶</sup>	
<b>Reverse Phalen (wrist extension) test</b>			
MacDermid et al <sup>170</sup>	II		$\kappa = 0.72$ (0.55, 0.88)
<b>ULNT1<sup>#</sup></b>			
Wainner et al <sup>263</sup>	II		$\kappa = 0.76$ (0.51, 1.00)
<b>Scratch-collapse test</b>			
Cheng et al <sup>162</sup>	II		$\kappa = 0.98$
Blok et al <sup>41</sup>	II		$\kappa = 0.63$

Abbreviations: ICC, intraclass correlation coefficient; ULNT, upper-limb neurodynamic test.

\*No reliability data were available for the wrist flexion with compression (Phalen test with compression), Gilliat pneumatic compression (tourniquet), and hand elevation tests.

<sup>†</sup>Values in parentheses are 95% confidence interval.

<sup>‡</sup>A reflex hammer, held 6 inches above the patient's wrist crease, is allowed to fall and strike the patient between the tendons of the flexor carpi radialis and palmaris longus, with a positive test being a nonpainful tingling sensation radiating distally along the path of the median nerve.

<sup>§</sup>The examiner taps the patient with a reflex hammer using mild to moderate force between the tendons of the flexor carpi radialis and palmaris longus, with a positive test including discomfort or pain at the wrist or radiating distally along the nerve's course.

<sup>¶</sup>When creating compression using low pressure (100 mmHg).

<sup>¶</sup>When creating compression using high pressure (150 mmHg).

<sup>#</sup>With the patient positioned in supine, the examiner sequentially performed the following to the symptomatic upper extremity: (1) scapular depression; (2) shoulder abduction, forearm supination, wrist and finger extension; (3) shoulder lateral rotation; (4) elbow extension; and (5) contralateral and then ipsilateral sidebending. Any of the following were considered positive: (1) symptoms were reproduced; (2) side-to-side differences in elbow extension (greater than 10°) for part A or wrist flexion for part B on completion of all motion sequences; (3) contralateral neck sidebending increased symptoms or ipsilateral sidebending decreased symptoms in the symptomatic limb.

TABLE 3

DIAGNOSTIC ACCURACY VALUES FOR PROVOCATIVE TESTS

Test/Study	Level of Evidence	Sensitivity, %*	Specificity, %*	PPV, %*	NPV, %*	Reference Standard	Comparison Group
Phalen test							
MacDermid and Wessel <sup>173</sup>	I	68	73	...	...	Systematic review	Average across asymptomatic and symptomatic subjects with negative electrodiagnostic tests
Mondelli et al <sup>196</sup>	II	59 (overall) <sup>a</sup>	93	91	65	Clinical presentation and EDS	Asymptomatic hands
			72	90	27	Clinical presentation and EDS	Polynuropathy
Wainner et al <sup>283</sup>	II	77 (61, 93)	40 (26, 53)	...	...	Clinical presentation and EDS	...
Thüngen et al <sup>274</sup>	II	90 (78, 97)	33 (0, 91)	...	...	EDS	...
		83 (59, 96)	9 (2, 24)	...	...	Clinical presentation	...
		92 (78, 98)	11 (0, 48)	...	...	Ultrasonography	...
		96 (82, 99)	0 (0, 41)	...	...	Postoperative resolution of symptoms	...
Makanji et al <sup>178</sup>	II	67	33	75	25	Positive EDS	Negative EDS
Kasundra et al <sup>144</sup>	II	84.9	73.9	...	...	EDS	Asymptomatic individuals or hands
Williams et al <sup>292</sup>	IV	88	100	...	...	Clinical presentation	Asymptomatic individuals
Goloborod'ko <sup>113</sup>	IV	93	93	93	93	Postoperative resolution of symptoms	Asymptomatic hands
Amirfeyz et al <sup>9</sup>	IV	83 (76, 91)	98 (92, 100)	98 (94, 100)	85 (78, 92)	Postoperative resolution of symptoms	Asymptomatic hands
LaJoie et al <sup>157</sup>	IV	92 (85, 98)	88 (79, 97)	...	...	None described (used latent class analysis)	...
El Miedany et al <sup>189</sup>	IV	47 (40.5, 53.6)	17 (12.5, 22.6)	...	...	Clinical presentation and EDS	Asymptomatic individuals
Boland and Kiernan <sup>42</sup>	IV	64 (52, 74)	75 (47, 91)	...	...	EDS	Contralateral asymptomatic hands
Amirfeyz et al <sup>8</sup>	IV	87.1	84.3	84.7	86.8	Symptoms and EDS	Asymptomatic individuals
Ma and Kim <sup>168</sup>	IV	84.4	86.7	...	...	EDS and ultrasonography	Asymptomatic individuals
Al-Dabbagh and Mohamad <sup>3</sup>	IV	78	94	...	...	EDS (NIOSH criteria)	Asymptomatic individuals
Tinel sign							
MacDermid and Wessel <sup>173</sup>	I	50	77	...	...	Systematic review	Average across asymptomatic and symptomatic subjects with negative electrodiagnostic tests
Mondelli et al <sup>196</sup>	II	41 (overall) <sup>b</sup>	90	83	56	Clinical presentation and EDS	Asymptomatic individuals
			56	81	17	Clinical presentation and EDS	Polynuropathy
Wainner et al <sup>283c</sup>	II	41 (22, 59)	58 (45, 72)	...	...	Clinical presentation and EDS	...
Wainner et al <sup>283d</sup>	II	48 (29, 67)	67 (54, 79)	...	...	Clinical presentation and EDS	...
Cheng et al <sup>162</sup>	II	32	99	96	59	Clinical presentation and EDS	Asymptomatic individuals
Thüngen et al <sup>274</sup>	II	39 (25, 54)	100 (29, 100)	...	...	EDS	...
		39 (17, 64)	65 (47, 80)	...	...	Clinical presentation	...
		44 (28, 62)	67 (30, 93)	...	...	Ultrasonography	...
		50 (31, 69)	71 (29, 96)	...	...	Postoperative resolution of symptoms	...
Makanji et al <sup>178</sup>	II	43	56	74	25	Positive EDS	Negative EDS
Kasundra et al <sup>144</sup>	II	78.5	91.3	...	...	EDS	Asymptomatic individuals or hands
Williams et al <sup>292</sup>	IV	67	100	...	...	Clinical presentation	Asymptomatic individuals
Goloborod'ko <sup>113</sup>	IV	66	83	79	71	Postoperative resolution of symptoms	Asymptomatic hands
Amirfeyz et al <sup>9</sup>	IV	48 (38, 58)	94 (89, 99)	88 (82, 95)	64 (54, 73)	Postoperative resolution of symptoms	Asymptomatic hands
LaJoie et al <sup>157</sup>	IV	97 (93, 100)	91 (82, 99)	...	...	None described (used latent class analysis)	...
El Miedany et al <sup>189</sup>	IV	30 (24.3, 36.4)	65 (58.4, 71.1)	...	...	Clinical presentation and EDS	Asymptomatic individuals

Table continues on page CPG27.

TABLE 3

DIAGNOSTIC ACCURACY VALUES FOR PROVOCATIVE TESTS (CONTINUED)

Test/Study	Level of Evidence	Sensitivity, %*	Specificity, %*	PPV, %*	NPV, %*	Reference Standard	Comparison Group
Amirfeyz et al <sup>6</sup>	IV	52.9	92.9	88.1	66.3	Symptoms and EDS	Asymptomatic individuals
Ma and Kim <sup>68</sup>	IV	82.2	88.9	...	...	EDS and ultrasonography	Asymptomatic individuals
Al-Dabbagh and Mohamad <sup>3</sup>	IV	66	77	...	...	EDS (NIOSH criteria)	Asymptomatic individuals
Carpal compression test							
Massy-Westropp et al <sup>84</sup>	II	49, 87	54, 90	...	...	Systematic review	NA
Mondelli et al <sup>96</sup>	II	42 (overall) <sup>e</sup>	99	97	58	Clinical presentation and EDS	Asymptomatic individuals
			95	97	26	Clinical presentation and EDS	Polyneuropathy
MacDermid and Wessel <sup>73</sup>	II	64	83	...	...	Systematic review	Average across asymptomatic and symptomatic subjects with negative electrodiagnostic tests
Wainner et al <sup>283</sup>	II	64 (45, 83)	30 (17, 42)	...	...	Clinical presentation and EDS	...
Thüngen et al <sup>274</sup>	II	90 (78, 97)	33 (0, 91)	...	...	EDS	...
		100 (81, 100)	18 (7, 35)	...	...	Clinical presentation	...
		92 (78, 98)	11 (0, 48)	...	...	Ultrasonography	...
		93 (77, 99)	29 (4, 71)	...	...	Postoperative resolution of symptoms	...
Makanji et al <sup>78</sup>	II	77	18	73	21	Positive EDS	Negative EDS
Kasundra et al <sup>144</sup>	II	81.7	69.6	...	...	EDS	Asymptomatic individuals or hands
Williams et al <sup>292f</sup>	IV	100	97	100	...	Clinical presentation	Asymptomatic individuals
Williams et al <sup>292g</sup>	IV	97	100	97	...	Clinical presentation	Asymptomatic individuals
Goloborod'ko <sup>113</sup>	IV	90	88	88	90	Postoperative resolution of symptoms	Asymptomatic hands
El Miedany et al <sup>89</sup>	IV	46 (39.5, 52.6)	25 (19.7, 31.2)	...	...	Clinical presentation and EDS	Asymptomatic individuals
Amirfeyz et al <sup>6</sup>	IV	84.3	78.6	79.7	83.3	Symptoms and EDS	Asymptomatic individuals
Ma and Kim <sup>68</sup>	IV	84.4	82.2	...	...	EDS and ultrasonography	Asymptomatic individuals
Wrist flexion with compression (Phalen test with compression)							
Cheng et al <sup>62</sup>	II	44	99	98	65	Clinical presentation and EDS	Asymptomatic individuals
Thüngen et al <sup>274</sup>	II	78 (63, 88)	33 (0, 91)	...	...	EDS	...
		89 (65, 99)	29 (15, 48)	...	...	Clinical presentation	...
		83 (67, 94)	33 (8, 70)	...	...	Ultrasonography	...
		82 (63, 94)	43 (10, 82)	...	...	Postoperative resolution of symptoms	...
MacDermid and Wessel <sup>73</sup>	IV	80	92	...	...	Systematic review	Average across asymptomatic and symptomatic subjects with negative electrodiagnostic tests
Reverse Phalen test							
Mondelli et al <sup>96</sup>	II	55 (overall) <sup>h</sup>	96	94	63	Clinical presentation and EDS	Asymptomatic individuals
			82	93	26	Clinical presentation and EDS	Polyneuropathy
MacDermid and Wessel <sup>73</sup>	II	57	78	...	...	Systematic review	Average across asymptomatic and symptomatic subjects with negative electrodiagnostic tests
Goloborod'ko <sup>113</sup>	IV	88	98	98	98	Postoperative resolution of symptoms	Asymptomatic hands
Gilliat pneumatic compression (tourniquet)							
Thüngen et al <sup>274</sup>	I	67 (53, 80)	33 (0, 91)	...	...	EDS	...
		67 (41, 87)	32 (17, 51)	...	...	Clinical presentation	...

Table continues on page CPG28.

TABLE 3

DIAGNOSTIC ACCURACY VALUES FOR PROVOCATIVE TESTS (CONTINUED)

Test/Study	Level of Evidence	Sensitivity, %*	Specificity, %*	PPV, %*	NPV, %*	Reference Standard	Comparison Group
Thüngen et al <sup>274</sup>	I	69 (52, 84)	56 (21, 86)	...	...	Ultrasonography	...
		75 (55, 89)	57 (18, 90)	...	...	Postoperative resolution of symptoms	...
		55 (40, 69)	100 (29, 100)	...	...	EDS	...
		50 (26, 74)	47 (30, 65)	...	...	Clinical presentation	...
		53 (36, 70)	67 (30, 93)	...	...	Ultrasonography	...
MacDermid and Wessel <sup>173</sup>	IV	59	61	...	...	Systematic review	Average across asymptomatic and symptomatic subjects with negative electrodiagnostic tests
		85	95	95	87	Postoperative resolution of symptoms	Asymptomatic hands
Amirfeyz et al <sup>8</sup>	IV	93	64	72	90	Symptoms and EDS	Asymptomatic individuals
Hand elevation test							
Ahn <sup>k</sup>	III	75.5	98.8	...	...	Clinical presentation and EDS	Asymptomatic individuals
Amirfeyz et al <sup>9</sup>	IV	88 (81, 94)	98 (95, 100)	98 (95, 100)	88 (82, 95)	Postoperative resolution of symptoms	Asymptomatic hands
Amirfeyz et al <sup>8</sup>	IV	98.6	91.4	92	98.5	Symptoms and EDS	Asymptomatic individuals
Ma and Kim <sup>468</sup>	IV	86.7	88.9	...	...	EDS and ultrasonography	Asymptomatic individuals
Scratch-collapse test							
Cheng et al <sup>62</sup>	II	99	86	...	...	Clinical presentation and EDS	Asymptomatic individuals
Makanji et al <sup>178</sup>	II	34	61	71	25	Positive EDS	Negative EDS
ULNT1							
Bueno-Gracia et al <sup>45i</sup>	I	58 (45, 71)	84 (72, 96)	...	...	Clinical presentation and EDS	...
Bueno-Gracia et al <sup>45m</sup>	I	74 (61, 83)	50 (35, 65)	...	...	Clinical presentation and EDS	...
Wainner et al <sup>283n</sup>	II	75 (58, 92)	13 (4, 22)	...	...	Clinical presentation and EDS	...
Vanti et al <sup>280n</sup>	II	92 (74, 98)	15 (5, 36)	...	...	Clinical presentation and EDS	...
Vanti et al <sup>281o</sup>	II	54 (35, 72)	70 (48, 85)	...	...	Clinical presentation and EDS	...
Vanti et al <sup>281o</sup>	II	40 (26, 56)	79 (66, 88)	58 (39, 76)	65 (52, 76)	Clinical presentation and EDS	...
Vanti et al <sup>281p</sup>	II	29 (16, 45)	82 (69, 91)	56 (34, 75)	60 (47, 70)	Clinical presentation and EDS	...
Vanti et al <sup>281q</sup>	II	6 (2, 19)	93 (82, 98)	40 (12, 77)	56 (45, 67)	Clinical presentation and EDS	...

Abbreviations: EDS, electrodiagnostic studies; NA, not applicable; NIOSH, National Institute for Occupational Safety and Health; NPV, negative predictive value; PPV, positive predictive value; ULNT, upper-limb neurodynamic test.

\*Values in parentheses are 95% confidence interval.

<sup>a</sup>Varied by EDS stage, from 10 to 72.

<sup>b</sup>Varied by EDS stage, from 10 to 53.

<sup>c</sup>A reflex hammer, held 6 inches above the patient's wrist crease, is allowed to fall and strike the patient between the tendons of the flexor carpi radialis and palmaris longus, with a positive test being a nonpainful tingling sensation radiating distally along the path of the median nerve.

<sup>d</sup>The examiner taps the patient with a reflex hammer using mild to moderate force between the tendons of the flexor carpi radialis and palmaris longus, with a positive test including discomfort or pain at the wrist or radiating distally along the nerve's course.

<sup>e</sup>Varied by EDS stage, from 0 to 62.

<sup>f</sup>Using a sphygmomanometer at 150 mmHg.

<sup>g</sup>Using a sphygmomanometer at 100 mmHg.

<sup>h</sup>Varied by EDS stage, from 10 to 60.

<sup>i</sup>Compression applied at suprasystolic blood pressure (approximately 140-160 mmHg).

<sup>j</sup>Compression applied at infrasystolic blood pressure (approximately 70 mmHg).

<sup>k</sup>Ahn DS. Hand elevation: a new test for carpal tunnel syndrome. *Ann Plast Surg.* 2001;46:120-124.

<sup>l</sup>Positive if the patient's clinical symptoms are provoked at the wrist or hand and changed during structural differentiation.

<sup>m</sup>Positive if any symptoms were provoked at the wrist or radial 3 digits and changed during structural differentiation.

<sup>n</sup>Any of the following were considered positive: (1) symptoms were reproduced, (2) side-to-side differences in elbow extension (greater than 10°) for part A or wrist flexion (part B) on completion of all motion sequences, (3) contralateral neck sidebending increased symptoms or ipsilateral sidebending decreased symptoms in the symptomatic limb.

<sup>o</sup>Positive if symptoms are in the radial 3 digits.

<sup>p</sup>Positive if symptoms are in the radial 3 digits and increased with contralateral cervical sidebending.

<sup>q</sup>Positive if symptoms are in the radial 3 digits and decreased with spine ipsilateral cervical sidebending.

TABLE 4

LIKELIHOOD RATIOS FOR PROVOCATIVE TESTS

Test/Study	Level of Evidence	+LR*	-LR*
Phalen test			
Wainner et al <sup>283</sup>	II	1.30 (0.94, 1.7)	0.58 (0.27, 1.3)
Boland and Kiernan <sup>42</sup>	IV	2.54 (0.94, 6.87)	0.49 (0.31, 0.76)
Tinel sign			
Wainner et al <sup>283a</sup>	II	0.98 (0.56, 1.7)	0.78 (0.52, 1.2)
Wainner et al <sup>283b</sup>	II	1.4 (0.84, 2.5)	1.0 (0.69, 1.5)
Carpal compression test			
Wainner et al <sup>283</sup>	II	0.91 (0.65, 1.3)	1.20 (0.62, 2.4)
ULNT1			
Bueno-Gracia et al <sup>45c</sup>	I	3.67 (1.70, 7.89)	0.50 (0.36, 0.70)
Bueno-Gracia et al <sup>45d</sup>	I	1.47 (1.03, 2.10)	0.53 (0.31, 0.90)
Wainner et al <sup>283e</sup>	II	0.86 (0.67, 1.1)	1.90 (0.72, 5.1)
Vanti et al <sup>280e</sup>	II	1.08 (0.38, 3.08)	0.56 (0.19, 1.59)
Vanti et al <sup>280f</sup>	II	1.80 (1.13, 2.88)	0.65 (0.41, 1.04)
Vanti et al <sup>281f</sup>	II	1.96 (1.28, 3.01)	0.75 (0.49, 1.16)
Vanti et al <sup>281g</sup>	II	1.61 (0.94, 2.76)	0.87 (0.51, 1.49)
Vanti et al <sup>281h</sup>	II	0.86 (0.22, 3.30)	1.01 (0.26, 3.89)
Combinations			
Boland and Kiernan <sup>42</sup> (Phalen and thenar pinprick sensation)	IV	2.22 (0.81, 6.03)	0.60 (0.39, 0.90)
Boland and Kiernan <sup>42</sup> (carpal compression and thenar pinprick sensation)	IV	3.29 (0.20, 53.20)	0.91 (0.79, 1.04)
Wainner et al <sup>283</sup> (shaking hands relieves symptoms, wrist ratio index greater than 0.67, CTQ-SSS score greater than 1.9, diminished sensation in median nerve distribution, and aged older than 45 y)	II	1.10 (1.0, 1.3) with 2 or more positive tests 2.10 (1.6, 2.8) with 3 or more positive tests 4.60 (2.5, 8.7) with 4 or more positive tests 18.30 (1.0, 328.3) with all 5 tests positive	

Abbreviations: CTQ-SSS, Boston Carpal Tunnel Questionnaire-symptom severity scale; -LR, negative likelihood ratio; +LR, positive likelihood ratio; ULNT, upper-limb neurodynamic test.

\*Values in parentheses are 95% confidence interval.

<sup>a</sup>A reflex hammer, held 6 inches above the patient's wrist crease, is allowed to fall and strike the patient between the tendons of the flexor carpi radialis and palmaris longus, with a positive test being a nonpainful tingling sensation radiating distally along the path of the median nerve.

<sup>b</sup>The examiner taps the patient with a reflex hammer using mild to moderate force between the tendons of the flexor carpi radialis and palmaris longus, with a positive test including discomfort or pain at the wrist or radiating distally along the nerve's course.

<sup>c</sup>Positive if the patient's clinical symptoms are provoked at the wrist or hand and changed during structural differentiation.

<sup>d</sup>Positive if any symptoms were provoked at the wrist or radial 3 digits and changed during structural differentiation.

<sup>e</sup>Any of the following were considered positive: (1) symptoms were reproduced, (2) side-to-side differences in elbow extension (greater than 10°) for part A or wrist flexion (part B) on completion of all motion sequences, (3) contralateral neck sidebending increased symptoms or ipsilateral sidebending decreased symptoms in the symptomatic limb.

<sup>f</sup>Positive if symptoms are in the radial 3 digits.

<sup>g</sup>Positive if symptoms are in the radial 3 digits and increased with contralateral cervical sidebending.

<sup>h</sup>Positive if symptoms are in the radial 3 digits and decreased with spine ipsilateral cervical sidebending.

TABLE 5

DIAGNOSTIC ACCURACY AND RELIABILITY VALUES FOR SENSORY MEASURES

Test/Study	Level of Evidence	Sensitivity, %*	Specificity, %*	PPV, %*	NPV, %*	Intrarater Reliability	Interrater Reliability*
Semmes-Weinstein mono-filament testing							
MacDermid and Wessel <sup>173</sup>	I	72	62	...	...	...	...
MacDermid et al <sup>171a</sup>	II	...	...	...	...	...	$\kappa = 0.49^b, \kappa = 0.44^c$
MacDermid et al <sup>171d</sup>	II	...	...	...	...	...	$\kappa = 0.39^b, \kappa = 0.51^c$
MacDermid et al <sup>170</sup>	II	...	...	...	...	...	$\kappa = 0.22 (0.26, 0.42)$
Yildirim and Gunduz <sup>200</sup>	II	98 <sup>e</sup>	17	44	93	...	...
		29	97 <sup>f</sup>	88	68	...	...
Yildirim and Gunduz <sup>200g</sup>	II	80 <sup>h</sup>	93	83	92	...	...
Clark et al <sup>67i</sup>	IV	Thenar eminence, 73; thumb, 59; index, 61; middle, 64; ring, 52; small, 44	<14	...	...	...	...
Clark et al <sup>67j</sup>	IV	Thenar eminence, 28; thumb, 20; index, 22; middle, 22; ring, 16; small, 13	<14	...	...	...	...
Marx et al <sup>183</sup>	IV	...	...	...	...	ICC = 0.71	ICC = 0.15
2-point discrimination							
Gerr and Letz <sup>107</sup>	I	28 <sup>k</sup>	88	42	80	...	...
Thüngen et al <sup>274</sup>	II	33 (20, 48) <sup>j</sup>	67 (9, 99) <sup>j</sup>	...	...	...	...
		38 (18, 62) <sup>m</sup>	71 (52, 86) <sup>m</sup>	...	...	...	...
Marlowe et al <sup>182</sup>	III	25	87.5	85	29.2	...	...
MacDermid and Wessel <sup>173</sup>	III	24	95	...	...	...	...
Marx et al <sup>183</sup>	IV	...	...	...	...	Static ICC = 0.77; moving ICC = 0.58	Static ICC = 0.66; moving ICC = 0.45

Abbreviation: ICC, intraclass correlation coefficient; NPV, negative predictive value; PPV, positive predictive value.

\*Values in parentheses are 95% confidence interval.

<sup>a</sup>Using the 2.83 filament as normal. Sensitivity and specificity were reported as part of the systematic review by MacDermid and Wessel.<sup>173</sup>

<sup>b</sup>The highest value of any radial digit was used.

<sup>c</sup>The long finger was used.

<sup>d</sup>Using the 3.22 filament as normal. Sensitivity and specificity were reported as part of the systematic review by MacDermid and Wessel.<sup>173</sup>

<sup>e</sup>Using the 2.83 filament as normal, with any radial digit testing higher than 2.83.

<sup>f</sup>Using the 3.22 filament as normal and comparing the middle finger with the small finger.

<sup>g</sup>Patients with moderate to severe carpal tunnel syndrome (determined by electrodiagnostic studies).

<sup>h</sup>Using the 3.22 filament as normal, with any radial digit testing higher than 3.22.

<sup>i</sup>Using the 2.83 filament as normal.

<sup>j</sup>Using the 3.61 filament as normal.

<sup>k</sup>Less than 4 mm is considered normal.

<sup>l</sup>Less than 5 mm is considered normal; electrodiagnostic tests were used as the gold standard.

<sup>m</sup>Less than 5 mm is considered normal; clinical examination was used as the gold standard.

# CARPAL TUNNEL SYNDROME: CLINICAL PRACTICE GUIDELINES

**TABLE 6**

## RELIABILITY VALUES FOR VIBRATION SENSE TESTING

Study	Level of Evidence	Vibration Frequency	Instrument	Intrarater Reliability*	Interrater Reliability*
Hubbard et al <sup>a</sup>	II	50 Hz	PVC50 computerized vibrometer	Right hand: ICC = 0.86 (0.77, 0.92); SEM, 5.9 Left hand: ICC = 0.89 (0.81, 0.93); SEM, 4.8	...
MacDermid et al <sup>70</sup>	II	256 Hz	Tuning fork	...	$\kappa = 0.71$ (0.56, 0.86)
Grunert et al <sup>b</sup>	IV	8, 16, 32.5, 63, 125, 250, 500 Hz	Bruel and Kjaer vibrometer	$r = 0.72-0.87^c$	...

Abbreviations: ICC, intraclass correlation coefficient; SEM, standard error of the measurement.

\*Values in parentheses are 95% confidence interval.

<sup>a</sup>Hubbard MC, MacDermid JC, Kramer JF, Birmingham TB. Quantitative vibration threshold testing in carpal tunnel syndrome: analysis strategies for optimizing reliability. *J Hand Ther.* 2004;17:24-30. <https://doi.org/10.1197/j.jht.2003.10.004>

<sup>b</sup>Grunert BK, Wertsch JJ, Matloub HS, McCallum-Burke S. Reliability of sensory threshold measurement using a digital vibrogram. *J Occup Med.* 1990;32:100-102.

<sup>c</sup>Authors recommend 1 practice trial.

**TABLE 7**

## DIAGNOSTIC ACCURACY VALUES AND KNOWN-GROUPS VALIDITY FOR VIBRATION SENSE TESTING

Study	Level of Evidence	Vibration Frequency	Sensitivity, %	Specificity, %	PPV, %	NPV, %	Difference Versus Control Group
Checkosky et al <sup>59*</sup>	I	1 Hz	...	...	...	...	$P = .81$
		10 Hz	...	...	...	...	$P = .028$
		300 Hz	...	...	...	...	$P = .43$
Werner et al <sup>291</sup>	I	8 Hz	...	...	...	...	$P = .002$
		16 Hz	...	...	...	...	$P = .11$
		32.5 Hz	...	...	...	...	$P = .16$
		63 Hz	...	...	...	...	$P = .02$
		125 Hz	...	...	...	...	$P = .23$
		250 Hz	...	...	...	...	$P = .29$
		500 Hz	...	...	...	...	$P = .18$
Gerr and Letz <sup>107*</sup>	I	Multifrequency	69.7	57.5	28.8	88.5	
Hardy et al <sup>126</sup>	III	128 Hz	...	...	57	82	
		50 Hz	78	53	...	...	
MacDermid and Wessel <sup>173</sup>	III	150 Hz	58	68	...	...	
		256 Hz	55	81	...	...	
Jetzer <sup>39</sup>	IV	Multifrequency	50	73	...	...	
		Multifrequency	...	...	...	...	Workers with CTS symptoms compared to those without ( $P < .01$ ); workers with confirmed CTS using electrodiagnostic studies compared to other workers ( $P < .0001$ )

Abbreviations: CTS, carpal tunnel syndrome; NPV, negative predictive value; PPV, positive predictive value.

\*Sensitivity and specificity were reported as part of the systematic review by MacDermid and Wessel.<sup>173</sup>

## CLINICAL PRACTICE GUIDELINES

## Examination

## OUTCOME MEASURES

## Activity Limitations/Self-reported Measures

*Boston Carpal Tunnel Questionnaire-Symptom Severity Scale*

**II** The Boston Carpal Tunnel Questionnaire-symptom severity scale (CTQ-SSS) is an 11-item questionnaire used to assess symptom severity in individuals with CTS. Each item is scored on a Likert scale from 1 to 5 (5 being worst), with the patient's CTQ-SSS score being the average score of all items. Final scores can range from 1 (no symptoms) to 5 (worst symptoms). Internal consistency (Cronbach  $\alpha = .89^{162}$  and  $.96^{30}$ ) and test-retest reliability ( $r = 0.82-0.95$ )<sup>30,118,162</sup> are excellent. The CTQ-SSS shows a strong correlation with the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire ( $r = 0.74-0.77$ ).<sup>30,101</sup> CTQ-SSS scores have shown weak to no correlation with NCS,<sup>30,83,162</sup> but it has demonstrated higher sensitivity to change than any other outcome measure in individuals following surgery at 6 weeks,<sup>30,101</sup> 3 months,<sup>6,23,101,118</sup> 4 months,<sup>138</sup> 6 months,<sup>19,58</sup> 8 months,<sup>138</sup> and 14 months.<sup>162</sup> The CTQ-SSS has also been shown to be responsive in individuals following 6 weeks of orthosis management<sup>64</sup> and 3 weeks following cortisone injection.<sup>219</sup>

**II** Conflicting results have been published on the predictive and discriminant validity of the CTQ-SSS. Baker and Livengood<sup>27</sup> reported that baseline score was a significant predictor of progression to surgery in patients without atrophy in the thenar muscles (OR = 12.5; 95% CI: 3.1, 50.7), and Boyd et al<sup>43</sup> concluded that baseline CTQ-SSS was a predictor of failed nonsurgical management whereas the Boston Carpal Tunnel Questionnaire-functional scale (CTQ-FS), the DASH, the Medical Outcomes Study 36-Item Short-Form Health Survey, and age were not. Olliver et al<sup>212</sup> found the CTQ-SSS was the best predictor of success with nonsurgical management in that baseline scores less than 2.5 were 89% specific for success. Kaye and Reynolds<sup>147</sup> reported that people with a mean CTQ-SSS score of 3.0 had a 72% probability of progression to surgery and a score of 3.5 had an 86% probability. However, Gerritsen et al<sup>109</sup> identified the CTQ-SSS as a predictor of outcome at 12 months in a single variable analysis, but the measure did not remain significant when placed into a multiple logistic backward regression model. Reported values for the minimal clinically important difference (MCID) for the CTQ-SSS are reported in **TABLE 8**.

**II** One study investigated the factor structure of the CTQ-SSS.<sup>25</sup> Following factor analysis, authors suggested shortening the original 11-item instrument to

a 6-item instrument (CTQ-6).<sup>25,26,167</sup> The internal consistency (Cronbach  $\alpha = .86$ ) and test-retest reliability (ICC = 0.95; 95% CI: 0.90, 0.98) of the 6-item instrument were excellent.<sup>25</sup> Correlation, measured using Pearson's correlation coefficients, with the original, 11-item instrument was 0.80 (95% CI: 0.73, 0.86) and with the 11-item version of the DASH (QuickDASH) was 0.87 (95% CI: 0.82, 0.91).<sup>25</sup> Responsiveness for the CTQ-6 evaluated within a year following CTR surgery was excellent (ES was 2.03 for all patients and 2.53 for those reporting large improvement).<sup>26</sup> The MCID is 0.90.<sup>25,26,167</sup> The instrument also discriminated between different levels of change and patient satisfaction.<sup>25</sup> However, there are no data on the CTQ-6 on patients managed nonsurgically, and it has not been independently validated outside the original authors.

*Boston Carpal Tunnel Questionnaire-Functional Scale*

**II** The CTQ-FS is an 8-item questionnaire to assess the functional status of patients with CTS. Each item is scored on a Likert scale from 1 to 5 (5 being worst), with the score being the average of all 8 items. Final scores can range from 1 (no functional deficits) to 5 (worst function possible). Internal consistency (Cronbach  $\alpha = .91$ )<sup>30,162</sup> and test-retest reliability ( $r = 0.85^{30}$  and  $0.93^{162}$ ) are excellent. The CTQ-FS shows a strong correlation to the DASH ( $r = 0.87^{30}$  and  $r = 0.88, 0.91$ ).<sup>101</sup> The CTQ-FS has shown no correlation with NCS.<sup>30,162</sup>

*Disabilities of the Arm, Shoulder and Hand Questionnaire*

**II** The DASH is a 30-item questionnaire designed to assess disability in patients with upper extremity pathology. Measurement properties, including internal consistency (Cronbach  $\alpha = .97^{134}$  and  $.95^{30}$ ) and test-retest reliability ( $r = 0.77^{30}$  and  $0.88^{10}$ ; ICC = 0.90<sup>118</sup>) are excellent. As reported above, it strongly correlates to the CTQ-FS. The DASH has shown no correlation with NCS.<sup>30</sup>

*QuickDASH*

**III** The test-retest reliability for the QuickDASH (ICC = 0.69)<sup>263</sup> is lower than the CTQ-SSS, the CTQ-FS, and the DASH. The correlation between QuickDASH scores and electrodiagnostic findings is not statically significant ( $r = -0.18, P = .08$ ).<sup>276</sup>

*Responsiveness and MCID for the CTQ-FS, DASH, and QuickDASH*

**II** Responsiveness and MCID of the CTQ-FS, DASH, and QuickDASH have not been evaluated in those undergoing nonsurgical management. Neither the



CTQ-FS nor the DASH were able to predict progression to surgery.<sup>43</sup> Post CTR surgery, the CTQ-FS,<sup>6,10,19,30,58,101,118,138,303</sup> DASH,<sup>10,30,101,118,134,154,187,303</sup> and QuickDASH<sup>26,167</sup> have been shown responsive to change and values are similar, ranging from moderate to high. The CTQ-SSS showed greater responsiveness compared with the CTQ-FS and DASH.<sup>101,118</sup> Bessette et al<sup>38</sup> reported the MCID for the CTQ-FS at 6 months postsurgery was 0.74. Ozer et al<sup>216</sup> reported the MCID for the CTQ-FS was 1.95 for individuals with diabetes and 1.25 for those without (also evaluated 6 months post surgery). The MCID for the DASH reported at 6 weeks post CTR surgery was 21%.<sup>10</sup> Amirfeyz et al<sup>10</sup> reported the MCID at 6 weeks postsurgery for the CTQ-SSS and CTQ-FS were 0.16 and 0.47, respectively. The total score from the CTQ-SSS and CTQ-FS has also been shown to be responsive following surgery.<sup>38,101</sup>

### Evidence Synthesis and Clinical Rationale

Psychometric properties of the CTQ-SSS, CTQ-FS, and the DASH are excellent. There is more evidence available on those undergoing surgical management and only limited evidence on those undergoing nonsurgical management. Only the CTQ-SSS has been shown to be responsive to change in those undergoing nonsurgical management.

### Gaps in Knowledge

More research is needed to validate the shorter version of the CTQ-SSS and to examine the psychometric properties of the functional measures in patients with CTS undergoing nonsurgical management. While higher baseline CTQ-SSS scores have shown to predict progression to CTR surgery in some studies,<sup>43,147</sup> further validation in larger, independent samples is needed.

### Recommendation

**B** Clinicians should use the CTQ-SSS to assess symptoms and the CTQ-FS or the DASH questionnaire to assess function when examining patients with CTS. Clinicians should use the CTQ-SSS to assess change in those undergoing nonsurgical management.

## ACTIVITY LIMITATIONS

### Physical Performance Measures

While activity limitations and participation restrictions can be evaluated in part using self-report measures, there are data available on patient-performance measures including the Purdue Pegboard (PPB), the Dellon-modified Moberg pick-up test (DMPUT), the Jebsen-Taylor Hand Function Test, and the Nine-Hole Peg Test in individuals with CTS.

### Purdue Pegboard

**III** Normative data for the PPB test exist.<sup>1,82,299</sup> Test-retest reliability as a measure of dexterous hand function in individuals with CTS has been reported

in a sample of 51 individuals (20-86 years old) with electrophysiologically confirmed CTS and is excellent (ICC = 0.97).<sup>13</sup> The PPB discriminates between those with and without CTS in individuals 66 years old and under ( $P < .001$ ).<sup>81,95</sup>

**III** Amirjani et al<sup>13</sup> included people with CTS aged 20 to 86 years old and found decreased PPB test scores in young (age, 20-39 years) and middle-aged (age, 40-59 years) participants compared with controls, but in the elderly (age, 60 years or older), there was only a difference in participants with moderate and severe CTS. Authors concluded that performance on the PPB declines with age regardless of carpal tunnel pathology.<sup>13</sup> Atalay et al<sup>20</sup> found lower PPB subtest scores in those with severe CTS compared to those with mild disease.

**III** When compared to NCS, there were no meaningful associations between PPB test scores and DSL or DML ( $r < 0.15$ ,  $P > .05$ ),<sup>81</sup> or between PPB test scores and the total CTQ score for younger individuals ( $r < 0.22$ ,  $P > .05$ ).<sup>13</sup> The correlations between the subtests of the PPB and CTQ scores for individuals 60 and older were higher ( $r = 0.33$  to  $0.45$ ,  $P < .05$ ).<sup>13</sup> PPB test scores have moderate to high correlations ( $r = -0.50$  to  $-0.76$ ,  $P < .001$ ) with pain duration and severity.<sup>95</sup>

**III** There is conflicting evidence on the ability of the PPB to discriminate between individuals with different CTS severities. de la Llave-Rincón et al<sup>81</sup> found no difference in scores of all PPB subtests in individuals with mild, moderate, or severe CTS, while Atalay et al<sup>20</sup> reported a significant difference in PPB scores between individuals with mild CTS and those with severe CTS, but only for the dominant hand. Last, authors have reported bilateral deficits in fine hand use measured by the PPB in patients with unilateral mild to moderate CTS.<sup>95</sup>

**II** Olsen and Knudson<sup>213</sup> examined recovery of fine hand use using the PPB in 11 patients, 5 months following CTR surgery using trend analysis. Recovery followed a linear path with a flat slope, suggesting that surgery did not result in a marked improvement in PPB scores even though the preoperative scores were well below normal.

### Dellon-modified Moberg Pick-up Test

**III** Normative data for the DMPUT have been reported for 116 individuals 20 years and older and indicate better performance for women compared to men and declining performance with age.<sup>11</sup> Test-retest reliability in patients with CTS has been reported in a sample of 46 individuals with electrophysiologically confirmed CTS and is excellent (ICC = 0.91; 95% CI: 0.87, 0.95).<sup>12</sup> For known-

groups validity, authors found significant differences in scores between those with and without CTS, suggesting the DMPUT is useful in discriminating between those with and without CTS. However, when stratifying by age, the authors found similar scores in the elderly individuals with mild CTS and the control group.<sup>12</sup>

**II** Appleby et al<sup>16</sup> reported a statistically significant change in DMPUT scores in 29 patients tested before and 12 weeks following CTR surgery. Using the means and standard deviations reported in the study, responsiveness could be calculated (standardized response mean [SRM], 0.90 and ES, 0.71) suggesting the DMPUT is acceptable at assessing change following surgery. There are no data on the responsiveness of the DMPUT in individuals undergoing nonsurgical management.

**Jebsen-Taylor Hand Function Test and Nine-Hole Peg Test**

**II** Neither the Jebsen-Taylor Hand Function Test nor the Nine-Hole Peg Test have established reliability in individuals with CTS. Sears and Chung<sup>254</sup> examined the responsiveness of the Jebsen-Taylor Hand Function Test and reported it was a poor indicator for improvement after CTR surgery (ES, 0.05; SRM, 0.04). Hobby et al<sup>134</sup> studied responsiveness of the Nine-Hole Peg test following CTR surgery and found this measure was also not responsive to change (ES, 0.16; SRM, 0.12). There are no data on these measures for individuals undergoing nonsurgical management.

**Evidence Synthesis and Clinical Rationale**

Norms are available for both the PPB and the DMPUT. While the PPB test discriminates between those with and without CTS aged 60 and under, it is not useful in monitoring progress after CTR surgery. The DMPUT also discriminates between those with and without CTS in younger patients and can help in assessing change following CTR surgery because data presented on responsiveness of this instrument are from individuals who underwent CTR surgery.

**Gaps in Knowledge**

More research is needed to establish reliability of the Jebsen-Taylor Hand Function Test and the Nine-Hole Peg Test in individuals with CTS. Also, more research is needed to determine responsiveness of all physical performance-based measures in individuals with CTS undergoing nonsurgical management.

**C** Clinicians may use the PPB or the DMPUT to quantify dexterity at the onset of treatment and compare scores with established norms. Clinicians should **not** use the PPB test, Jebsen-Taylor Hand Function Test, or the Nine-Hole Peg Test to assess clinical change following

CTR surgery. Clinicians may use the DMPUT to assess change following CTR surgery.

**ACTIVITY LIMITATIONS**

**Physical Impairment Measures**

**Strength Measures**

**II** For predictive validity, Boyd et al<sup>43</sup> reported no significant difference in grip strength between individuals with CTS who progressed to surgery and those who did not. Studies on sensitivity to change of grip strength have been done following CTR surgery. In those studies, grip strength was not sensitive to change over time.<sup>6,19,134,138,145,230</sup> Following surgery, grip strength actually decreases and doesn't begin to increase until the third post-operative month.<sup>102,303</sup>

**II** Lateral pinch is not sensitive to change following CTR surgery.<sup>102</sup> Additionally, lateral pinch receives motor input from median and ulnar-innervated muscles making it an invalid measure in individuals with CTS.<sup>102</sup> While tip and 3-point pinch both target more median-innervated muscles, there are no data on the sensitivity to change of tip or 3-point pinch in patients managed nonsurgically. There is conflicting evidence on the sensitivity to change of tip and 3-point pinch following CTR surgery.<sup>102</sup> Existing data on assessment of APB muscle strength from patients following CTR surgery also present conflicting results.<sup>102,138,145</sup>

**III** Reliability values of strength measures in patients with CTS including grip,<sup>4,72</sup> tip pinch,<sup>95</sup> 3-point pinch,<sup>4</sup> and lateral (key) pinch<sup>4</sup> are all greater than 0.81. For grip strength, reliability is best when using a single trial or using the highest score of 3 trials.<sup>72</sup> Known-groups validity has also been studied in this population.<sup>28,95</sup> Significant differences in grip strength, 3-point pinch, lateral pinch,<sup>28</sup> and tip pinch<sup>95</sup> have been found between those with and without CTS. Atalay et al<sup>20</sup> reported significant differences in tip and 3-point pinch between those with mild and moderate CTS compared to those with severe CTS but no differences in grip strength.

**Evidence Synthesis and Clinical Rationale**

Lateral pinch receives dual innervation from the median and ulnar-innervated muscles making it unacceptable as a measure in CTS. Tip and 3-point pinch receive innervation from more median-innervated muscles, but there is innervation from branches proximal and distal to the carpal tunnel but evidence supports weakness in the presence of CTS when compared to controls. The available evidence on the value of tip and 3-point pinch in the assessment of change in individuals with CTS is conflicting. Evidence on strength testing of the APB muscle is also conflicting.

Journal of Orthopaedic & Sports Physical Therapy®  
Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

**Gaps in Knowledge**

There are no data on the sensitivity to change of instruments to assess strength in individuals with CTS being managed nonsurgically. All available data are on individuals being managed with CTR and suggest that strength measures are not useful in these individuals. However, due to the presence of a postsurgical wound/scar, one should not expect to apply these results for patients managed nonsurgically. Also, there is conflicting evidence on the presence of grip strength weakness in individuals with CTS, and there is a need for more research in this area.

**Recommendations**

- A** Clinicians should **not** use lateral pinch strength as an outcome measure for patients with nonsurgically or surgically managed CTS.
- B** Clinicians should **not** use grip strength when assessing short-term (less than 3 months) change in individuals following CTR surgery.
- C** Clinicians may assess grip strength and 3-point or tip pinch strength in individuals presenting with signs and symptoms of CTS and compare scores with established norms.
- D** There is conflicting evidence on the use of tip and 3-point pinch strength and abductor pollicis brevis muscle strength testing in individuals following CTR surgery.

**Sensory and Provocative Measures**

Reliability for provocative and sensory measures have been reported in the Diagnosis section of this guideline and are shown in **TABLES 2 and 5**, respectively. Here, these instruments will be discussed with regards to their ability to detect change over time.

**II** There are no studies assessing sensitivity to change of static 2PD in patients undergoing nonsurgical management for CTS. There were 5 studies using the interpretation provided by Cohen's criteria (small  $d = 0.2$ , medium  $d = 0.5$ , large  $d = 0.8$ )<sup>70</sup> following CTR with conflicting results. Authors of 4 studies reported small-to-medium ES at 1, 3, 4, and 8 months after CTR surgery (0.39,<sup>135</sup> 0.51,<sup>145</sup> 0.22,<sup>138</sup> and 0.33,<sup>138</sup> respectively). Authors of a study deemed to be lower in quality reported a large ES of 0.88 at 18 weeks following surgery.<sup>134</sup> Other authors found low-to-moderate SRMs at 3, 4, 6, and 8 months after surgery (0.30-0.76,<sup>22,134,145</sup> 0.57,<sup>138</sup> 0.40,<sup>22</sup> and 0.51,<sup>138</sup> respectively). There was 1 study on the sensitivity to change of moving 2PD following CTR (ES, 0.44) at 1 month following surgery.<sup>135</sup>

**II** There was only 1 published study on the responsiveness of threshold testing in individuals undergoing nonsurgical management.<sup>64</sup> Authors used both distribution-based methods to assess sensitivity to change, and anchor-based methods for determining responsiveness of the Pressure Specified Sensory Device in individuals treated with an orthosis for 6 weeks. Results indicated low sensitivity to change (ES less than 0.08 and SRM less than 0.09) for those who responded to treatment as measured by change score on the CTQ-SSS. Based on the receiver operating curve (area under the curve = 0.46), authors concluded the instrument did not discriminate between those who improved and those who did not. Five studies reported low-to-moderate responsiveness for threshold testing following CTR surgery. Effect size values were 0.76 (1 month post CTR),<sup>135</sup> 0.41 (3 months post CTR),<sup>145</sup> 0.55 (4 months post CTR), and 0.73 (8 months post CTR).<sup>138</sup> Standardized response means were 0.30 to 0.70 (3 months post CTR),<sup>6,22,145</sup> 0.59 (4 months post CTR),<sup>138</sup> and 0.60 (6 months post CTR).<sup>22</sup> The highest quality study reported a large SRM (0.84) at 8 months post release.<sup>138</sup> These values are lower compared to ESs and SRMs reported for the CTQ-SSS which exceeded 1.0 in many of the same studies.<sup>6,22,138,145</sup>

**II** Vibration sense before and after intervention has been evaluated using a tuning fork and different vibrometers. There was no published evidence on the sensitivity or responsiveness of using a tuning fork in those undergoing nonsurgical management. There was only 1 study on the sensitivity to change of vibration sense measured using a 50-Hz computer-controlled vibrometer in individuals undergoing nonsurgical management.<sup>64</sup> Cheung et al<sup>64</sup> reported moderate sensitivity using the vibrometer in those that responded to treatment (ES, 0.46; 95% CI: 0.05, 0.47; SRM, 0.61; 95% CI: 0.20, 1.02). However, these authors concluded that their results did not provide sufficient evidence that it was useful for clinical decision making in determining whether a clinically important difference occurred.

**II** Pransky et al<sup>230</sup> assessed sensitivity to change in the Upper Extremity Functional Scale scores, pain, symptom severity, Phalen test, grip strength, pinch strength, and median nerve motor conduction across the wrist in a group of patients post CTR surgery who reported improvement (average follow-up, 18 months). The Phalen test was more sensitive to change (SRM, 0.92) than grip (SRM, 0.38) or pinch strength (SRM, 0.39).

**Evidence Synthesis and Clinical Rationale**

For 2PD and SWMT, there is conflicting evidence on the sensitivity to change following CTR surgery. Data available for threshold and vibration sense are limited and do not support use of these measures.

Journal of Orthopaedic & Sports Physical Therapy ©  
 Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
 Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

**Gaps in Knowledge**

There is a need for research examining the use of 2PD and provocative measures in individuals undergoing nonsurgical management. The use of the Phalen test to assess change in CTS needs further validation.

**Recommendations**

**C** Clinicians should **not** use threshold or vibration testing to assess change in individuals with CTS undergoing nonsurgical management until more evidence becomes available. Clinicians may use the Phalen test to assess change in those with CTR surgery at long-term follow-ups.

**D** There is conflicting evidence on the use of sensory measures, including 2PD and threshold testing, to assess change over time in patients with surgically managed CTS.

**BEST-PRACTICE POINT**  
**Essential Data Elements**

In the course of the examination and episode of care, clinicians should document results of the following questions, tests, and measures. Upon collection of the initial patient/client data, clinicians should differentiate CTS from other nerve injuries and then assess the CTS severity to determine if an immediate surgical referral is warranted. Patients may require electrodiagnostic studies when the clinical exam is inconclusive. When assessing effectiveness of nonsurgical management, results should be documented again at discharge or at 1 other follow-up point. Documentation of standard elements supports standardization for quality improvement in clinical care and research.

**Examination**

- Patient age
- Katz hand diagram (location of symptoms)
- Wrist ratio index
- Whether shaking hands provides relief
- Duration of symptoms
- Intensity of symptoms
- Frequency of symptoms
- Prior nonsurgical interventions
- Presence of thenar atrophy (indication of severe CTS)

**Activity Limitations – Self-report Measures**

- CTQ-SSS<sup>a,b</sup> and the CTQ-FS<sup>b</sup> or the DASH<sup>b</sup>

**Activity Limitations – Physical Performance Measures**

- PPB or the DMPUT<sup>b</sup> to assess dexterity (compare to established normative values for age and sex)

**Physical Impairment Measures**

- SWMT (compare to normal value of 2.83 or 3.22)
- Static 2PD on the middle finger (compare to normal value of 6 mm)
- Phalen test,<sup>b</sup> Tinel sign, and carpal compression test
- Grip strength<sup>c</sup> and tip or 3-point pinch strength to assess strength (compare to established normative values for age and sex)

<sup>a</sup>Measures validated to assess change over time in those undergoing nonsurgical management.

<sup>b</sup>Measures validated to assess change over time following CTR surgery.

<sup>c</sup>Grip strength should **not** be used to assess change following surgery until the 12th postoperative week.

**TABLE 8**

MINIMAL CLINICALLY IMPORTANT DIFFERENCE FOR THE BOSTON CARPAL TUNNEL QUESTIONNAIRE-SYMPTOM SEVERITY SCALE

Study	Condition	MCID Value	Sample Size
Cheung et al <sup>64</sup>	6 wk of orthosis use	0.50	63
Özyürekoğlu et al <sup>219</sup>	3 wk following steroid injection	1.04 (AUC = 0.82)	28
Amirfeyz et al <sup>10</sup>	6 wk post CTR surgery	0.16	43
Jerosch-Herold et al <sup>138</sup>	4 mo post CTR surgery	1.25	57 at 4-mo assessment; 55 at 8-mo assessment
Astifidis et al <sup>19</sup>	6 mo post CTR surgery	1.36 (unilateral involvement)	635
	6 mo post CTR surgery	1.55 (bilateral involvement)	635
Ozer et al <sup>216</sup>	3 mo post CTR surgery	1.45 (diabetics)	114 (87 nondiabetic, 27 diabetic)
	3 mo post CTR surgery	0.80 (nondiabetics)	114 (87 nondiabetic, 27 diabetic)
	6 mo post CTR surgery	1.55 (diabetics)	114 (87 nondiabetic, 27 diabetic)
	6 mo post CTR surgery	1.60 (nondiabetics)	114 (87 nondiabetic, 27 diabetic)

Abbreviations: AUC, area under the curve; CTR, carpal tunnel release; MCID, minimal clinically important difference.

## CLINICAL PRACTICE GUIDELINES

## Interventions

**ASSISTIVE TECHNOLOGY****Computer Component Design**

The benefits attributed to ergonomically designed computer equipment include (1) reduction of carpal tunnel pressure<sup>103</sup>; (2) alignment of the wrist in the position that maximizes the space in the carpal tunnel<sup>210</sup>; (3) reduction of the work of the tendons within the carpal tunnel through reduced force output<sup>240</sup>; (4) reduction of the velocity and frequency of relative sliding between the contents of the carpal tunnel<sup>98,151</sup>; and (5) reduction of finger flexion range of motion, thereby preventing migration of the extrinsic or intrinsic muscle bellies into the carpal tunnel.<sup>68</sup>

**II** In a Cochrane review, O'Connor et al<sup>210</sup> analyzed 2 randomized placebo-controlled trials evaluating the effectiveness of ergonomic keyboards.<sup>239,275</sup> Rempel et al<sup>239</sup> compared self-reported pain level, symptom relief, hand function, and NCS in individuals with CTS (all severities) using an ergonomic keyboard to those using a standard keyboard for 6 and 12 weeks. Both keyboards included a conventional layout but differed in the required force needed for key displacement. Rempel et al<sup>239</sup> found improvement in pain levels between 6 and 12 weeks for those in the reduced key-strike force group (weighted MD [WMD], -2.40; 95% CI: -4.45, -0.35).<sup>210</sup> Tittiranonda et al<sup>275</sup> compared pain severity in 80 individuals with CTS (unspecified severity) using 1 of 3 ergonomic keyboards or a standard keyboard and found no significant difference in pain severity at 6 months compared to baseline. Neither study reported adverse effects associated with the use of the keyboards. O'Connor et al<sup>210</sup> concluded there was insufficient evidence for or against the short or long-term effectiveness of the studied ergonomic keyboards in patients with CTS.

**II** In a cohort study consisting of 21 individuals with mild or moderate CTS, Schmid et al<sup>253</sup> compared the effects of a vertical mouse, a standard mouse used with a gel mouse pad, a standard mouse used with a gliding palm support, and a standard mouse alone on carpal tunnel pressure, wrist angle, and comfort level during a 5-minute mouse task. Authors reported a significant increase in carpal tunnel pressure during the mouse task for all 4 devices compared to baseline (MD, 20 mmHg;  $P < .0001$ ) with mean measured pressures ranging from 46.5 mmHg to 66.2 mmHg. For wrist angle, the gel mouse pad and pad with gliding palm support decreased wrist extension/flexion angles compared to the standard mouse ( $P < .003$ ), but did not

change radio-ulnar deviation angles ( $P > .07$ ). The vertical mouse showed the largest extension angle ( $P < .001$ ) but the smallest ulnar deviation angle ( $P < .006$ ). There was no difference in patient-reported comfort across the 4 devices ( $P = .71$ ). Schmid et al<sup>253</sup> concluded there was insufficient evidence to make recommendations for or against any of the devices studied.

**Evidence Synthesis and Clinical Rationale**

Ergonomic devices are more expensive than standard devices.<sup>210</sup> There is insufficient evidence to support the use of the studied ergonomic keyboards, mice, or mouse pads to reduce risk of developing CTS. Evidence suggests that mouse use further increases carpal tunnel pressure with all the studied mouse designs. As noted earlier in this guideline, increased carpal tunnel pressure above 30 mmHg<sup>165</sup> and forceful hand exertions are strongly associated with CTS.<sup>128</sup> The mean pressures recorded with all studied mouse designs exceeded the 30-mmHg diagnostic minimum.

**Gaps in Knowledge**

High-quality studies to evaluate the effectiveness of nonstandard keyboards, mice, and mouse pads using valid, reliable, and responsive outcome measures in individuals with CTS are needed. These studies should also include device use for time periods reflecting a typical 8-hour work day. More studies are needed to identify equipment designs justifying the additional expense.

**Recommendation**

**C** Clinicians may educate their patients regarding the effects of mouse use on carpal tunnel pressure and assist patients in developing alternate strategies including the use of arrow keys, touch screens, or alternating the mouse hand. Clinicians may recommend keyboards with reduced strike force for patients with CTS who report pain with keyboard use.

**ORTHOSES**

The rationale for using static wrist orthoses for individuals with CTS is based on several theories including: reducing tendon and nerve movement through the carpal tunnel and thereby reducing inflammation; immobilizing the wrist in the position of least internal pressure in the carpal tunnel; altering the shape or dimensions of the tunnel to increase space; reducing tunnel contents by positioning the wrist and

fingers to prevent the lumbrical muscle origins from migrating proximally into the carpal tunnel or prevent the proximal muscles from advancing distally.<sup>75,86,148,237</sup>

In a Cochrane review, Page et al<sup>221</sup> reviewed 19 studies published before January 2012. They performed subanalyses on the effectiveness of orthoses versus no intervention, orthoses versus other nonsurgical interventions, and orthosis design and position. The review also reported on the combined effects of orthoses and steroid injection, orthoses and nonsteroidal anti-inflammatory drugs (NSAIDs), and orthoses and ergonomic education. The results of the subanalyses are included below in addition to studies published after the Cochrane review.

### Orthosis Versus No Intervention

**II** Page et al<sup>221</sup> reviewed 2 level II studies comparing orthosis use to no intervention. In the first study, a randomized controlled trial, Manente et al<sup>180</sup> evaluated 80 individuals using a soft, hand-based support at night. Use of the support for 4 weeks resulted in short-term symptom improvement in the CTQ-SSS (MD, -1.07; 95% CI: -1.29, -0.85) and the CTQ-FS (MD, -0.55; 95% CI: -0.82, -0.28).<sup>221</sup> Page et al<sup>221</sup> concluded that the orthosis group was more than 3 times as likely to report improvement than the no-orthosis group (RR = 3.86; 95% CI: 2.29, 6.51). In the second study, a quasi-randomized trial, Premoselli et al<sup>231</sup> evaluated symptom and functional improvement in 50 wrists at 3 (n = 48) and 6 months (n = 34) following use of a custom-fabricated, volar, neutral wrist orthoses worn at night compared to no intervention. At 3 months, the difference in scores between the orthosis group and the control favored the orthosis group on the CTQ-SSS (MD, -0.94; 95% CI: -1.10, -0.78) and the CTQ-FS (MD, -0.22; 95% CI: -0.40, -0.04).<sup>221</sup> At 6 months, the difference between groups persisted on the CTQ-SSS (MD, -0.90; 95% CI: -1.11, -0.69) and CTQ-FS (MD, -0.25; 95% CI: -0.68, 0.18). Results from the NCS parameters were conflicting. Page et al<sup>221</sup> concluded the precision of the effect estimates was low and both studies were determined to have a high risk of bias. Adverse effects were reported in the orthosis group in the Manente et al<sup>180</sup> study which included difficulty falling asleep (3/40 individuals) and transient morning paresthesias (4/40 individuals).

### Orthosis Design and Position

Orthosis design includes material (cloth, thermoplastic, plaster), limb placement (volar, dorsal, or ulnar) and the specific joints included in the orthosis (wrist, thumb, metacarpophalangeal [MP] joints, interphalangeal [IP] joints). Orthosis position describes the angle of immobilization of the included joints.

**II** Page et al<sup>221</sup> analyzed 5 level II studies comparing orthosis design and position, including wrist immobilization ranging from 30° of extension to

neutral, inclusion of MP joint immobilization, and/or thumb immobilization. They concluded there was insufficient evidence to recommend one design or position over another.

### Wrist Position

**IV** Özgen et al<sup>217</sup> used sonography to determine the immobilization position associated with the greatest median nerve area for 21 individuals (37 wrists) with idiopathic CTS of all severity levels. Median nerve dimensions in the carpal tunnel were taken in 4 wrist positions. The results showed individual variation. Forty-three percent of wrists showed the greatest median nerve area at 15° of wrist flexion, 32% at 0°, 16% at 15° of extension, and 8% at 30° of extension. Participants were immobilized in the position that demonstrated their greatest median nerve dimension for 6 weeks with a custom-fabricated volar wrist orthosis. Outcome measures included CTQ-SSS, CTQ-FS, pinch strength, and grip strength. The participants positioned in 30° of wrist extension were eliminated due to the small group size and were not accounted for in the final analysis. The remaining 3 groups demonstrated significantly improved CTQ-SSS scores ( $P < .05$ ). For the CTQ-FS, only the wrist flexion group demonstrated a significant improvement (MD, -3.0;  $P < .05$ ), and for grip strength, only the neutral position group demonstrated significant improvement (MD, 1.85 kg;  $P < .05$ ). Despite the differences within the groups, there were no statistically significant differences between the groups for any outcome measure ( $P > .05$ ). No group demonstrated improvement in pinch.<sup>217</sup>

**III** The following cross-sectional studies provide foundational, or physiological justification for neutral (0°) wrist positioning of the orthosis based on carpal tunnel pressure measurement. Gelberman et al<sup>103</sup> (n = 27) and Rojviroj et al<sup>245</sup> (n = 49) measured carpal tunnel pressure via indwelling catheters in individuals with and without CTS with the wrist in neutral (0° of wrist flexion/extension), 90° of flexion, and 90° of extension. Authors of both studies demonstrated the neutral wrist position was associated with the least carpal tunnel pressure and full extension was associated with the greatest pressure. Weiss et al<sup>287</sup> (n = 24) used indwelling catheters to evaluate carpal tunnel pressure during active positioning. These authors concluded that the lowest carpal tunnel pressure in those with CTS (n = 4) occurred with the wrist positioned at a mean ± standard deviation of 2° ± 9° of flexion and 1° ± 9° of ulnar deviation and in controls (n = 20) with the wrist at 2° ± 9° of extension and 2° ± 6° of ulnar deviation. Kuo et al<sup>156</sup> (n = 17) concluded neutral wrist position (0° of extension) was most frequently associated with the least pressure in the carpal tunnel, but that optimal position varied between individuals.

**MP Joint Position**

**II** Bulut et al<sup>47</sup> compared the use of a prefabricated, cotton polyester wrist orthosis (0°-5° of extension) to a volar, custom-fabricated, thermoplastic wrist (0°-5° of extension) and MP joint (0°-10° of flexion) orthosis in a nonblinded trial of 33 patients (54 hands) with mild to moderate CTS in a RCT. After 4 weeks of night use, both groups improved in all clinical, subjective, and electrophysiological outcome measures. The only statistically significant difference between groups was the CTQ-FS in favor of the custom-fabricated wrist and MP joint orthosis (MD, -0.61 ± 0.52) versus the prefabricated wrist-only support (MD, -0.06 ± 0.84; *P* = .012).

**II** In a nonblinded, randomized trial, Golriz et al<sup>114</sup> compared the use of 6 weeks of wrist immobilization with either a custom-fabricated volar, neutral wrist orthosis or the same orthosis with the MP joints positioned in 0° to 10° of flexion in 24 individuals with mild to moderate CTS symptoms. Outcome measures were pain visual analog scale (VAS), the DASH questionnaire, and grip and lateral pinch strength. Participants wore the orthoses at night and during the day “as much as possible.” Both groups improved in all outcome measures (*P* ≤ .040) but differences between the groups were significant for pain VAS (*P* = .02) and the DASH questionnaire (*P* = .03), both favoring the wrist plus MP joint orthosis.<sup>114</sup>

**III** In a cross-sectional study, Manente et al<sup>179</sup> measured carpal tunnel and flexor retinaculum dimensions and lumbrical insertion to flexor retinaculum distances via ultrasound imaging in individuals with mild to moderate CTS (*n* = 5) and a control group (*n* = 5) with and without an orthosis. The orthosis was a prefabricated, soft, hand-based orthosis that immobilized the middle and ring fingers in composite extension, the MP joints of the small and index fingers at 0° of extension and the IP joints of the index and small fingers free to move from 0° of extension to full flexion. Participants were positioned with their wrists in “neutral” during sonographic measurements of the carpal tunnel. Measurements were taken at the level of the pisiform and the hook of the hamate. With the orthosis in place, the transverse diameter and total carpal tunnel area increased in individuals with CTS (*P* < .05), as did the transverse diameter in the control group while wearing the support. The same result was reported when measurements were taken at the hook of the hamate for the CTS group with the addition of a significant reduction in the flexor retinaculum thickness and increase in the distance from the proximal origin of the second lumbrical muscle to the distal edge of the tunnel (*P* < .05). For the control group at the level of the hook of the hamate, the only significant results were a decrease in the flexor retinaculum thickness and an increase in the lumbrical origin to

flexor retinaculum distance (*P* < .05). The author concluded the use of the support increased carpal tunnel space and prevented lumbrical muscle incursion into the tunnel. These results should be interpreted with caution due to the small sample size, lack of blinding and opportunity for bias, as the lead author was the inventor of the orthosis.<sup>179</sup>

**III** In additional cross-sectional studies, Keir et al<sup>148</sup> and Rempel et al<sup>237</sup> noted the impact of MP joint and forearm position on carpal tunnel pressure. Keir et al<sup>148</sup> reported that the position of the MP joints had a significant effect on carpal tunnel pressure during passive wrist motion in all planes, with 0° of MP flexion producing the highest pressures, 90° of MP flexion the next highest, and 45° of MP flexion the least pressure in 14 asymptomatic<sup>237</sup> individuals. Rempel et al<sup>237</sup> reported the highest carpal tunnel pressures were recorded during active forearm supination with 90° of MP joint flexion and the lowest were recorded with the forearm actively positioned in 45° of pronation with 45° of MP joint flexion. Participants (*n* = 17) maintained a neutral wrist position (0° of flexion/extension, 0° of ulnar/radial deviation) during the trial.

**Orthosis Prescription**

Orthosis prescription consists of duration and length of wear.

**II** In a randomized clinical trial, Walker et al<sup>284</sup> compared full-time use of a custom-fabricated, thermoplastic neutral wrist orthosis with night-only use in 17 individuals (24 hands) with CTS symptoms of all severity levels. Following 6 weeks of treatment, both groups showed improvement in median DSL, CTQ-SSS, and the CTQ-FS. The full-time orthosis group also demonstrated improved DML compared to the night-only group. Adverse effects were not reported. Page et al’s<sup>221</sup> analysis revealed MDs favoring the full time wear group (CTQ-SSS MD, -0.21; 95% CI: -0.83, 0.41; CTQ-FS MD, -0.21; 95% CI: -0.87, 0.45; DML MD, -0.63; 95% CI: -2.05, 0.79; and DSL MD, 0.05; 95% CI: -0.87, 0.45) compared to night use but concluded the bidirectional ESs and low effect estimate precision prevented identification of a benefit of full-time use compared to night-only use.

**Orthosis Versus Tendon and Nerve Gliding Exercises**

**II** In a RCT, Schmid et al<sup>252</sup> compared the short-term effects of a prefabricated, night wrist orthosis (unspecified wrist position) versus tendon and nerve gliding exercises (10 repetitions performed 10 times per day) on signal intensity changes and palmar ligament bowing recorded via magnetic resonance imaging (MRI), CTQ (combined SSS and FS) scores, pain VAS, numbness VAS, and patient-specific functional scale scores. Authors examined 20 participants at baseline, 10 minutes following the intervention (MRI changes only), and at 1 week following the inter-

vention. Results following 1 week of treatment indicated that both groups improved in median nerve signal intensity at the carpal tunnel inlet ( $P = .036$ ), combined CTQ scores (MD,  $-0.3$  for both groups;  $P = .001$ ), and the patient-specific functional scale (MD,  $2.1$  for exercise and  $2.9$  for the orthosis;  $P < .05$ ). Numbness VAS scores did not change significantly following either treatment. Authors concluded the decrease in MRI signal intensity could represent either a decrease in edema or a decrease in blood flow.<sup>252</sup>

### Orthosis Versus Oral Steroid

**II** In a RCT, Mishra et al<sup>192</sup> ( $n = 40$ ) compared a neutral prefabricated orthosis worn for 4 weeks at night and “as much as possible” during the day with 4 weeks of oral steroid use. Both groups improved on the CTQ-SSS and CTQ-FS at the end of 4 and 12 weeks ( $P < .001$ ). Both groups improved on DSL and SNCV at 12 weeks compared to baseline ( $P < .03$ ). The oral steroid group also improved on DML at 12 weeks ( $P = .001$ ). The only significant differences between the 2 groups were for the CTQ-FS at 4 and 12 weeks ( $P < .03$ ) and for SNCV at 4 weeks ( $P < .047$ ), favoring the steroid intervention. Madjdinasab et al<sup>176</sup> compared 6 weeks of orthosis use (commercially available orthosis worn at night and as long as possible during the day) to 2 weeks of oral prednisolone (20 mg/d) use in 43 individuals with mild to moderate CTS. Outcome measures included median DSL, DML, and sensory and motor conduction velocity and were evaluated at baseline and 6 weeks. Both groups showed improvement in DSL and SNCV at 6 weeks ( $P = .0001$ ). There were no statistically significant differences on any outcome measure between the 2 groups.

### Orthosis Versus Steroid Injection

**II** In a randomized, parallel clinical trial, So et al<sup>264</sup> compared the effects of a local steroid injection versus a cotton-polyester, neutral wrist orthosis after 4 weeks of treatment in 50 individuals (25 per group) with CTS (all severities). Outcome measures included the CTQ-SSS, CTQ-FS, patient satisfaction, the Nine-Hole Peg Test, duration of sick leave, pain medication use, and side effects. Both groups showed statistically significant improvement on the CTQ-SSS and CTQ-FS ( $P < .022$ ), and the steroid group improved on the Nine-Hole Peg Test ( $P = .038$ ). The only change score to reach clinical significance was the CTQ-SSS for the steroid group ( $-0.67$ ). There were differences between the 2 groups on patient satisfaction (MD between groups was equal to 2 points on 5-point numeric rating scale;  $P = .04$ ) and use of pain medication (measured in days of use; raw data not provided;  $P = .04$ ), favoring the injection. There were no other differences between the 2 groups at 4 weeks after treatment. Four individuals in the orthosis group reported discomfort while wearing the device, and 3 individuals in the injection group reported short-lasting pain after the injection.

**II** In a RCT, Chesterton et al<sup>63</sup> compared the effects of a steroid injection ( $n = 96$ ) to 6 weeks of night-time prefabricated wrist orthosis use ( $n = 96$ ). The orthoses were positioned from “neutral to  $20^\circ$  of extension.” Outcomes were collected at 6 weeks and 6 months. Measures included CTQ-total score, CTQ-SSS, CTQ-FS, pain intensity, insomnia due to hand/wrist pain, referral to surgery, surgery, use of herbal remedies at 6 months, and use of over-the-counter or prescription medication use at 6 months. Authors reported significant improvement in the injection group at 6 weeks in the CTQ total score (adjusted MD,  $-0.32$ ; 95% CI:  $-0.48, -0.16$ ;  $P = .0001$ ) and similar findings in the CTQ-SSS (adjusted MD,  $-0.35$ ; 95% CI:  $-0.53, -0.17$ ;  $P = .0001$ ), CTQ-FS scales (adjusted MD,  $-0.26$ ; 95% CI:  $-0.43, -0.09$ ;  $P = .0031$ ), and pain intensity (adjusted MD,  $-0.97$ ; 95% CI:  $-1.64, -0.30$ ;  $P = .0049$ ) compared to the orthosis group. However, at the 6-month follow-up, the orthosis group continued to improve on the CTQ scales and in pain intensity while the injection group did not, and there were no significant differences between the 2 groups on any of the outcome variables studied at this time point. Adverse effects were reported by both groups. The steroid group adverse effects included skin changes (3%), hot flushes (15%), and transient increase in wrist or hand pain (46%), with 34% reported pain lasting greater than 3 days. In the night support group, 6% reported the supports were uncomfortable, resulting in inconsistent use.<sup>63</sup>

### Orthosis Versus CTR

**II** In a single-blinded trial, Gerritsen et al<sup>108</sup> compared the short and long-term effectiveness of orthoses (fabricated or off-the-shelf, worn at night and during the day as needed) and CTR in 147 individuals with mild-to-moderate idiopathic CTS. Participants were randomly assigned to use the orthosis for 6 weeks or to undergo surgery (open CTR). Participants were assessed at 1, 3, 6, 12, and 18 months (84% retention) post randomization. Primary outcome measures were self-reported improvement, number of nights of symptom-disturbed sleep, and the severity of the patient-determined “most important symptom” (ranked on an 11-point scale). Secondary measures included CTQ scales and electrodiagnostic studies. Treatment success was defined as completely recovered or much improved on a patient-reported 6-point scale ranked from “completely recovered” to “much worse.” At 1 month, the orthosis group showed greater success (42% versus 29% for the surgery group), but at all other time points, more participants in the surgery group reported greater success. At 18 months, 90% of surgery participants reported successful treatment compared to 75% of participants in the orthosis group. By 18 months, 41% of those in the orthosis group had undergone surgery. In the surgery group, 67% of patients reported adverse effects compared to 52% of the orthosis group. These effects included



complex regional pain syndrome, pillar pain, swelling, discomfort from the orthosis, wound complications, skin irritation, wrist stiffness, and painful or hypertrophic scars. Because these were reported in the original assigned groups, comparison of the rates of adverse effects between interventions could not be made.

**II** In a nonblinded, randomized trial, Ucan et al<sup>277</sup> studied 57 participants with mild to moderate CTS divided into 3 groups: neutral-positioned, prefabricated wrist orthosis worn at night and during the day “whenever possible” (n = 23), a local steroid injection and orthosis (n = 23), or open CTR surgery (n = 11). Nonsurgically-managed participants wore the orthoses for 3 months. Outcomes were evaluated using the NCS results and CTQ scales at 3 and 6 months. At 3 months, all 3 groups demonstrated statistically significant improvements in median DML, CMAP, SNCV, and CTQ scales ( $P < .006$ ). For the CTQ-SSS, the CTR group score was higher (indicating greater symptoms) than the other 2 groups ( $P < .011$ ), and for the CTQ-FS, the orthosis and CTR group demonstrated higher scores (indicating more difficulty with function) than the injection and orthosis group ( $P = .001$ ). At 6 months, all groups remained statistically improved in DML, CMAP, SNCV, and CTQ scales. For the CTQ scales, the CTR group scores continued to improve compared to the other groups (CTQ-FS,  $P = .03$ ; CTQ-SSS,  $P = .004$ ) while the other 2 groups’ scores worsened. Complications were reported for 2 of the participants in the CTR surgery group: one with scar tenderness which resolved and one developed complex regional pain syndrome.<sup>277</sup>

#### Orthosis Combined With Patient Instruction

**II** Hall et al<sup>125</sup> concluded CTS management consisting of a full-time, neutral-positioned wrist orthosis plus patient instruction was more effective than no intervention. In this randomized, single-blinded trial, 30 patients with all severity levels of CTS wore 1 of 3 commercially available supports or a custom-fabricated wrist orthosis for 8 weeks and attended 2 sessions of patient instruction (pathology, risk identification, symptom self-management, and postures/activities that aggravate symptoms including sleeping postures and repetitive wrist and hand movements). The 24 participants in the control-group received no intervention. At the end of the treatment period, the orthosis group showed statistically significant improvements in the CTQ (CTQ-SSS MD, -0.42 versus control MD, 0.03;  $P < .001$ ; CTQ-FS MD, -0.20 versus control MD, 0.08;  $P = .015$ ) and pain VAS (MD, -1.58 versus control MD, 0.65;  $P = .001$ ). Improvement was significant for grip strength, but the control group demonstrated greater grip improvement (MD, 1.85 kg versus 1.07 kg;  $P = .02$ ) than the intervention group. No significant changes were demonstrated for Phalen’s test, PPB test, or SWMT for either group.<sup>125</sup>

#### Orthosis Combined With Steroid Injection

**II** Wang et al<sup>285</sup> studied the effect of an ultrasound-guided steroid injection into the carpal tunnel combined with orthosis use compared to the injection alone in 52 individuals with mild or moderate CTS in a RCT. Participants in the experimental group wore a volar, custom-fabricated neutral wrist orthosis during sleep and as much as possible during the day for 12 weeks following injection. Outcome measures included CTQ scores, pain VAS, and NCS results, and they were evaluated at baseline and 6 and 12 weeks. Both groups showed significant improvement in CTQ scores, VAS, DML, SNCV, and SNAP at 6 and 12 weeks ( $P < .001$ ). There were no differences between the groups at 6 or 12 weeks. At 12 weeks, the response to treatment diminished in the injection-alone group (CTQ-SSS increased, which suggests worsening symptoms from 1.28 to 1.49 between 6 and 12 weeks), while the effects of treatment in the combined group remained. There were statistical differences in change scores between groups at 12 weeks in the CTQ-SSS (MD, 0.48; 95% CI: 0.09, 0.88;  $P = .032$ ), CTQ-FS (MD, 0.37; 95% CI: 0.06, 0.67;  $P = .019$ ), SNCV (MD, 3.38; 95% CI: 0.54, 6.22;  $P = .015$ ), and SNAP (MD, 3.21; 95% CI: 0, 6.46;  $P = .025$ ) favoring the combined treatment. The authors concluded the combined treatment had sustained effects on sensation, function, and NCS that were not present in the injection-only group.<sup>285</sup>

#### Orthosis During Pregnancy

**IV** Courts<sup>75</sup> evaluated grip, pinch, and symptom reduction following the use of a wrist orthosis positioned in 10° to 15° of extension in a group of women who developed CTS during pregnancy (n = 82). The orthoses were worn at night and during the day. After 1 week, grip and pinch strength improved and symptoms were reduced. Of the 58% participants who returned postpartum, 76% reported complete resolution of symptoms. Ekman-Ordeberg et al<sup>86</sup> reported that 82% of 56 pregnant women with carpal tunnel symptoms improved after wearing a night wrist orthosis for 2 weeks and 93% were resolved postpartum.

#### Evidence Synthesis and Clinical Rationale

The use of an orthosis for treatment of CTS is widely accepted despite the lack of high-quality studies. There are limited data supporting orthosis use over no intervention to improve symptoms and function in the short term for individuals with mild or moderate severity of CTS. The most frequently studied orthoses were commercially available wrist orthoses (multiple manufacturers and designs) and custom-fabricated volar or ulnar orthoses immobilizing the wrist or adding the MP and IP joints in a variety of positions. Some studies used a variety of wrist supports within the same experimental group. Evidence from basic science studies supports positioning the wrist near neutral in both the sagittal and frontal planes, although

individual variation has been demonstrated. Including the MP joints has shown positive effects in clinical and bench studies, although the evidence on the desired angle is conflicting (0°-10° versus 45°) and MP joint inclusion further limits functional use during wear.

There are conflicting results comparing an orthosis to oral steroid use in the short term; however, when an orthosis was compared to steroid injection, results favored the injection in the short term.<sup>63,264</sup> However, the effects of the 2 treatments when implemented separately, were equal at 6 months post treatment.<sup>63</sup> When an orthosis was combined with a steroid injection, the effects were superior to the injection alone.<sup>277,285</sup> Drawing conclusions is difficult in these studies due to the lack of a control group. Adverse reactions for the steroid injection include thinning skin, pigment changes, hot flushes, and increased pain.<sup>63</sup>

When comparing an orthosis to surgery, the orthosis demonstrated improvement over surgery in the short term, but long-term results favored surgery.<sup>109,277</sup> Surgery is associated with increased cost and may have a higher rate of complication as reported in these studies. Reported surgical risks included pillar pain, wound complications, swelling, and hypertrophic or painful scars. Reported orthosis risks included difficulty falling asleep, temporary paresthesia upon removal, stiffness, skin irritation, discomfort, and swelling. An additional risk is skin breakdown, especially when sensation is impaired and the orthosis does not fit properly. The availability of prefabricated orthoses and the lower cost make this a convenient intervention; however, the angle of wrist immobilization varies among manufacturers and should be checked and adjusted by a practitioner to find the most comfortable angle for the patient. The use of a neutral-positioned orthosis may reduce symptoms for individuals considering or waiting for surgery. There is evidence to support orthosis use in the short term for relieving symptoms and improving strength in women who develop CTS during pregnancy.

### Gaps in Knowledge

There is no consensus on the most appropriate orthosis material, design, prescription, or position, or evidence to accurately identify ideal candidates for orthosis intervention. Many studies lacked a control group, an adequate sample size, adequate randomization, and/or blinding. Most studies lacked participant compliance data for orthosis use, as well as use of meaningful, validated outcome measures. Many studies were confounded by the use of multiple interventions, masking the effect of any single intervention. Identification of the most effective orthosis characteristics should be determined prior to investigating combining nonsurgical interventions. The majority of studies enrolled patients with mild to moderate CTS and no conclusion can be drawn with

respect to the effects of orthoses on those with severe CTS. A noninvasive tool for measuring carpal tunnel pressure could provide guidance regarding individual wrist and MP joint positioning.

### Recommendations

**B** Clinicians should recommend a neutral-positioned wrist orthosis worn at night for short-term symptom relief and functional improvement for individuals with CTS seeking nonsurgical management.

**C** Clinicians may suggest adjusting wear time to include daytime, symptomatic, or full-time use when night-only use is ineffective at controlling symptoms in individuals with mild to moderate CTS. Clinicians may also add MP joint immobilization or modify the wrist joint position for individuals with CTS who fail to experience relief. Clinicians may add patient education on pathology, risk identification, symptom self-management, and postures/activities that aggravate symptoms.

**C** Clinicians should recommend an orthosis for women experiencing CTS during pregnancy and should provide a postpartum follow-up evaluation to examine the resolution of symptoms.

### BIOPHYSICAL AGENTS

#### Thermotherapy

##### Dry Heat

**II** In a randomized, single-blinded trial, Michlovitz et al<sup>191</sup> compared the effect of a disposable wrist low-level heat wrap to an oral placebo in 24 individuals diagnosed with CTS (all severities). The heat wrap was worn for 8 hours per day while the control group took an oral placebo 4 times per day. Both groups were treated for 3 days and followed for an additional 2 days. After 3 days, the heat wrap group demonstrated improved outcomes relative to the placebo group including reduced pain (MD, -2.18 versus -0.95;  $P = .001$ ); reduced joint stiffness (MD, -21.8 versus -4.9;  $P = .004$ ); increased grip strength (MD, 6.6 versus -0.3;  $P = .003$ ); self-reported disability scores (MD, -27.1 versus -2.67;  $P = .0015$ ); CTQ-SSS (MD, -0.90 versus -0.20;  $P = .001$ ) and CTQ-FS (MD, -0.65 versus 0.00;  $P = .006$ ). While the symptom improvements for both groups persisted to day 5, improvement in CTQ-FS scores did not. Adverse effects reported for the heat wrap included coldness in the fingers and for the oral placebo, dyspepsia.<sup>191</sup>

##### Paraffin

**II** Chang et al<sup>87</sup> compared the use of paraffin (dip-and-wrap applied for 20 minutes) to pulsed, direct-contact ultrasound (1 MHz, 1.0 W/cm<sup>2</sup>, 1:4 duty

cycle, 5-cm<sup>2</sup> sound head, 5 minutes) given twice per week for 8 weeks in 47 patients with CTS (all severities) in a RCT. Participants in both groups wore a custom-fabricated neutral wrist orthosis at night for 8 weeks. Outcome measures included the CTQ-SSS and CTQ-FS, pain scale, sensory threshold, palmar pinch strength, DML, and DSL. After 8 weeks, both groups improved on the CTQ-SSS (ES for both groups was equal to 0.63) and sensory threshold ( $P < .03$ ). The ultrasound group demonstrated significant improvement in CTQ-FS, pain scale, and palmar pinch following treatment when compared to baseline; however, the only significant difference between the paraffin and ultrasound groups was the CTQ-FS score favoring ultrasound (MD, -0.3 compared to paraffin MD, 0.1;  $P = .04$ ; ES, 0.38). A limitation of this study was that there was no control group. No adverse effects were reported.<sup>57</sup>

### Microwave and Shortwave Diathermy

**II** Frasca et al<sup>99</sup> compared the effectiveness of microwave diathermy to sham diathermy in patients with idiopathic mild to moderate CTS. In this double-blind trial, 22 patients (34 hands) were randomized to receive active or sham microwave diathermy for 20-minute sessions, twice weekly for 3 weeks. Outcome measures included pain VAS, CTQ-SSS, CTQ-FS, and NCS (DML and sensory NCV). At the end of 3 weeks, the active treatment group demonstrated statistically significant improvement in pain severity (MD, -2.0;  $P = .002$ ), CTQ-SSS (MD, -0.54;  $P = .0001$ ), and CTQ-FS (MD, -0.50;  $P = .002$ ). There were significant differences between the active and sham treatment groups in pain severity ( $P = .004$ ) and CTQ-SSS ( $P = .009$ ) but not in the CTQ-FS. There were no significant differences for either group in electrophysiology parameters studied. There were no reported adverse effects.<sup>99</sup>

**II** Incebiyik et al<sup>136</sup> compared the effectiveness of shortwave diathermy combined with a hot pack and nerve and tendon gliding exercises to sham shortwave diathermy in 28 patients (52 wrists) with mild to moderate severity CTS in a randomized, double-blinded, placebo-controlled study. Participants received a hot pack application for 15 minutes followed by sham or active shortwave diathermy for 15 minutes, followed by 3 sets of 10 repetitions of nerve and tendon gliding exercises. Treatments were given 5 times per week for 3 weeks. Outcome variables included the Tinel sign, Phalen test, reverse Phalen test, carpal compression test, pain VAS, CTQ-SSS, and the CTQ-FS. At the end of 3 weeks, improvement in all outcome variables for the active treatment group were statistically better than the sham group ( $P < .003$ ). The MDs between the 2 groups for pain, CTQ-SSS, and CTQ-FS were 1.88, 9.09, and 8.37. There was no significant improvement in any outcome measure for the sham group. Adverse effects were not provided.<sup>136</sup>

### Evidence Synthesis and Clinical Rationale

Studies have shown positive, short-term effects of using superficial heat in individuals with CTS. Heat wraps, paraffin, and shortwave and microwave diathermy have shown positive effects in the short term. When combined with an orthosis, the use of paraffin was not superior to pulsed ultrasound.<sup>57</sup> Individuals with CTS should be instructed in the risks of applying thermal agents to sensory-impaired tissue and should be advised to perform frequent skin checks. Heat should not be used in the presence of inflammation.

Diathermy is contraindicated in areas where sensation is severely impaired and over areas with metal implants. It should not be performed on a patient who is pregnant or be performed by a pregnant operator.<sup>37</sup> Other forms of superficial heat (wrist heat wrap) have shown similar results and can be done without concerns for pregnancy, metal implants, or need for clinic visits and can be delivered at lower expense.

### Recommendations

**C** Clinicians may recommend a trial of superficial heat for short-term symptom relief for individuals with CTS.

**C** Clinicians may recommend the application of microwave or shortwave diathermy for short-term pain and symptom relief for patients with mild to moderate idiopathic CTS.

### Electrical Stimulation Interferential Current

**II** Koca et al<sup>150</sup> randomly allocated 63 individuals with mild to moderate CTS to a prefabricated, night-wear wrist orthosis group (wrist positioned in 0° to 15° of extension), a transcutaneous electrical nerve stimulation (TENS) group (100 Hz; 80-millisecond pulse duration) with electrodes placed on the transverse carpal ligament and the palm, or an interferential current (IFC) group (base frequency, 4000 Hz; modulation frequency range, 20 Hz; change in  $F$  of 10 Hz; slope of 1/1) using a quadrupolar electrode placement with 2 electrodes on the mid portion of the volar forearm, 1 on the palm, and 1 on the thenar eminence area. Electrical modalities were administered for 20 minutes, 5 times per week for 3 weeks. Outcomes were measured by pain VAS, CTQ-SSS, CTQ-FS, and NCS. At 3 weeks post treatment, all groups improved significantly on VAS, CTQ-SSS, CTQ-FS, and median SNCV but not on DML. There were no statistically significant differences between the orthosis and TENS groups. The IFC group was significantly better than the other groups for 6-week pain VAS (4.80 for IFC group versus 6.37 for orthosis group and 6.68 for TENS group,  $P < .01$ ) and for SNCV (41.80 for IFC group versus 40.75 for orthosis group and 41.38 for TENS group,  $P < .05$ ).

The IFC group demonstrated significant improvement over the TENS group for CTQ-SSS (MD, -1.2 compared to TENS MD, -0.69;  $P < .05$ ) and CTQ-FS (MD, -0.90 versus TENS MD, -0.43;  $P < .05$ ), but there was no difference compared to the orthosis scores. In this study, IFC demonstrated greater pain change scores than orthosis or TENS; however, the small sample size and lack of a control group weakened the result. The frequency of IFC treatment (5 days per week) and additional cost may not be justified in light of other nonsurgical interventions. Interferential current should not be used in patients with a pacemaker.<sup>37</sup>

**C** Clinicians may offer a trial of IFC for short-term pain symptom relief in adults with idiopathic, mild to moderate CTS. As with all electrical modalities, contraindications should be taken into consideration before choosing this intervention.

#### Light Agents

**II** Low-level laser therapy (LLLT) is a form of electromagnetic energy that is monochromatic (single wavelength) and coherent (in phase).<sup>52</sup> In a recent, high-quality Cochrane review, Rankin et al<sup>236</sup> reviewed 22 RCTs on LLLT for treatment of CTS published through December 2016. Trials compared LLLT to placebo and other nonsurgical interventions. Authors concluded there was insufficient evidence of a clinical effect of LLLT in the nonsurgical management of CTS. They also concluded there was insufficient evidence to support long-term benefits of LLLT versus placebo or ultrasound.<sup>236</sup>

**II** Raeissadat et al<sup>234</sup> used Bioptron light therapy, a form of nonlaser, low-energy light therapy (polychromatic, incoherent) with wavelengths ranging from 480 to 3400 nm in 44 adult patients with mild or moderate CTS in a nonblinded, RCT. The experimental group received 12 eight-minute light treatments over a 4-week period and wore a neutral wrist orthosis full time except for hygiene. The control group also wore the orthosis but did not receive the light therapy. Outcome measures included pain VAS and electrophysiological parameters. At 8 weeks, both groups demonstrated improvement in pain VAS (control MD, -2.28;  $P < .05$  and light therapy MD, -2.42;  $P < .05$ ) and median DSL (control MD, 0.23 m/s;  $P < .05$  and light therapy MD, 0.18 m/s;  $P < .05$ ), but there were no statistical differences between the 2 groups on any measure ( $P > .05$ ). There were no adverse effects.<sup>234</sup>

**IV** Stasinopoulos et al<sup>268</sup> also applied Bioptron light therapy for 6 minutes 3 times per week for 4 weeks in patients with idiopathic mild to moderate CTS ( $n = 25$ ) and provided outcome data using descriptive statistics. At 4 weeks, 92% reported improvement in nocturnal

pain and 84% reported improvement in paresthesia. At the 6-month follow-up, 100% reported improvement in night pain and 36% were pain free. Paresthesia improved in 92% of participants and 28% had complete resolution. The results of this study are inconclusive due to the lack of blinding, not using validated outcome measures, a small sample size, and lack of a control group.<sup>268</sup>

#### Evidence Synthesis and Clinical Rationale

There is no evidence of a biological effect of LLLT or light therapy on CTS. There is a lack of consensus regarding the optimal wavelength, dosage, frequency, and duration of treatment. Side effects of LLLT, including pain and tingling that subsided after the treatment, have been reported<sup>236</sup>; however, Rankin et al<sup>236</sup> concluded there is insufficient evidence on adverse events.

#### Recommendation

**B** Clinicians should **not** use LLLT or other types of nonlaser light therapy for individuals with CTS.

#### Sound Agents

##### Ultrasound

**II** Oztas et al<sup>218</sup> compared 2 different continuous ultrasound intensities to sham ultrasound in 18 female participants (30 hands; 10 per group) with mild to moderate idiopathic CTS of more than 6 months duration in a single-blinded, randomized, placebo-controlled study. Groups were treated with 3-MHz ultrasound applied for 5 minutes at either 1.5 W/cm<sup>2</sup>, 0.8 W/cm<sup>2</sup>, or 0.0 W/cm<sup>2</sup> (sham), 5 times per week for 2 weeks. Outcomes were measured 5 days after the last session and included pain VAS, night or day pain or paresthesia (4-point scale), frequency of night waking (4-point scale), and NCS. All groups improved significantly in all outcome measures ( $P < .05$ ) except NCS ( $P > .05$ ). There were no statistically significant differences between the 3 groups on any outcome measure.<sup>218</sup>

**II** Armagan et al<sup>17</sup> compared pulsed (1:4) and continuous ultrasound (1.0 MHz, 1.0 W/cm<sup>2</sup>) to sham ultrasound (0.0 W/cm<sup>2</sup>) in 46 females with mild to moderate idiopathic CTS in a prospective, randomized, double-blinded study. The length of each treatment session was not reported, but the frequency and duration were 5 times per week for 3 weeks. All participants also wore a custom-fabricated orthosis (night and day) during the treatment period. Outcome measures included CTQ-SSS, CTQ-FS, pain VAS, and NCS. At the end of 3 weeks, there was significant improvement in all groups in the CTQ scales ( $P < .05$ ) and VAS ( $P < .01$ ), but there were no significant differences between groups ( $P > .08$ ). For DSL and SNCV, there were small, but statistically significant improvements in the pulsed ultrasound and sham groups from baseline ( $P < .05$ ) but no differences between the groups

for any NCS values ( $P > .09$ ).<sup>17</sup> Due to the lack of a true control group, the difference could have been due to the orthosis or the natural course of the disease.

**II** In a randomized double-blinded trial, Ebenbichler et al<sup>85</sup> compared sham ultrasound to pulsed ultrasound (25% duty cycle; 1 MHz; 1.0 W/cm<sup>2</sup>) applied for 15 minutes in 34 adults with bilateral, mild to moderate idiopathic CTS (duration greater than 6 months). Participants were treated for 7 weeks (5 times per week for 2 weeks and twice weekly for 5 weeks) for a total of 20 sessions. Outcome measures included grip and pinch strength, NCS (DML and SNCV), VAS for pain, paresthesia, worst complaint, sensory loss, and overall improvement (5-point scale). Changes in scores were evaluated between baseline and 2 weeks, 7 weeks (end of treatment), and 6 months post treatment. Self-reported measures favored the active treatment at each time point ( $P < .05$ ) except for worst pain at 2 weeks ( $P = .125$ ). Grip strength was better in the active treatment group at 7 weeks (active treatment MD, 3.87 kg versus sham MD, -0.09 kg;  $P < .0005$ ) and 6 months (active treatment MD, 5.44 kg versus sham MD, -1.99 kg;  $P < .0005$ ). Pinch strength was better in the treatment group compared to the control group at 6 months (active treatment MD, 0.49 kg versus sham MD, -0.22 kg;  $P = .014$ ). All nerve conduction study data favored the active treatment group at each time point ( $P < .001$ ). Good or excellent results were reported by 76% of individuals in the active treatment group compared to 32% of individuals in the sham group.<sup>85</sup> No adverse effects of ultrasound treatment were reported.

**II** In a randomized, single-blinded trial of 46 wrists with bilateral mild-to-moderate CTS, Baysal et al<sup>35</sup> compared 3 groups: (1) pulsed ultrasound plus an orthosis; (2) tendon and nerve gliding plus an orthosis; and (3) pulsed ultrasound plus tendon and nerve gliding plus an orthosis. All orthoses were custom-fabricated (volar, neutral position, worn day and night for 3 weeks), and ultrasound treatments were provided using 1:4 duty cycle, 1.0 MHz at 1.0 W/cm<sup>2</sup> for 15 minutes. The ultrasound was delivered 5 times per week for 3 weeks. Outcomes were assessed at the end of treatment and at an 8-week follow-up, and included pain VAS, presence of a positive Tinel sign and Phalen test, grip and pinch strength, 2PD, CTQ-SSS, CTQ-FS, DSL, DML, and patient satisfaction. All groups improved in all measures at the 3- and 8-week follow-ups ( $P < .05$ ) except 2PD and DML (no group improved;  $P > .05$ ), and DSL (only the ultrasound-orthosis and ultrasound-exercise-orthosis groups improved;  $P < .05$ ). For patient satisfaction, 25% of the exercise-orthosis group reported excellent/good satisfaction, and 61% of the exercise-ultrasound-orthosis group reported excellent/good satisfaction. There were no significant differences between groups on any outcome variable.<sup>35</sup> The improvement cannot be attributed to a single intervention or to

the combination of interventions due to the lack of a control group.

### Evidence Synthesis and Clinical Rationale

Based on the results of 2 level II randomized studies, thermal ultrasound has not been shown to be better than sham ultrasound.<sup>17,218</sup> Evidence on pulsed ultrasound is conflicting. One study found positive benefits, but authors reported a priori differences between groups in subjective complaints and grip strength (active ultrasound treatment being worse) that may suggest greater severity in this group.<sup>85</sup> Also, based on findings from studies where ultrasound was combined with other treatments, there is conflicting evidence on the benefit of adding nonthermal ultrasound to treatment regimens that include an orthosis and/or tendon and nerve gliding exercises.<sup>17,35,57</sup> Last, there is insufficient evidence to support 1.5 W/cm<sup>2</sup> versus 0.8 W/cm<sup>2</sup>, and there is insufficient evidence to support 1 MHz versus 3 MHz.<sup>218</sup> Given the additional treatment expense and time commitment, there is not enough evidence for or against the use of nonthermal ultrasound in patients with mild to moderate CTS.

### Gaps in Knowledge

High-quality, controlled studies on the effects of both thermal and pulsed ultrasound in individuals with CTS are needed.

### Recommendations

**C** Clinicians should **not** use thermal ultrasound in the treatment of patients with mild to moderate CTS.

**D** There is conflicting evidence on the use of nonthermal ultrasound in the treatment of patients with mild to moderate CTS, and therefore no recommendation can be made.

### Transdermal Drug Delivery

The use of topical anti-inflammatory drugs, both steroid and nonsteroid, has been investigated for treatment of CTS based on the inflammatory model of pathology. Localized inflammation has been suggested to contribute to the pathology of CTS in 1 of 4 ways: by decreasing the space in the tunnel due to the presence of inflammatory infiltrates, decreasing the circulation within the median nerve due to intraneural infiltrates, fibrosis of the nerve due to inflammatory infiltrates, or increasing the work of the flexor tendons gliding through resistance produced by inflammatory infiltrates.

### Phonophoresis

**II** In a double-blinded trial, Yildiz et al<sup>301</sup> randomized 51 adults (76 hands) with idiopathic mild to moderate CTS to 1 of 3 groups: sham ultrasound, active pulsed ultrasound, or 2.5% ketoprofen gel phonophoresis. Forty-four individuals (68 wrists) completed the protocol.

Intention-to-treat analysis was performed using all participants who were initially randomized. Ultrasound parameters for the active treatment groups were: 1 MHz frequency, 1.0 W/cm<sup>2</sup>, and 25% duty cycle. Participants were treated for 15 minutes, 5 times per week for 2 weeks. Participants also wore custom-fabricated volar wrist orthoses (0°-5° of wrist extension) full time for 8 weeks. Outcomes were measured at 2 and 8 weeks, and included CTQ scales, pain VAS, and NCS. All groups improved in all measures; however, the phonophoresis group improvement for the pain VAS (MD, -5.06) was statistically greater than the other 2 groups (sham ultrasound MD, -2.48;  $P = .002$ ; pulsed ultrasound MD, -2.19;  $P = .004$ ). There were no other statistically significant differences between the 3 groups.<sup>301</sup> Authors reported there were no complications from the interventions.

**II** Soyupek et al<sup>266</sup> compared 4 different interventions for mild to moderate CTS. In this randomized, single-blinded (assessors) trial, 51 patients (84 hands) were assigned to 1 of 4 groups: local steroid injection (LSI group), corticosteroid (0.1% betamethasone valerate cream) phonophoresis (PCS group), NSAID (diclofenac diethylammonium gel) phonophoresis (PNS group), or a volar, neutral wrist orthosis. Phonophoresis was applied at 3 MHz, 1.5 W/cm<sup>2</sup> for 10 minutes, 5 days per week for 3 weeks using a 5-cm<sup>2</sup> sound head. The orthoses were worn full time for 15 days, and only when symptomatic for the remaining 6 days. Outcome data were collected at baseline and 3 months following treatment. There were significant baseline differences for some outcome measures between the groups (Duruöz Hand Index, SNCV, SNAP, DSL), but no baseline differences for grip strength, hand dexterity, sensory threshold (SWMT), Phalen sign, Tinel test, VAS. The only statistically significant difference between groups was for Tinel sign, favoring PCS group ( $P = .04$ ). Pretreatment and posttreatment differences for the PCS group were significant for Tinel's ( $P \leq .003$ ), grip ( $P \leq .003$ ), SWMT of the middle finger ( $P = .046$ ) and NCS (SNCV, MDL, DSL) ( $P \leq .049$ ). The PNS group demonstrated improvement in pain VAS, grip and dexterity ( $P \leq .003$ ). The orthosis group demonstrated improved pain VAS ( $P = .006$ ) and DSL ( $P = .002$ ), and the LSI group improved in the Duruöz Hand Index and pain VAS ( $P \leq .006$ ). Authors concluded the greatest improvements were observed with the PCS group in strength, function, SNCV, DSL, and DML, and with the PNS group for pain.<sup>266</sup>

**II** In another study, Soyupek et al<sup>267</sup> compared phonophoresis with corticosteroid (PCS), phonophoresis with NSAID (PNS) (medications listed above), and volar neutral wrist orthoses in patients with mild to moderate CTS. In this trial, 47 patients (74 hands) were randomized into 1 of the 3 groups. Phonophoresis was applied at 3 MHz, 1.5 W/cm<sup>2</sup> for 10 minutes, 5 days per week for 3 weeks using a 5-cm<sup>2</sup>

sound head. After 3 months, all groups improved in all clinical measures. The PCS group scores improved for VAS (MD, -30;  $P < .017$ ), CTQ (MD, -1.5;  $P < .017$ ), percentage of participants with positive Phalen test (MD, -32.1%;  $P < .017$ ), Tinel sign (MD, -39.3%;  $P < .017$ ), and nerve dimensions, as measured by ultrasound imaging (anterior-posterior MD, -0.24; cross-sectional area MD, -0.03;  $P < .017$ ) (unit of measure not reported). The PNS group scores improved in VAS (MD, -23.48;  $P < .017$ ), CTQ (MD, -1.18;  $P < .017$ ) and percentage of subjects with positive Phalen sign (MD, -32.9%;  $P < .017$ ). The orthosis group scores improved in CTQ-SSS (MD, -1.54;  $P < .017$ ). No group improved in nerve conduction measures ( $P > .017$ ).<sup>267</sup>

### Iontophoresis

**II** Amirjani et al<sup>14</sup> performed a randomized, double-blinded study of 17 individuals with mild to moderate CTS comparing iontophoresis with 0.4% dexamethasone sodium phosphate to distilled water iontophoresis. The treatment was administered every other day for 2 weeks, for a total of 6 treatments at a rate of 2 mA-min, for a total treatment dosage of 80 mA-min. Participants were followed monthly for 6 months after treatment. Outcome measures included CTQ total score (SSS and FS), sensory threshold (measured using the SWMT), and NCS. At 6 months post treatment, both the treatment and sham group showed similar improvements on CTQ scores (distilled-water iontophoresis median difference, -2.0;  $P = .028$ ; steroid iontophoresis median difference, -12;  $P < .05$ ), and the difference between the groups was not significant ( $P = .25$ ). There were no significant improvements for either group in sensory threshold ( $P \geq .10$ ) or nerve conduction ( $P \geq .10$ ). One participant reported skin erythema under the electrode which resolved in a few hours.<sup>14</sup>

**II** In a randomized, unblinded trial, Gökoğlu et al<sup>112</sup> compared a single 40-mg methyl prednisone acetate injection with 3 sessions of iontophoresis (0.4% dexamethasone sodium phosphate) in 30 individuals (48 hands) with mild to moderate CTS. The iontophoresis was applied every other day for 20 minutes for a total dosage of 40 to 45 mA-min. Outcomes were measured at 2 and 8 weeks and included CTQ-SSS, CTQ-FS, and pain VAS. Both groups improved on all outcome measures; however, the injection group showed greater improvements at both 2 and 8 weeks. For the CTQ-SSS, MDs at 2 and 8 weeks for the injection group were -0.8 and -1.1, respectively, and -0.6 and -0.9, respectively, for iontophoresis group ( $P < .05$ ). For the CTQ-FS at 2 and 8 weeks, MDs for the injection group were -0.8 and -1.1, respectively, and for iontophoresis group were -0.2 and -0.4, respectively ( $P < .05$ ). For pain VAS, the injection group at 2 and 8 weeks showed MDs of -1.7 and -4.4, respectively, compared to the iontophoresis group MDs of -2.1 and -3.7, respectively ( $P < .001$ ).<sup>112</sup> There were no side effects for either treatment.

**Phonophoresis Versus Iontophoresis**

**II** In a single-blind, randomized trial, Bakhtiary et al<sup>31</sup> compared phonophoresis and iontophoresis in 34 individuals (52 hands) diagnosed with mild to moderate CTS who were randomized into 1 of 2 groups. Each group was treated 5 times weekly for 2 weeks with 0.4% dexamethasone sodium phosphate. Phonophoresis was applied at a frequency of 1 MHz, 1.0-W/cm<sup>2</sup> intensity, and 25% duty cycle for 5 minutes. Iontophoresis was applied with the steroid under the negative electrode at 2 mA-min for 20 minutes (total dose, 40 mA-min). Outcome measures included pain VAS, motor and sensory nerve latencies, action potential amplitudes, pinch strength, and grip strength. At 2 weeks, both groups improved in all parameters, but changes in the phonophoresis group were significantly larger than those in the iontophoresis group (pain VAS MD, 2.1; 95% CI: 1.3, 2.9; *P* = .001; grip strength MD, 27.1 N; 95% CI: 13.5, 40.5; *P* = .006; pinch strength MD, 31.6 N; 95% CI: 15.9, 47.3; *P* = .0002; DML MD, 0.8; 95% CI: 0.5, 1.1; *P* = .0008; CMAP MD, 4.1; 95% CI: 3.0, 5.2; *P* = .0001; thumb DSL MD, 8.8; 95% CI: 5.6, 12.1; *P* = .004; index DSL MD, 0.8; 95% CI: 0.5, 1.1; *P* = .0001). At 4 weeks, both groups demonstrated worsening in all outcome measures except pain VAS in the iontophoresis group and DML and DSL in the phonophoresis group. Despite the declines, the phonophoresis improvements remained significant for all outcome measures (*P* ≤ .032).<sup>31</sup>

**II** In a randomized, controlled, nonblinded study, Gurcay et al<sup>121</sup> compared phonophoresis (0.1% betamethasone; 1 MHz, 1.0 W/cm<sup>2</sup>, 10 minutes 3 times per week for 3 weeks, continuous mode) to iontophoresis (0.1% betamethasone; 2 mA for 10 minutes; 3 days per week for 3 weeks) to a control group in individuals with mild to moderate CTS. All participants (*n* = 52) wore a night-time, volar wrist orthosis for 3 weeks (custom; thermoplastic; neutral position). Outcome measures, including the CTQ-SSS, grip strength, and dexterity measured by the nine-hole peg test, were assessed at baseline and 3 months after treatment. Results were reported in bar graph and narrative form, and no baseline or outcome scores were provided. The CTQ-SSS scores improved in all groups (*P* ≤ .001). There was a statistically significant difference between the change scores in the phonophoresis and control groups in favor of the phonophoresis group (*P* = .012). There were no other significant differences between the groups.<sup>121</sup> There was no report of adverse effects of the interventions.

**II** In another nonblinded randomized trial, Karatay et al<sup>142</sup> compared a single 4 mg injection of dexamethasone plus local anesthetic to 3 weeks (15 sessions) of iontophoresis (0.4% dexamethasone sodium phosphate, 1-to-4-mA current) or phonophoresis (0.1% dexamethasone

sodium phosphate delivered at 1 MHz, 1.0 W/cm<sup>2</sup>, 25% duty cycle) in patients with CTS. Forty-five individuals (90 hands) with early, mild, bilateral CTS were randomly assigned to 1 of the 3 groups. Outcome measures (night pain VAS, CTQ-SSS, CTQ-FS, DML, and DSL) were measured at 1 and 6 months after the start of the study. At 1 month, there were significant improvements in clinical and electrophysiological parameters for the injection and phonophoresis groups (*P* < .001). In the iontophoresis group, there were significant changes for the clinical parameters only (*P* < .001). At 6 months, the injection group outcomes remained significantly improved on all parameters (*P* < .01), the phonophoresis group remained significantly improved in clinical parameters only (*P* < .001), and the iontophoresis group did not demonstrate significant improvement over baseline for any parameter. The injection group outcomes were significantly better than the iontophoresis group for night pain at 6 months (*P* = .020), CTQ-SSS at 1 (*P* = .031) and 6 months (*P* = .003), CTQ-FS at 6 months (*P* = .011) and DSL at 1 month (*P* = .036). The injection group outcomes were better than the phonophoresis group for night pain at 6 months (*P* = .022) and CTQ-SSS at 6 months (*P* = .030) but the injection and phonophoresis were similar on all other outcome measures. Authors concluded that injection or steroid phonophoresis could be used in the management of CTS.<sup>142</sup> Authors did not report between-group differences for iontophoresis versus phonophoresis.

**Evidence Synthesis and Clinical Rationale**

While there is evidence that iontophoresis with 0.4% dexamethasone sodium phosphate resulted in a positive effect on self-reported outcomes, distilled-water iontophoresis produced similar results, suggesting the active agent could be the electrical stimulation. Steroid and nonsteroid phonophoresis demonstrated positive effects in the short term for individuals with mild or moderate severity CTS. There is evidence demonstrating improvement for short term pain relief, clinical signs, weakness, functional deficits, sensory deficits and nerve cross-sectional area.<sup>121,266,267,301</sup> Changes in NCS were conflicting.<sup>142,266,267</sup> No study included a control group, and the magnitude of improvement due to the treatment compared to the natural course of CTS could not be determined. Two of the 3 studies combined phonophoresis or iontophoresis with an orthosis masking the magnitude of the effect of the drug administration alone. For patients considering the use of anti-inflammatory medications, a local steroid injection combined with a neutral wrist orthosis may be more cost effective and efficient.

**Gaps in Knowledge**

To determine the efficacy of transdermal drug administration, evidence for the role of inflammation in CTS should be determined. The iontophoresis studies used dexamethasone

sodium phosphate or diphosphate, while the phonophoresis studies used a variety of steroid and nonsteroid active drugs. No evidence was presented for the choice of drug or concentration or for treatment variables including dosage, frequency, and treatment duration. Well-designed trials with control groups and appropriate outcome measures are needed.

### Recommendations

**B** Clinicians should **not** use iontophoresis in the management of mild to moderate CTS.

**C** Clinicians may perform phonophoresis within non-surgical management of patients with mild to moderate CTS for the treatment of clinical signs and symptoms but should consider other interventions.

### Athermal Agents

#### Magnet Therapy

**II** There were 2 studies comparing the effects of magnet therapy with a placebo in individuals with CTS. In a randomized, double-blind, placebo-controlled trial, Carter et al<sup>54</sup> studied 30 individuals with CTS (all severities) who wore a 1000 gauss magnet or placebo magnet strapped to their wrist for 45 minutes. Outcomes were measured at 15-minute intervals during treatment and 2 weeks post treatment. At the end of treatment, both groups reported significant pain reduction (MD for both groups, -2.4) as measured by an 11-point VAS with no statistical difference in improvement between groups. At 2 weeks post treatment, mean pain was identical for both (4.3/10), and remained below baseline levels. In a randomized, controlled, double-blinded study of 60 individuals with CTS of all severity levels, Colbert et al<sup>71</sup> compared 2 static magnetic field strengths (15 and 45 mT) with a sham magnet applied over the carpal tunnel nightly for 6 weeks. At 6 and 18 weeks, all groups demonstrated statistically significant improvements in CTQ scales, but there were no differences between the groups ( $P \geq .463$ ). In summary, neither of these studies showed any benefits of using magnet therapy over sham. Adverse effects included pain under the 45-mT magnet ( $n = 1$ ) which resolved in 2 days, and skin rash under the adhesive ( $n = 2$ ) used to secure the magnets which also resolved with topical ointment.

### Recommendation

**B** Clinicians should **not** use or recommend the use of magnets in the intervention for individuals with CTS.

### MANUAL THERAPY TECHNIQUES

**II** A variety of different exercise and manual therapy interventions have been studied as potential non-surgical treatment for CTS. A Cochrane review was

published in 2012 based on 16 Level II studies evaluating the effects of exercise and mobilization interventions for CTS.<sup>222</sup> Included studies were randomized or quasi-randomized studies comparing the exercise or mobilization interventions to a control group, placebo, or other nonsurgical intervention. Interventions included were carpal bone mobilization, yoga, tendon and nerve gliding exercises, neurodynamic mobilization, instrument-assisted soft tissue massage, and standard soft tissue massage. Exercise and manual interventions were delivered as components of single or multi-intervention treatments, and they were compared to one or more other nonsurgical interventions including orthotic devices, steroid injections, or other physical agents. Authors of the review consistently found bias, lack of blinding, small between group differences, and CIs including effects in both directions. The use of multiple interventions precluded identifying the effect of a specific intervention. Authors of the review concluded there was limited and very low-quality evidence of any benefit for exercise and mobilization interventions for CTS and there is a need for higher-quality studies to investigate the long-term effects of these interventions compared to orthoses.<sup>222</sup>

The remainder of this summary includes studies published since the Cochrane review.

### Neural Tissue Mobilization

**II** In a systematic review of randomized clinical trials, Basson et al<sup>34</sup> investigated the use of neurodynamic mobilization for the treatment of neuromusculoskeletal conditions, including CTS. The authors analyzed 12 papers evaluating the effect of neural mobilization in individuals with CTS, only 3<sup>214,252,295</sup> of which were published after the Cochrane review<sup>222</sup> described above. Meta-analysis was performed on patient-reported outcome measures including pain VAS (WMD, -0.22; 95% CI: -0.74, 0.30) and the DASH questionnaire (WMD, -1.55; 95% CI: -7.84, 4.75). Clinical outcome measures included timed Phalen's test (relative effect, 0.81; 95% CI: 0.87, 1.86), grip strength (relative effect, 1.18; 95% CI: -1.29, 3.66), and 2PD (relative effect, 0.36; 95% CI: -0.8, 0.08). Basson et al<sup>34</sup> found high or uncertain risk of bias in 7 of the 12 studies, and no statistically significant effects (small ESs and large CIs, reflecting bidirectional effects). Authors concluded the evidence was insufficient to support the effectiveness of neural mobilization for improving clinical outcomes in patients with CTS.

**II** Wolny and Linek<sup>293</sup> studied the effects of neurodynamic techniques (provided twice weekly for 10 weeks) versus no treatment in individuals with mild or moderate CTS ( $n = 103$ ) in a randomized trial. Outcome measures included NCS parameters, a numeric pain-



rating scale (NPRS), grip and pinch strength, the CTQ-SSS and CTQ-FS. Measurements were taken at baseline and 10 weeks. Authors reported statistically significant differences between the treatment and control groups in SNCV (MD, 12.4; 95% CI: 9.1, 15.6), DML (MD, 0.92; 95% CI: 0.58, 1.23), NPRS (MD, 4.08; 95% CI: 3.73, 4.43), CTQ-SSS (MD, 1.79; 95% CI: 0.91, 1.31), and CTQ-FS (MD, 0.91; 95% CI: 0.78, 1.24) in favor of the neurodynamic techniques. The same authors found similar results in another randomized study comparing the effects of neurodynamic treatment to a sham nerve gliding technique (n = 150).<sup>294</sup> Differences between groups were as follows: SNCV (MD, 14.7; 95% CI: 10.5, 15.9), 2PD (long finger) (MD, 2.38; 95% CI: 2.09, 2.65), DML (MD, 0.90; 95% CI: 0.63, 1.15), NPRS (MD, 4.0; 95% CI: 3.71, 4.28), CTQ-SSS (MD, 1.09; 95% CI: 0.93, 1.27), and CTQ-FS (MD, 1.15; 95% CI: 0.91, 1.27). Adverse effects were not reported.

### Manual Therapy

**II** Maddali Bongi et al<sup>175</sup> investigated the effect of bi-weekly manual therapy on 22 participants (41 hands) with CTS of all severity levels using a repeated-measures, crossover design. In the initial phase, 9 participants (16 hands) were tested on all outcome measures and followed without intervention for 12 weeks and then reassessed. Outcome measures included CTQ-SSS, CTQ-FS, sensory NCV, DML, severity and clinical signs including presence of pain, night waking frequency, hypoesthesia, strength, Phalen test time, hand sensitivity, and thenar muscle atrophy. There were no significant differences on any outcome measures in this phase, except the number of hands with a positive Phalen test increased from 6 to 11 ( $P = .0041$ ). While 16 hands were in the control group, data were only provided on 14 hands. Participants then entered the treatment phase and received two, 45-minute sessions of education including activity modifications for performing work and home tasks followed by manual therapy sessions twice per week for 3 weeks. Manual therapy techniques included soft tissue and wrist joint mobilization performed by the same provider. Outcome measures were assessed at 3 and 24 weeks following the initial treatment. For both data collection periods, CTQ-SSS scores improved (3-week MD, -8.14 and 24-week MD, -4.49;  $P < .05$ ). The CTQ-FS scores also improved (3-week MD, -3.78 and 24-week MD, -3.12;  $P < .05$ ). There were no differences in nerve conduction or DML at 3 or 24 weeks. Reports of paresthesia, pain, night waking, and hand sensitivity improved significantly ( $P < .05$ ) after 3 weeks. At 24 weeks, some scores worsened yet remained improved over the baseline scores; however, no statistical comparisons were reported for clinical signs. No methodology was provided on how pain and paresthesia were measured. It is unclear whether improvements were due to the manual therapy or activity modifications.

### Manual Therapy Versus Surgery

**II** Fernández-de-Peñas et al<sup>93</sup> compared manual therapy interventions to carpal tunnel decompression surgery in 94 women diagnosed with CTS in a randomized, single-blinded trial. Manual therapy and cervical muscle stretches were performed during 30-minute sessions once per week for 3 weeks. Surgical decompression was either open or endoscopic, depending on patient and surgeon preference. Individuals treated with surgery received an educational session for performing the cervical muscle stretches. Outcome measures included the CTQ-FS, the CTQ-SSS, cervical range of motion, and tip pinch strength (thumb to index and thumb to small fingers). Outcomes were measured at 0, 1, 3, 6, and 12 months post intervention. The authors reported statistically significant differences between groups on the CTQ-FS (MD, 0.6; 95% CI: 0.45, 0.75), thumb-to-index pinch strength (MD, 2.2; 95% CI: 1.8, 2.6), and thumb-to-little pinch strength (MD, 0.8; 95% CI: 0.5, 1.1) at 1 month favoring manual therapy. The ESs for these differences were large (1.6 and 1.1). Otherwise, both groups showed similar improvements on all variables at all data collection time points. Authors reported there were no adverse effects or postoperative complications.<sup>93</sup>

**II** Fernández-de-las-Peñas et al<sup>94</sup> compared manual therapy interventions to carpal tunnel decompression surgery in 111 women diagnosed with CTS in a randomized, single-blinded trial. Manual therapy was performed for 30 minutes, once per week for 3 weeks. Treatment varied based on clinical findings and provider judgement, and could include vertebral glides, soft tissue and neural mobilization, and tendon gliding. Surgical decompression was either open or endoscopic, depending on patient and surgeon preference. Outcome measures were average pain, worst pain NPRS, CTQ-SSS, CTQ-FS, and global rating of change (GROC) and were measured at 0, 1, 3, 6, and 12 months post intervention. At 1 and 3 months post treatment, the manual therapy group reported greater pain reduction (MD, -3.4 versus -1.5 and MD, -3.7 versus -2.4, respectively), with a large ES favoring manual therapy (1.1 greater than standardized MD greater than 1.8). CTQ-FS scores at 1 month and 3 months also favored the manual therapy group, with standardized MD of 1.2 (large ES) and 0.8 (medium ES), respectively. No significant differences between groups were found at any point for the CTQ-SSS or at 6 or 12 months for pain or the CTQ-FS. Reported ESs for groups pretreatment and posttreatment were large for both groups (standardized MD greater than 1.3). GROC was similar for both groups at 6 ( $P = .663$ ) and 12 months ( $P = .169$ ). Authors reported there were no clinically important adverse events or surgical complications.<sup>94</sup>

### Evidence Synthesis and Clinical Rationale

Evidence on the use of neurodynamic techniques is conflicting. The evidence supporting manual therapy interventions

is limited by potential for bias, lack of control groups, and nonuniformity in examination and intervention techniques, sometimes within the same study. Early advantages of manual therapy compared to surgical intervention are most likely due to postoperative healing, leading to greater short-term pain and dysfunction in surgically managed individuals. The decision to use manual therapy should be based on patient preference and therapist experience. Clinicians must discontinue any manual therapy intervention if symptoms increase or do not improve. While no adverse effects were reported from either surgery or a variety of manual therapies in these studies, surgical complications have been reported elsewhere in this guideline.

### Gaps in Knowledge

There is a need for high-quality randomized controlled studies using valid, condition-appropriate outcome measures comparing specific, reproducible, manual therapy interventions to identify the most effective techniques and the appropriate dosage. Use of control groups, blinded assessors, uniform interventions, and evaluation of long-term outcomes are needed. There is no evidence that neural mobilization increases longitudinal, lateral, or anterior-posterior movement of the median nerve in the carpal tunnel in individuals with CTS, or that an increase in movement is associated with a reduction in carpal tunnel pressure or carpal tunnel symptoms.

### Recommendations

**C** Clinicians may perform manual therapy, directed at the cervical spine and upper extremity, for individuals with mild to moderate CTS in the short term.

**D** There is conflicting evidence on the use of neurodynamic mobilizations in the management of mild or moderate CTS.

### THERAPEUTIC EXERCISE

#### Stretching

**II** Baker et al<sup>29</sup> examined 4 different orthosis-stretching combinations and progression to surgery in 103 participants with mild to moderate CTS without thenar atrophy and normal 2PD. Participants were randomized into 4 different treatment protocols that combined or-

thotic intervention and stretching. Individuals wore 1 of 3 orthosis designs during sleep (a custom-fabricated orthosis with the wrist at 0° and the MP joints at 0° to 10° [lumbrical orthosis], or 1 of 2 prefabricated wrist orthoses [general orthosis]) and were randomly assigned to 1 of 2 stretching groups (lumbrical stretches or general stretches) to be done 6 times per day. Outcome measures were the CTQ-SSS, CTQ-FS, and the DASH, and authors determined the clinically important change (CIC) for the instruments as -0.16, -0.47, and -20.9 points, respectively. There were no differences between groups at any time points except for 12 weeks. The post hoc analysis showed the lumbrical orthosis/general stretch and general orthosis/lumbrical stretch were significantly improved compared to the lumbrical orthosis/lumbrical stretch for CTQ-FS, and the lumbrical orthosis/general stretch was significantly improved compared to the lumbrical orthosis/lumbrical stretch for the DASH. There were no significant 3-way interactions at 4 or 24 weeks.

When considering the CIC for CTQ-SSS, CTQ-FS, and DASH in the Baker et al<sup>29</sup> study, at 4 weeks, 66%, 34%, and 8% of participants demonstrated a CIC, respectively. At 12 weeks, 68%, 37%, and 18% of participants reached a CIC, respectively, and at 24 weeks, 72%, 41%, and 22% reached CIC, respectively. At 24 weeks, 25.5% of participants progressed to surgery, with no difference between groups. No intervention was shown to be superior, and the absence of a control group and the use of multiple interventions prevents recommending one intervention. No adverse effects were reported.

### Gaps in Knowledge

More evidence is needed on the effects of general and lumbrical muscle stretching in individuals with CTS that include a control group. Studies are needed that examine the effects of stretching versus other types of exercise. Studies examining the combined effects of stretching and orthoses versus orthoses alone are also needed.

### Recommendation

**C** Clinicians may use a combined orthotic/stretching program in individuals with mild to moderate CTS who do not have thenar atrophy and have normal 2PD. Clinicians should monitor those undergoing treatment for clinically significant improvement.

AFFILIATIONS AND CONTACTS

**AUTHORS**

Mia Erickson, PT, EdD  
 Professor  
 College of Health Sciences  
 Physical Therapy Program  
 Midwestern University  
 Glendale, AZ  
 merick@midwestern.edu

Marsha Lawrence, PT, DPT  
 Senior Physical Therapist  
 University of Iowa Hospitals & Clinics  
 Iowa City, IA  
 marsha-lawrence@uiowa.edu

Caroline W. Stegink Jansen, PT, PhD  
 Associate Professor  
 School of Medicine  
 Department of Orthopaedic Surgery  
 and Rehabilitation  
 University of Texas Medical Branch  
 Galveston, TX  
 cwsjansen@gmail.com

Diane Coker, PT, DPT  
 South County Hand Center  
 Laguna Woods, CA  
 dacoker@cox.net

Peter Amadio, MD  
 Orthopaedic Surgeon  
 Mayo Clinic  
 Rochester, MN  
 pamadio@mayo.edu

Carla Cleary, PT, DPT  
 Assistant Director  
 St Dominic's Hand Management Center  
 Jackson, MS  
 ckcleary@hotmail.com

**REVIEWERS**

Roy Altman, MD  
 Professor of Medicine  
 Division of Rheumatology and  
 Immunology  
 David Geffen School of Medicine at  
 UCLA  
 Los Angeles, CA

journals@royaltman.com  
 Paul Beattie, PT, PhD  
 Clinical Professor  
 Doctoral Program in Physical Therapy,  
 Department of Exercise Science  
 Arnold School of Public Health  
 University of South Carolina  
 Columbia, SC  
 pbeattie@mailbox.sc.edu

Eugene Boeglin, DPT  
 Hand Therapist  
 Physical and Occupational Therapy at  
 Beth Israel Deaconess HealthCare-  
 Chestnut Hill  
 Newton, MA  
 erboeglin@verizon.net

John Dewitt, DPT  
 Director of Physical Therapy  
 Residencies and Fellowships  
 The Ohio State University  
 Columbus, OH  
 john.dewitt@osumc.edu

Lauren Detullio, OT  
 Assistant Clinical Director  
 Philadelphia Hand to Shoulder Center  
 Philadelphia, PA  
 ldetullio@handcenters.com

Amanda Ferland, DPT  
 Clinical Faculty  
 Tongji University/USC Division of  
 Biokinesiology and Physical Therapy  
 Orthopaedic Physical Therapy  
 Residency  
 and  
 Spine Rehabilitation Fellowship  
 Shanghai, China  
 AmandaFerland@incarehab.com

Christopher Hughes, PT, PhD  
 Professor  
 Slippery Rock University  
 Slippery Rock, PA  
 Christopher.hughes@sru.edu

Sandra Kaplan, PT, PhD

Clinical Practice Guidelines Coordinator  
 Academy of Pediatric Physical Therapy,  
 APTA, Inc  
 Alexandria, VA  
 and  
 Professor  
 Doctoral Programs in Physical Therapy  
 Rutgers University  
 Newark, NJ  
 kaplansa@shp.rutgers.edu

David Killoran, PhD  
 Patient/Consumer Representative  
 for the ICF-Based Clinical Practice  
 Guidelines  
 Academy of Orthopaedic Physical  
 Therapy, APTA, Inc  
 La Crosse, WI  
 and  
 Professor Emeritus  
 Loyola Marymount University  
 Los Angeles, CA  
 david.killoran@lmu.edu

Murray E. Maitland, PT, PhD  
 Associate Professor  
 University of Washington  
 Department of Rehabilitation Medicine  
 Division of Physical Therapy  
 Seattle, WA  
 mmaitlan@uw.edu

Saurabh Mehta, PT, MS, PhD  
 Assistant Professor  
 School of Physical Therapy  
 Marshall University  
 Huntington, WV  
 mehtas@marshall.edu

Leslie Torburn, DPT  
 Principal and Consultant  
 Silhouette Consulting, Inc  
 Sacramento, CA  
 torburn@yahoo.com

Emmanuel Yung, PT, DPT  
 Assistant Clinical Professor  
 Physical Therapy  
 Sacred Heart University

Fairfield, CT  
 yunge@sacredheart.edu

**GUIDELINES EDITORS**

Christine M. McDonough, PT, PhD  
 ICF-Based Clinical Practice Guidelines  
 Editor  
 Academy of Orthopaedic Physical  
 Therapy, APTA, Inc  
 La Crosse, WI  
 and  
 Assistant Professor of Physical Therapy  
 School of Health and Rehabilitation  
 Sciences  
 University of Pittsburgh  
 Pittsburgh, PA  
 cmm295@pitt.edu

Guy G. Simoneau, PT, PhD, FAPTA  
 ICF-Based Clinical Practice Guidelines  
 Editor  
 Academy of Orthopaedic Physical  
 Therapy, APTA, Inc  
 La Crosse, WI  
 and  
 Professor  
 Physical Therapy Department  
 Marquette University  
 Milwaukee, WI  
 guy.simoneau@marquette.edu

Robroy L. Martin, PT, PhD  
 ICF-Based Clinical Practice Guidelines  
 Editor  
 Academy of Orthopaedic Physical  
 Therapy, APTA, Inc  
 La Crosse, WI  
 and  
 Professor  
 Rangos School of Health Sciences  
 Duquesne University  
 Pittsburgh, PA  
 and  
 Staff Physical Therapist  
 UPMC Center for Sports Medicine  
 Pittsburgh, PA  
 martin280@duq.edu

Journal of Orthopaedic & Sports Physical Therapy®  
 Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
 Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

REFERENCES

1. Agnew J, Bolla-Wilson K, Kawas CH, Bleecker ML. Purdue Pegboard age and sex norms for people 40 years old and older. *Dev Neuropsychol*. 1988;4:29-35. <https://doi.org/10.1080/87565648809540388>
2. Ahn SY, Hong YH, Koh YH, Chung YS, Lee SH, Yang HJ. Pressure measurement in carpal tunnel syndrome: correlation with electrodiagnostic and ultrasonographic findings. *J Korean Neurosurg Soc*. 2009;46:199-204. <https://doi.org/10.3340/jkns.2009.46.3.199>
3. Al-Dabbagh KAO, Mohamad SA. Sensitivity and specificity of Phalen's test and Tinell's test in patients with carpal tunnel syndrome. *Diyala J Med*. 2013;5:1-14.
4. Alderson M, McGall D. The Alderson-McGall hand function questionnaire for patients with carpal tunnel syndrome: a pilot evaluation of a future outcome measure. *J Hand Ther*. 1999;12:313-322. [https://doi.org/10.1016/s0894-1130\(99\)80070-2](https://doi.org/10.1016/s0894-1130(99)80070-2)
5. Al-Hashem FH, Khalid ME. The effect of long-term use of computer mouse devices on median nerve entrapment. *Neurosciences (Riyadh)*. 2008;13:131-135.
6. Amadio PC, Silverstein MD, Ilstrup DM, Schleck CD, Jensen LM. Outcome assessment for carpal tunnel surgery: the relative responsiveness of generic, arthritis-specific, disease-specific, and physical examination measures. *J Hand Surg Am*. 1996;21:338-346. [https://doi.org/10.1016/S0363-5023\(96\)80340-6](https://doi.org/10.1016/S0363-5023(96)80340-6)
7. American Academy of Orthopaedic Surgeons. Management of Carpal Tunnel Syndrome: Evidence-Based Clinical Practice Guideline. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2016.
8. Amirfeyz R, Clark D, Parsons B, et al. Clinical tests for carpal tunnel syndrome in contemporary practice. *Arch Orthop Trauma Surg*. 2011;131:471-474. <https://doi.org/10.1007/s00402-010-1150-z>
9. Amirfeyz R, Gozzard C, Leslie IJ. Hand elevation test for assessment of carpal tunnel syndrome. *J Hand Surg Br*. 2005;30:361-364. <https://doi.org/10.1016/j.jhsb.2005.04.007>
10. Amirfeyz R, Pentlow A, Foote J, Leslie I. Assessing the clinical significance of change scores following carpal tunnel surgery. *Int Orthop*. 2009;33:181-185. <https://doi.org/10.1007/s00264-007-0471-1>
11. Amirjani N, Ashworth NL, Gordon T, Edwards DC, Chan KM. Normative values and the effects of age, gender, and handedness on the Moberg Pick-Up Test. *Muscle Nerve*. 2007;35:788-792. <https://doi.org/10.1002/mus.20750>
12. Amirjani N, Ashworth NL, Olson JL, Morhart M, Chan KM. Discriminative validity and test-retest reliability of the Dellon-modified Moberg pick-up test in carpal tunnel syndrome patients. *J Peripher Nerv Syst*. 2011;16:51-58. <https://doi.org/10.1111/j.1529-8027.2011.00312.x>
13. Amirjani N, Ashworth NL, Olson JL, Morhart M, Chan KM. Validity and reliability of the Purdue Pegboard Test in carpal tunnel syndrome. *Muscle Nerve*. 2011;43:171-177. <https://doi.org/10.1002/mus.21856>
14. Amirjani N, Ashworth NL, Watt MJ, Gordon T, Chan KM. Corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial. *Muscle Nerve*. 2009;39:627-633. <https://doi.org/10.1002/mus.21300>
15. Andersen JH, Fallentin N, Thomsen JF, Mikkelsen S. Risk factors for neck and upper extremity disorders among computers (sic) users and the effect of interventions: an overview of systematic reviews. *PLoS One*. 2011;6:e19691. <https://doi.org/10.1371/journal.pone.0019691>
16. Appleby MA, Neville-Smith M, Parrott MW. Functional outcomes post carpal tunnel release: a modified replication of a previous study. *J Hand Ther*. 2009;22:240-248; quiz 249. <https://doi.org/10.1016/j.jht.2009.03.001>
17. Armagan O, Bakilan F, Ozgen M, Mehmetoglu O, Oner S. Effects of placebo-controlled continuous and pulsed ultrasound treatments on carpal tunnel syndrome: a randomized trial. *Clinics (São Paulo)*. 2014;69:524-528. [https://doi.org/10.6061/clinics/2014\(08\)04](https://doi.org/10.6061/clinics/2014(08)04)
18. Arslan Y, Bülbül I, Öcek L, Şener U, Zorlu Y. Effect of hand volume and other anthropometric measurements on carpal tunnel syndrome. *Neuro Sci*. 2017;38:605-610. <https://doi.org/10.1007/s10072-017-2809-9>
19. Astifidis RP, Koczan BJ, Dubin NH, Burke FD, Wilgis EFS. Patient satisfaction with carpal tunnel surgery: self-administered questionnaires versus physical testing. *Hand Ther*. 2009;14:39-45. <https://doi.org/10.1258/ht.2009.009007>
20. Atalay NS, Sarsan A, Akkaya N, Yildiz N, Topuz O. The impact of disease severity in carpal tunnel syndrome on grip strength, pinch strength, fine motor skill and depression. *J Phys Ther Sci*. 2011;23:115-118. <https://doi.org/10.1589/jpts.23.115>
21. Atcheson SG, Ward JR, Lowe W. Concurrent medical disease in work-related carpal tunnel syndrome. *Arch Intern Med*. 1998;158:1506-1512. <https://doi.org/10.1001/archinte.158.14.1506>
22. Atroshi I, Gummesson C, Johnsson R, Sprinchorn A. Symptoms, disability, and quality of life in patients with carpal tunnel syndrome. *J Hand Surg Am*. 1999;24:398-404. [https://doi.org/10.1016/S0363-5023\(99\)70014-6](https://doi.org/10.1016/S0363-5023(99)70014-6)
23. Atroshi I, Gummesson C, McCabe SJ, Ornstein E. The SF-6D health utility index in carpal tunnel syndrome. *J Hand Surg Eur Vol*. 2007;32:198-202. <https://doi.org/10.1016/J.JHSB.2006.11.002>
24. Atroshi I, Gummesson C, Ornstein E, Johnsson R, Ranstam J. Carpal tunnel syndrome and keyboard use at work: a population-based study. *Arthritis Rheum*. 2007;56:3620-3625. <https://doi.org/10.1002/art.22956>
25. Atroshi I, Lyrén PE, Gummesson C. The 6-item CTS symptoms scale: a brief outcomes measure for carpal tunnel syndrome. *Qual Life Res*. 2009;18:347-358. <https://doi.org/10.1007/s11136-009-9449-3>
26. Atroshi I, Lyrén PE, Ornstein E, Gummesson C. The six-item CTS symptoms scale and palmar pain scale in carpal tunnel syndrome. *J Hand Surg Am*. 2011;36:788-794. <https://doi.org/10.1016/j.jhsa.2011.02.021>
27. Baker NA, Livengood HM. Symptom severity and conservative treatment for carpal tunnel syndrome in association with eventual carpal tunnel release. *J Hand Surg Am*. 2014;39:1792-1798. <https://doi.org/10.1016/j.jhsa.2014.04.034>
28. Baker NA, Moehling KK, Desai AR, Gustafson NP. Effect of carpal tunnel syndrome on grip and pinch strength compared with sex- and age-matched normative data. *Arthritis Care Res (Hoboken)*. 2013;65:2041-2045. <https://doi.org/10.1002/acr.22089>
29. Baker NA, Moehling KK, Rubinstein EN, Wollstein R, Gustafson NP, Baratz M. The comparative effectiveness of combined lumbrical muscle splints and stretches on symptoms and function in carpal tunnel syndrome. *Arch Phys Med Rehabil*. 2012;93:1-10. <https://doi.org/10.1016/j.apmr.2011.08.013>
30. Baksh H, Ibrahim I, Khan W, Smitham P, Goddard N. Assessment of validity, reliability, responsiveness and bias of three commonly used patient-reported outcome measures in carpal tunnel syndrome. *Ortop Traumatol Rehabil*. 2012;14:335-340. <https://doi.org/10.5604/15093492.1005085>
31. Bakhtiyari AH, Fatemi E, Emami M, Malek M. Phonophoresis of dexamethasone sodium phosphate may manage pain and symptoms of patients with carpal tunnel syndrome. *Clin J Pain*. 2013;29:348-353. <https://doi.org/10.1097/J.P.0b013e318255c090>
32. Barcenilla A, March LM, Chen JS, Sambrook PN. Carpal tunnel syndrome and its relationship to occupation: a meta-analysis. *Rheumatology (Oxford)*. 2012;51:250-261. <https://doi.org/10.1093/rheumatology/ker108>
33. Baselgia LT, Bennett DL, Silbiger RM, Schmid AB. Negative neurodynamic tests do not exclude neural dysfunction in patients with entrapment neuropathies. *Arch Phys Med Rehabil*. 2017;98:480-486. <https://doi.org/10.1016/j.apmr.2016.06.019>
34. Basson A, Olivier B, Ellis R, Coppieters M, Stewart A, Mudzi W. The effectiveness of neural mobilization for neuromusculoskeletal conditions: a systematic review and meta-analysis. *J Orthop Sports Phys Ther*. 2017;47:593-615. <https://doi.org/10.2519/jospt.2017.117>

35. Baysal O, Altay Z, Ozcan C, Ertem K, Yologlu S, Kayhan A. Comparison of three conservative treatment protocols in carpal tunnel syndrome. *Int J Clin Pract*. 2006;60:820-828. <https://doi.org/10.1111/j.1742-1241.2006.00867.x>
36. Becker J, Nora DB, Gomes I, et al. An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome. *Clin Neurophysiol*. 2002;113:1429-1434. [https://doi.org/10.1016/S1388-2457\(02\)00201-8](https://doi.org/10.1016/S1388-2457(02)00201-8)
37. Bélanger AY. *Therapeutic Electrophysical Agents: Evidence Behind Practice*. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015.
38. Bessette L, Sangha O, Kuntz KM, et al. Comparative responsiveness of generic versus disease-specific and weighted versus unweighted health status measures in carpal tunnel syndrome. *Med Care*. 1998;36:491-502. <https://doi.org/10.1097/00005650-199804000-00005>
39. Bland JD. A neurophysiological grading scale for carpal tunnel syndrome. *Muscle Nerve*. 2000;23:1280-1283. [https://doi.org/10.1002/1097-4598\(200008\)23:8<1280::AID-MUS20>3.0.CO;2-Y](https://doi.org/10.1002/1097-4598(200008)23:8<1280::AID-MUS20>3.0.CO;2-Y)
40. Bland JD. The relationship of obesity, age, and carpal tunnel syndrome: more complex than was thought? *Muscle Nerve*. 2005;32:527-532. <https://doi.org/10.1002/mus.20408>
41. Blok RD, Becker SJ, Ring DC. Diagnosis of carpal tunnel syndrome: interobserver reliability of the blinded scratch-collapse test. *J Hand Microsurg*. 2014;6:5-7. <https://doi.org/10.1007/s12593-013-0105-3>
42. Boland RA, Kiernan MC. Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. *J Clin Neurosci*. 2009;16:929-933. <https://doi.org/10.1016/j.jocn.2008.09.004>
43. Boyd KU, Gan BS, Ross DC, Richards RS, Roth JH, MacDermid JC. Outcomes in carpal tunnel syndrome: symptom severity, conservative management and progression to surgery. *Clin Invest Med*. 2005;28:254-260.
44. Boz C, Ozmenoglu M, Altunayoglu V, Velioglu S, Alioglu Z. Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements. *Clin Neurol Neurosurg*. 2004;106:294-299. <https://doi.org/10.1016/j.clineuro.2004.01.002>
45. Bueno-Gracia E, Tricás-Moreno JM, Fanlo-Mazas P, et al. Validity of the Upper Limb Neurodynamic Test 1 for the diagnosis of carpal tunnel syndrome. The role of structural differentiation. *Man Ther*. 2016;22:190-195. <https://doi.org/10.1016/j.math.2015.12.007>
46. Bugajska J, Żołnierczyk-Zreda D, Jędryka-Góral A, et al. Psychological factors at work and musculoskeletal disorders: a one year prospective study. *Rheumatol Int*. 2013;33:2975-2983. <https://doi.org/10.1007/s00296-013-2843-8>
47. Bulut GT, Caglar NS, Aytakin E, Ozgonenel L, Tutun S, Demir SE. Comparison of static wrist splint with static wrist and metacarpophalangeal splint in carpal tunnel syndrome. *J Back Musculoskelet Rehabil*. 2015;28:761-767. <https://doi.org/10.3233/BMR-140580>
48. Burt S, Deddens JA, Crombie K, Jin Y, Wurzelbacher S, Ramsey J. A prospective study of carpal tunnel syndrome: workplace and individual risk factors. *Occup Environ Med*. 2013;70:568-574. <https://doi.org/10.1136/oemed-2012-101287>
49. Burton CL, Chesterton LS, Chen Y, van der Windt DA. Clinical course and prognostic factors in conservatively managed carpal tunnel syndrome: a systematic review. *Arch Phys Med Rehabil*. 2016;97:836-852.e1. <https://doi.org/10.1016/j.apmr.2015.09.013>
50. Calfee RP, Dale AM, Ryan D, Descatha A, Franzblau A, Evanoff B. Performance of simplified scoring systems for hand diagrams in carpal tunnel syndrome screening. *J Hand Surg Am*. 2012;37:10-17. <https://doi.org/10.1016/j.jhsa.2011.08.016>
51. Caliandro P, La Torre G, Aprile I, et al. Distribution of paresthesias in carpal tunnel syndrome reflects the degree of nerve damage at wrist. *Clin Neurophysiol*. 2006;117:228-231. <https://doi.org/10.1016/j.clinph.2005.09.001>
52. Cameron MH. *Physical Agents in Rehabilitation: An Evidence-Based Approach to Practice*. 5th ed. St Louis, MO: Elsevier; 2018.
53. Capasso M, Manzoli C, Uncini A. Management of extreme carpal tunnel syndrome: evidence from a long-term follow-up study. *Muscle Nerve*. 2009;40:86-93. <https://doi.org/10.1002/mus.21265>
54. Carter R, Aspy CB, Mold J. The effectiveness of magnet therapy for treatment of wrist pain attributed to carpal tunnel syndrome. *J Fam Pract*. 2002;51:38-40.
55. Cartwright MS, Yeboah S, Walker FO, et al. Examining the association between musculoskeletal injuries and carpal tunnel syndrome in manual laborers. *Muscle Nerve*. 2016;54:31-35. <https://doi.org/10.1002/mus.24982>
56. Chang CW, Wang YC, Chang KF. A practical electrophysiological guide for non-surgical and surgical treatment of carpal tunnel syndrome. *J Hand Surg Eur Vol*. 2008;33:32-37. <https://doi.org/10.1177/1753193408087119>
57. Chang YW, Hsieh SF, Horng YS, Chen HL, Lee KC, Horng YS. Comparative effectiveness of ultrasound and paraffin therapy in patients with carpal tunnel syndrome: a randomized trial. *BMC Musculoskelet Disord*. 2014;15:399. <https://doi.org/10.1186/1471-2474-15-399>
58. Chatterjee JS, Price PE. Comparative responsiveness of the Michigan Hand Outcomes Questionnaire and the Carpal Tunnel Questionnaire after carpal tunnel release. *J Hand Surg Am*. 2009;34:273-280. <https://doi.org/10.1016/j.jhsa.2008.10.021>
59. Checkosky CM, Bolanowski SJ, Cohen JC. Assessment of vibrotactile sensitivity in patients with carpal tunnel syndrome. *J Occup Environ Med*. 1996;38:593-601.
60. Chen LH, Li CY, Kuo LC, et al. Risk of hand syndromes in patients with diabetes mellitus: a population-based cohort study in Taiwan. *Medicine (Baltimore)*. 2015;94:e1575. <https://doi.org/10.1097/MD.0000000000001575>
61. Chen SJ, Lin HS, Hsieh CH. Carpal tunnel pressure is correlated with electrophysiological parameters but not the 3 month surgical outcome. *J Clin Neurosci*. 2013;20:272-277. <https://doi.org/10.1016/j.jocn.2012.03.032>
62. Cheng CJ, Mackinnon-Patterson B, Beck JL, Mackinnon SE. Scratch collapse test for evaluation of carpal and cubital tunnel syndrome. *J Hand Surg Am*. 2008;33:1518-1524. <https://doi.org/10.1016/j.jhsa.2008.05.022>
63. Chesterton LS, Blagojevic-Bucknall M, Burton C, et al. The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial. *Lancet*. 2018;392:1423-1433. [https://doi.org/10.1016/S0140-6736\(18\)31572-1](https://doi.org/10.1016/S0140-6736(18)31572-1)
64. Cheung DK, MacDermid J, Walton D, Grewal R. The construct validity and responsiveness of sensory tests in patients with carpal tunnel syndrome. *Open Orthop J*. 2014;8:100-107. <https://doi.org/10.2174/1874325001408010100>
65. Chiotis K, Dimisianos N, Rigopoulou A, Chrysanthopoulou A, Chroni E. Role of anthropometric characteristics in idiopathic carpal tunnel syndrome. *Arch Phys Med Rehabil*. 2013;94:737-744. <https://doi.org/10.1016/j.apmr.2012.11.017>
66. Chroni E, Paschalis C, Arvaniti C, Zotou K, Nikolakopoulou A, Papapetropoulos T. Carpal tunnel syndrome and hand configuration. *Muscle Nerve*. 2001;24:1607-1611. <https://doi.org/10.1002/mus.1195>
67. Clark D, Amirfeyz R, Leslie I, Bannister G. Often atypical? The distribution of sensory disturbance in carpal tunnel syndrome. *Ann R Coll Surg Engl*. 2011;93:470-473. <https://doi.org/10.1308/003588411X586191>
68. Cobb TK, An KN, Cooney WP. Effect of lumbrical muscle incursion within the carpal tunnel on carpal tunnel pressure: a cadaveric study. *J Hand Surg Am*. 1995;20:186-192. [https://doi.org/10.1016/S0363-5023\(05\)80005-X](https://doi.org/10.1016/S0363-5023(05)80005-X)
69. Coggon D, Ntani G, Harris EC, et al. Differences in risk factors for neurophysiologically confirmed carpal tunnel syndrome and illness with similar symptoms but normal median nerve function: a case-control study. *BMC Musculoskelet Disord*. 2013;14:240. <https://doi.org/10.1186/1471-2474-14-240>

70. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
71. Colbert AP, Markov MS, Carlson N, Gregory WL, Carlson H, Elmer PJ. Static magnetic field therapy for carpal tunnel syndrome: a feasibility study. *Arch Phys Med Rehabil*. 2010;91:1098-1104. <https://doi.org/10.1016/j.apmr.2010.02.013>
72. Coldham F, Lewis J, Lee H. The reliability of one vs. three grip trials in symptomatic and asymptomatic subjects. *J Hand Ther*. 2006;19:318-326; quiz 327. <https://doi.org/10.1197/j.jht.2006.04.002>
73. Conlon CF, Rempel DM. Upper extremity mononeuropathy among engineers. *J Occup Environ Med*. 2005;47:1276-1284.
74. Cosgrove JL, Chase PM, Mast NJ, Reeves R. Carpal tunnel syndrome in railroad workers. *Am J Phys Med Rehabil*. 2002;81:101-107.
75. Courts RB. Splinting for symptoms of carpal tunnel syndrome during pregnancy. *J Hand Ther*. 1995;8:31-34. [https://doi.org/10.1016/S0894-1130\(12\)80154-2](https://doi.org/10.1016/S0894-1130(12)80154-2)
76. Dale AM, Gardner BT, Zeringue A, et al. Self-reported physical work exposures and incident carpal tunnel syndrome. *Am J Ind Med*. 2014;57:1246-1254. <https://doi.org/10.1002/ajim.22359>
77. Dale AM, Harris-Adamson C, Rempel D, et al. Prevalence and incidence of carpal tunnel syndrome in US working populations: pooled analysis of six prospective studies. *Scand J Work Environ Health*. 2013;39:495-505. <https://doi.org/10.5271/sjweh.3351>
78. Dale AM, Zeringue A, Harris-Adamson C, et al. General population job exposure matrix applied to a pooled study of prevalent carpal tunnel syndrome. *Am J Epidemiol*. 2015;181:431-439. <https://doi.org/10.1093/aje/kwu286>
79. Dekel S, Papaioannou T, Rushworth G, Coates R. Idiopathic carpal tunnel syndrome caused by carpal stenosis. *Br Med J*. 1980;280:1297-1299.
80. de Krom MC, Kester AD, Knipschild PG, Spaans F. Risk factors for carpal tunnel syndrome. *Am J Epidemiol*. 1990;132:1102-1110. <https://doi.org/10.1093/oxfordjournals.aje.a115753>
81. de la Llave-Rincón AI, Fernández-de-las-Peñas C, Pérez-de-Heredia-Torres M, Martínez-Perez A, Valenza MC, Pareja JA. Bilateral deficits in fine motor control and pinch grip force are not associated with electrodiagnostic findings in women with carpal tunnel syndrome. *Am J Phys Med Rehabil*. 2011;90:443-451. <https://doi.org/10.1097/PHM.0b013e31821a7170>
82. Desrosiers J, Hébert R, Bravo G, Dutil E. The Purdue Pegboard Test: normative data for people aged 60 and over. *Disabil Rehabil*. 1995;17:217-224. <https://doi.org/10.3109/09638289509166638>
83. Dhong ES, Han SK, Lee BI, Kim WK. Correlation of electrodiagnostic findings with subjective symptoms in carpal tunnel syndrome. *Ann Plast Surg*. 2000;45:127-131.
84. Dieck GS, Kelsey JL. An epidemiologic study of the carpal tunnel syndrome in an adult female population. *Prev Med*. 1985;14:63-69. [https://doi.org/10.1016/0091-7435\(85\)90021-0](https://doi.org/10.1016/0091-7435(85)90021-0)
85. Ebenbichler GR, Resch KL, Nicolakis P, et al. Ultrasound treatment for treating the carpal tunnel syndrome: randomised "sham" controlled trial. *BMJ*. 1998;316:731-735. <https://doi.org/10.1136/bmj.316.7133.731>
86. Ekman-Ordeberg G, Sälgeback S, Ordeberg G. Carpal tunnel syndrome in pregnancy. A prospective study. *Acta Obstet Gynecol Scand*. 1987;66:233-235. <https://doi.org/10.3109/00016348709020753>
87. Eleftheriou A, Rachiotis G, Varitimidis SE, Koutis C, Malizos KN, Hadji-christodoulou C. Cumulative keyboard strokes: a possible risk factor for carpal tunnel syndrome. *J Occup Med Toxicol*. 2012;7:16. <https://doi.org/10.1186/1745-6673-7-16>
88. Elfar JC, Yaseen Z, Stern PJ, Kieffhaber TR. Individual finger sensibility in carpal tunnel syndrome. *J Hand Surg Am*. 2010;35:1807-1812. <https://doi.org/10.1016/j.jhsa.2010.08.013>
89. El Miedany Y, Ashour S, Youssef S, Mehanna A, Meky FA. Clinical diagnosis of carpal tunnel syndrome: old tests–new concepts. *Joint Bone Spine*. 2008;75:451-457. <https://doi.org/10.1016/j.jbspin.2007.09.014>
90. Ettema AM, Amadio PC, Zhao C, Wold LE, An KN. A histological and immunohistochemical study of the subsynovial connective tissue in idiopathic carpal tunnel syndrome. *J Bone Joint Surg Am*. 2004;86-A:1458-1466.
91. Evanoff B, Dale AM, Deych E, Ryan D, Franzblau A. Risk factors for incident carpal tunnel syndrome: results of a prospective cohort study of newly-hired workers. *Work*. 2012;41 suppl 1:4450-4452. <https://doi.org/10.3233/WOR-2012-0745-4450>
92. Fan ZJ, Harris-Adamson C, Gerr F, et al. Associations between workplace factors and carpal tunnel syndrome: a multi-site cross sectional study. *Am J Ind Med*. 2015;58:509-518. <https://doi.org/10.1002/ajim.22443>
93. Fernández-de-las-Peñas C, Cleland J, Palacios-Ceña M, Fuensalida-Novo S, Pareja JA, Alonso-Blanco C. The effectiveness of manual therapy versus surgery on self-reported function, cervical range of motion, and pinch grip force in carpal tunnel syndrome: a randomized clinical trial. *J Orthop Sports Phys Ther*. 2017;47:151-161. <https://doi.org/10.2519/jospt.2017.7090>
94. Fernández-de-las Peñas C, Ortega-Santiago R, de la Llave-Rincón AI, et al. Manual physical therapy versus surgery for carpal tunnel syndrome: a randomized parallel-group trial. *J Pain*. 2015;16:1087-1094. <https://doi.org/10.1016/j.jpain.2015.07.012>
95. Fernández-de-las-Peñas C, Pérez-de-Heredia-Torres M, Martínez-Piédrola R, de la Llave-Rincón AI, Cleland JA. Bilateral deficits in fine motor control and pinch grip force in patients with unilateral carpal tunnel syndrome. *Exp Brain Res*. 2009;194:29-37. <https://doi.org/10.1007/s00221-008-1666-4>
96. Ferry S, Hannaford P, Warskyj M, Lewis M, Croft P. Carpal tunnel syndrome: a nested case-control study of risk factors in women. *Am J Epidemiol*. 2000;151:566-574. <https://doi.org/10.1093/oxfordjournals.aje.a010244>
97. Ferti E, Wöber C, Zeithofer J. The serial use of two provocative tests in the clinical diagnosis of carpal tunnel syndrome. *Acta Neurol Scand*. 1998;98:328-332. <https://doi.org/10.1111/j.1600-0404.1998.tb01743.x>
98. Filius A, Thoreson AR, Yang TH, et al. The effect of low- and high-velocity tendon excursion on the mechanical properties of human cadaver subsynovial connective tissue. *J Orthop Res*. 2014;32:123-128. <https://doi.org/10.1002/jor.22489>
99. Frasca G, Maggi L, Padua L, et al. Short-term effects of local microwave hyperthermia on pain and function in patients with mild to moderate carpal tunnel syndrome: a double blind randomized sham-controlled trial. *Clin Rehabil*. 2011;25:1109-1118. <https://doi.org/10.1177/0269215511400767>
100. Freeland AE, Tucci MA, Barbieri RA, Angel MF, Nick TG. Biochemical evaluation of serum and flexor tenosynovium in carpal tunnel syndrome. *Microsurgery*. 2002;22:378-385. <https://doi.org/10.1002/micr.10065>
101. Gay RE, Amadio PC, Johnson JC. Comparative responsiveness of the Disabilities of the Arm, Shoulder, and Hand, the Carpal Tunnel Questionnaire, and the SF-36 to clinical change after carpal tunnel release. *J Hand Surg Am*. 2003;28:250-254. <https://doi.org/10.1053/jhsu.2003.50043>
102. Geere J, Chester R, Kale S, Jerosch-Herold C. Power grip, pinch grip, manual muscle testing or thenar atrophy – which should be assessed as a motor outcome after carpal tunnel decompression? A systematic review. *BMC Musculoskelet Disord*. 2007;8:114. <https://doi.org/10.1186/1471-2474-8-114>
103. Gelberman RH, Hergenroeder PT, Hargens AR, Lundborg GN, Akeson WH. The carpal tunnel syndrome. A study of carpal canal pressures. *J Bone Joint Surg Am*. 1981;63:380-383.
104. Gelberman RH, Rydevik BL, Pess GM, Szabo RM, Lundborg G. Carpal tunnel syndrome. A scientific basis for clinical care. *Orthop Clin North Am*. 1988;19:115-124.
105. Gelfman R, Melton LJ, 3rd, Yawn BP, Wollan PC, Amadio PC, Stevens JC. Long-term trends in carpal tunnel syndrome. *Neurology*. 2009;72:33-41.

<https://doi.org/10.1212/01.wnl.0000338533.88960.b9>

106. Gell N, Werner RA, Franzblau A, Ulin SS, Armstrong TJ. A longitudinal study of industrial and clerical workers: incidence of carpal tunnel syndrome and assessment of risk factors. *J Occup Rehabil.* 2005;15:47-55. <https://doi.org/10.1007/s10926-005-0873-0>
107. Gerr F, Letz R. The sensitivity and specificity of tests for carpal tunnel syndrome vary with the comparison subjects. *J Hand Surg Br.* 1998;23:151-155. [https://doi.org/10.1016/S0266-7681\(98\)80163-0](https://doi.org/10.1016/S0266-7681(98)80163-0)
108. Gerritsen AA, de Vet HC, Scholten RJ, Bertelsmann FW, de Krom MC, Bouter LM. Splinting vs surgery in the treatment of carpal tunnel syndrome: a randomized controlled trial. *JAMA.* 2002;288:1245-1251. <https://doi.org/10.1001/jama.288.10.1245>
109. Gerritsen AA, Korthals-de Bos IB, Laboyrie PM, de Vet HC, Scholten RJ, Bouter LM. Splinting for carpal tunnel syndrome: prognostic indicators of success. *J Neurol Neurosurg Psychiatry.* 2003;74:1342-1344. <https://doi.org/10.1136/jnnp.74.9.1342>
110. Ghasemi M, Rezaee M, Chavoshi F, Mojtahed M, Shams Koushki E. Carpal tunnel syndrome: the role of occupational factors among 906 workers. *Trauma Mon.* 2012;17:296-300. <https://doi.org/10.5812/traumamon.6554>
111. Giersiepen K, Eberle A, Pohlabein H. Gender differences in carpal tunnel syndrome? Occupational and non-occupational risk factors in a population-based case-control study [abstract]. *Ann Epidemiol.* 2000;10:481. [https://doi.org/10.1016/S1047-2797\(00\)00133-2](https://doi.org/10.1016/S1047-2797(00)00133-2)
112. Gökoğlu F, Fındoğlu G, Yorgancıoğlu ZR, Okumuş M, Ceceli E, Kocaoğlu S. Evaluation of iontophoresis and local corticosteroid injection in the treatment of carpal tunnel syndrome. *Am J Phys Med Rehabil.* 2005;84:92-96. <https://doi.org/10.1097/01.PHM.0000151942.49031.DD>
113. Goloborod'ko SA. Provocative test for carpal tunnel syndrome. *J Hand Ther.* 2004;17:344-348. <https://doi.org/10.1197/j.jht.2004.04.004>
114. Golriz B, Ahmadi Bani M, Arazpour M, et al. Comparison of the efficacy of a neutral wrist splint and a wrist splint incorporating a lumbrical unit for the treatment of patients with carpal tunnel syndrome. *Prosthet Orthot Int.* 2016;40:617-623. <https://doi.org/10.1177/0309364615592695>
115. Goodson JT, DeBerard MS, Wheeler AJ, Colledge AL. Occupational and psychosocial risk factors for carpal tunnel syndrome. *J Occup Environ Med.* 2014;56:965-972. <https://doi.org/10.1097/JOM.0000000000000202>
116. Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. *J Clin Epidemiol.* 2003;56:1150-1156. [https://doi.org/10.1016/S0895-4356\(03\)00211-7](https://doi.org/10.1016/S0895-4356(03)00211-7)
117. Greathouse DG, Ernst G, Halle JS, Shaffer SW. GEHS neurophysiological classification system for patients with carpal tunnel syndrome. *US Army Med Dep J.* 2016:60-67.
118. Greenslade JR, Mehta RL, Belward P, Warwick DJ. DASH and Boston questionnaire assessment of carpal tunnel syndrome outcome: what is the responsiveness of an outcome questionnaire? *J Hand Surg Br.* 2004;29:159-164. <https://doi.org/10.1016/j.jhsb.2003.10.010>
119. Gulliford MC, Latinovic R, Charlton J, Hughes RA. Increased incidence of carpal tunnel syndrome up to 10 years before diagnosis of diabetes. *Diabetes Care.* 2006;29:1929-1930. <https://doi.org/10.2337/dc06-0939>
120. Gül Yurdakul F, Bodur H, Öztıp Çakmak Ö, et al. On the severity of carpal tunnel syndrome: diabetes or metabolic syndrome. *J Clin Neurol.* 2015;11:234-240. <https://doi.org/10.3988/jcn.2015.11.3.234>
121. Gurcay E, Unlu E, Gurcay AG, Tuncay R, Cakci A. Assessment of phonophoresis and iontophoresis in the treatment of carpal tunnel syndrome: a randomized controlled trial. *Rheumatol Int.* 2012;32:717-722. <https://doi.org/10.1007/s00296-010-1706-9>
122. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. *JAMA.* 1995;274:1800-1804. <https://doi.org/10.1001/jama.1995.03530220066035>
123. Hagberg M, Morgenstern H, Kelsch M. Impact of occupations and job tasks on the prevalence of carpal tunnel syndrome. *Scand J Work Environ Health.* 1992;18:337-345. <https://doi.org/10.5271/sjweh.1564>
124. Hakim AJ, Cherkas L, El Zayat S, MacGregor AJ, Spector TD. The genetic contribution to carpal tunnel syndrome in women: a twin study. *Arthritis Rheum.* 2002;47:275-279. <https://doi.org/10.1002/art.10395>
125. Hall B, Lee HC, Fitzgerald H, Byrne B, Barton A, Lee AH. Investigating the effectiveness of full-time wrist splinting and education in the treatment of carpal tunnel syndrome: a randomized controlled trial. *Am J Occup Ther.* 2013;67:448-459. <https://doi.org/10.5014/ajot.2013.006031>
126. Hardy M, Jimenez S, Jabaley M, Horch K. Evaluation of nerve compression with the Automated Tactile Tester. *J Hand Surg Am.* 1992;17:838-842. [https://doi.org/10.1016/0363-5023\(92\)90453-V](https://doi.org/10.1016/0363-5023(92)90453-V)
127. Harris-Adamson C, Eisen EA, Dale AM, et al. Personal and workplace psychosocial risk factors for carpal tunnel syndrome: a pooled study cohort. *Occup Environ Med.* 2013;70:529-537. <https://doi.org/10.1136/oemed-2013-101365>
128. Harris-Adamson C, Eisen EA, Kapellusch J, et al. Biomechanical risk factors for carpal tunnel syndrome: a pooled study of 2474 workers. *Occup Environ Med.* 2015;72:33-41. <https://doi.org/10.1136/oemed-2014-102378>
129. Harris-Adamson C, Eisen EA, Neophytou A, et al. Biomechanical and psychosocial exposures are independent risk factors for carpal tunnel syndrome: assessment of confounding using causal diagrams. *Occup Environ Med.* 2016;73:727-734. <https://doi.org/10.1136/oemed-2016-103634>
130. Hegmann KT, Thiese MS, Kapellusch J, et al. Association between cardiovascular risk factors and carpal tunnel syndrome in pooled occupational cohorts. *J Occup Environ Med.* 2016;58:87-93. <https://doi.org/10.1097/JOM.0000000000000573>
131. Hemminki K, Li X, Sundquist K. Familial risks for nerve, nerve root and plexus disorders in siblings based on hospitalisations in Sweden. *J Epidemiol Community Health.* 2007;61:80-84. <https://doi.org/10.1136/jech.2006.046615>
132. Hirata H, Nagakura T, Tsujii M, Morita A, Fujisawa K, Uchida A. The relationship of VEGF and PGE2 expression to extracellular matrix remodelling of the tenosynovium in the carpal tunnel syndrome. *J Pathol.* 2004;204:605-612. <https://doi.org/10.1002/path.1673>
133. Hlebs S, Majhenic K, Vidmar G. Body mass index and anthropometric characteristics of the hand as risk factors for carpal tunnel syndrome. *Coll Antropol.* 2014;38:219-226.
134. Hobby JL, Watts C, Elliot D. Validity and responsiveness of the patient evaluation measure as an outcome measure for carpal tunnel syndrome. *J Hand Surg Br.* 2005;30:350-354. <https://doi.org/10.1016/j.jhsb.2005.03.009>
135. Hsu HY, Su FC, Kuo YL, Jou IM, Chiu HY, Kuo LC. Assessment from functional perspectives: using sensorimotor control in the hand as an outcome indicator in the surgical treatment of carpal tunnel syndrome. *PLoS One.* 2015;10:e0128420. <https://doi.org/10.1371/journal.pone.0128420>
136. Incebiyik S, Boyaci A, Tutoglu A. Short-term effectiveness of short-wave diathermy treatment on pain, clinical symptoms, and hand function in patients with mild or moderate idiopathic carpal tunnel syndrome. *J Back Musculoskeletal Rehabil.* 2015;28:221-228. <https://doi.org/10.3233/BMR-140507>
137. Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: electrodiagnostic studies in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. *Neurology.* 2002;58:1589-1592. <https://doi.org/10.1212/WNL.58.11.1589>
138. Jerosch-Herold C, Shepstone L, Miller L, Chapman P. The responsiveness of sensibility and strength tests in patients undergoing carpal tunnel

decompression. *BMC Musculoskelet Disord*. 2011;12:244. <https://doi.org/10.1186/1471-2474-12-244>

139. Jetzer TC. Use of vibration testing in the early evaluation of workers with carpal tunnel syndrome. *J Occup Med*. 1991;33:117-120.
140. Karmoloz LP, Beck H, Haslik W, et al. Carpal tunnel syndrome: a question of hand and wrist configurations? *J Hand Surg Br*. 2004;29:321-324. <https://doi.org/10.1016/j.jhsb.2003.09.010>
141. Kapellusch JM, Gerr FE, Malloy EJ, et al. Exposure-response relationships for the ACGIH threshold limit value for hand-activity level: results from a pooled data study of carpal tunnel syndrome. *Scand J Work Environ Health*. 2014;40:610-620. <https://doi.org/10.5271/sjweh.3456>
142. Karatay S, Aygul R, Melikoglu MA, et al. The comparison of phonophoresis, iontophoresis and local steroid injection in carpal tunnel syndrome treatment [letter]. *Joint Bone Spine*. 2009;76:719-721. <https://doi.org/10.1016/j.jbspin.2009.02.008>
143. Karne SS, Bhalerao NS. Carpal tunnel syndrome in hypothyroidism. *J Clin Diagn Res*. 2016;10:OC36-OC38. <https://doi.org/10.7860/JCDR/2016/16464.7316>
144. Kasundra GM, Sood I, Bhargava AN, et al. Carpal tunnel syndrome: analyzing efficacy and utility of clinical tests and various diagnostic modalities. *J Neurosci Rural Pract*. 2015;6:504-510. <https://doi.org/10.4103/0976-3147.169867>
145. Katz JN, Gelberman RH, Wright EA, Lew RA, Liang MH. Responsiveness of self-reported and objective measures of disease severity in carpal tunnel syndrome. *Med Care*. 1994;32:1127-1133.
146. Katz JN, Stirrat CR, Larson MG, Fossel AH, Eaton HM, Liang MH. A self-administered hand symptom diagram for the diagnosis and epidemiologic study of carpal tunnel syndrome. *J Rheumatol*. 1990;17:1495-1498.
147. Kaye JJ, Reynolds JM. Carpal tunnel syndrome: using self-report measures of disease to predict treatment response. *Am J Orthop (Belle Mead NJ)*. 2007;36:E59-E62.
148. Keir PJ, Bach JM, Rempel DM. Effects of finger posture on carpal tunnel pressure during wrist motion. *J Hand Surg Am*. 1998;23:1004-1009. [https://doi.org/10.1016/S0363-5023\(98\)80007-5](https://doi.org/10.1016/S0363-5023(98)80007-5)
149. Kerwin G, Williams CS, Seiler JG, 3rd. The pathophysiology of carpal tunnel syndrome. *Hand Clin*. 1996;12:243-251.
150. Koca I, Boyaci A, Tutoglu A, Ucar M, Kocaturk O. Assessment of the effectiveness of interferential current therapy and TENS in the management of carpal tunnel syndrome: a randomized controlled study. *Rheumatol Int*. 2014;34:1639-1645. <https://doi.org/10.1007/s00296-014-3005-3>
151. Kociolek AM, Tat J, Keir PJ. Biomechanical risk factors and flexor tendon frictional work in the cadaveric carpal tunnel. *J Biomech*. 2015;48:449-455. <https://doi.org/10.1016/j.jbiomech.2014.12.029>
152. Komurcu HF, Kilic S, Anlar O. Relationship of age, body mass index, wrist and waist circumferences to carpal tunnel syndrome severity. *Neurol Med Chir (Tokyo)*. 2014;54:395-400. <https://doi.org/10.2176/nmc.0a2013-0028>
153. Koris M, Gelberman RH, Duncan K, Boublick M, Smith B. Carpal tunnel syndrome. Evaluation of a quantitative provocative diagnostic test. *Clin Orthop Relat Res*. 1990;157-161.
154. Kotsis SV, Chung KC. Responsiveness of the Michigan Hand Outcomes Questionnaire and the Disabilities of the Arm, Shoulder and Hand questionnaire in carpal tunnel surgery. *J Hand Surg Am*. 2005;30:81-86. <https://doi.org/10.1016/j.jhnsa.2004.10.006>
155. Kouyoumdjian JA, Morita MP, Rocha PR, Miranda RC, Gouveia GM. Wrist and palm indexes in carpal tunnel syndrome. *Arq Neuropsiquiatr*. 2000;58:625-629. <https://doi.org/10.1590/S0004-282X2000000400005>
156. Kuo MH, Leong CP, Cheng YF, Chang HW. Static wrist position associated with least median nerve compression: sonographic evaluation. *Am J Phys Med Rehabil*. 2001;80:256-260. <https://doi.org/10.1097/00002060-200104000-00004>
157. LaJoie AS, McCabe SJ, Thomas B, Edgell SE. Determining the sensitivity and specificity of common diagnostic tests for carpal tunnel syndrome using latent class analysis. *Plast Reconstr Surg*. 2005;116:502-507. <https://doi.org/10.1097/01.prs.0000172894.21006.e2>
158. Lam N, Thurston A. Association of obesity, gender, age and occupation with carpal tunnel syndrome. *Aust N Z J Surg*. 1998;68:190-193.
159. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977;33:159-174. <https://doi.org/10.2307/2529310>
160. Leclerc A, Franchi P, Cristofari MF, et al. Carpal tunnel syndrome and work organisation in repetitive work: a cross sectional study in France. Study Group on Repetitive Work. *Occup Environ Med*. 1998;55:180-187. <https://doi.org/10.1136/oem.55.3.180>
161. Leclerc A, Landre MF, Chastang JF, Niedhammer I, Roquelaure Y, Study Group on Repetitive Work. Upper-limb disorders in repetitive work. *Scand J Work Environ Health*. 2001;27:268-278. <https://doi.org/10.5271/sjweh.614>
162. Levine DW, Simmons BP, Koris MJ, et al. A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. *J Bone Joint Surg Am*. 1993;75:1585-1592.
163. Liu CW, Chen TW, Wang MC, Chen CH, Lee CL, Huang MH. Relationship between carpal tunnel syndrome and wrist angle in computer workers. *Kaohsiung J Med Sci*. 2003;19:617-623. [https://doi.org/10.1016/S1607-551X\(09\)70515-7](https://doi.org/10.1016/S1607-551X(09)70515-7)
164. Luckhaupt SE, Dahlhamer JM, Ward BW, Sweeney MH, Sestito JP, Calvert GM. Prevalence and work-relatedness of carpal tunnel syndrome in the working population, United States, 2010 National Health Interview Survey. *Am J Ind Med*. 2013;56:615-624. <https://doi.org/10.1002/ajim.22048>
165. Lundborg G, Gelberman RH, Minteer-Convery M, Lee YF, Hargens AR. Median nerve compression in the carpal tunnel—functional response to experimentally induced controlled pressure. *J Hand Surg Am*. 1982;7:252-259. [https://doi.org/10.1016/S0363-5023\(82\)80175-5](https://doi.org/10.1016/S0363-5023(82)80175-5)
166. Lundborg G, Lie-Stenström AK, Sollerman C, Strömberg T, Pyykkö I. Digital vibrogram: a new diagnostic tool for sensory testing in compression neuropathy. *J Hand Surg Am*. 1986;11:693-699. [https://doi.org/10.1016/S0363-5023\(86\)80014-4](https://doi.org/10.1016/S0363-5023(86)80014-4)
167. Lyrén PE, Atroski I. Using item response theory improved responsiveness of patient-reported outcomes measures in carpal tunnel syndrome. *J Clin Epidemiol*. 2012;65:325-334. <https://doi.org/10.1016/j.jclinepi.2011.08.009>
168. Ma H, Kim I. The diagnostic assessment of hand elevation test in carpal tunnel syndrome. *J Korean Neurosurg Soc*. 2012;52:472-475. <https://doi.org/10.3340/jkns.2012.52.5.472>
169. MacDermid JC, Doherty T. Clinical and electrodiagnostic testing of carpal tunnel syndrome: a narrative review. *J Orthop Sports Phys Ther*. 2004;34:565-588. <https://doi.org/10.2519/jospt.2004.34.10.565>
170. MacDermid JC, Kramer JF, McFarlane RM, Roth JH. Inter-rater agreement and accuracy of clinical tests used in diagnosis of carpal tunnel syndrome. *Work*. 1997;8:37-44. <https://doi.org/10.3233/WOR-1997-8105>
171. MacDermid JC, Kramer JF, Roth JH. Decision making in detecting abnormal Semmes-Weinstein monofilament thresholds in carpal tunnel syndrome. *J Hand Ther*. 1994;7:158-162. [https://doi.org/10.1016/S0894-1130\(12\)80057-3](https://doi.org/10.1016/S0894-1130(12)80057-3)
172. MacDermid JC, Walton DM, Law M. Critical appraisal of research evidence for its validity and usefulness. *Hand Clin*. 2009;25:29-42. <https://doi.org/10.1016/j.hcl.2008.11.003>
173. MacDermid JC, Wessel J. Clinical diagnosis of carpal tunnel syndrome: a systematic review. *J Hand Ther*. 2004;17:309-319. <https://doi.org/10.1197/j.jht.2004.02.015>
174. Mackinnon SE. Pathophysiology of nerve compression. *Hand Clin*.



- 2002;18:231-241. [https://doi.org/10.1016/S0749-0712\(01\)00012-9](https://doi.org/10.1016/S0749-0712(01)00012-9)
175. Maddali Bongi S, Signorini M, Bassetti M, Del Rosso A, Orlandi M, De Scisciolo G. A manual therapy intervention improves symptoms in patients with carpal tunnel syndrome: a pilot study. *Rheumatol Int*. 2013;33:1233-1241. <https://doi.org/10.1007/s00296-012-2507-0>
  176. Madjdinasab N, Zadeh NS, Assarzagdegan F, Ali AMA, Pipelzadeh M. Efficacy comparison of splint and oral steroid therapy in nerve conduction velocity and latency median nerve in carpal tunnel syndrome. *Pak J Med Sci*. 2008;24:725-728.
  177. Maggard MA, Harness NG, Chang WT, et al. Indications for performing carpal tunnel surgery: clinical quality measures. *Plast Reconstr Surg*. 2010;126:169-179. <https://doi.org/10.1097/PRS.0b013e3181da8685>
  178. Makanji HS, Becker SJ, Mudgal CS, Jupiter JB, Ring D. Evaluation of the scratch collapse test for the diagnosis of carpal tunnel syndrome. *J Hand Surg Eur Vol*. 2014;39:181-186. <https://doi.org/10.1177/1753193413497191>
  179. Manente G, Melchionda D, Staniscia T, D'Archivio C, Mazzone V, Macarini L. Changes in the carpal tunnel while wearing the Manu soft hand brace: a sonographic study. *J Hand Surg Eur Vol*. 2013;38:57-60. <https://doi.org/10.1177/1753193412446112>
  180. Manente G, Torrieri F, Di Blasio F, Staniscia T, Romano F, Uncini A. An innovative hand brace for carpal tunnel syndrome: a randomized controlled trial. *Muscle Nerve*. 2001;24:1020-1025. <https://doi.org/10.1002/mus.1105>
  181. Mansfield M, Thacker M, Sandford F. Psychosocial risk factors and the association with carpal tunnel syndrome: a systematic review. *Hand (N Y)*. 2018;13:501-508. <https://doi.org/10.1177/1558944717736398>
  182. Marlowe ES, Bonner FJ, Jr., Berkowitz AR. Correlation between two-point discrimination and median nerve sensory response. *Muscle Nerve*. 1999;22:1196-1200. [https://doi.org/10.1002/\(Sici\)1097-4598\(199909\)22:9<1196::Aid-Mus5>3.0.Co;2-K](https://doi.org/10.1002/(Sici)1097-4598(199909)22:9<1196::Aid-Mus5>3.0.Co;2-K)
  183. Marx RG, Hudak PL, Bombardier C, Graham B, Goldsmith C, Wright JG. The reliability of physical examination for carpal tunnel syndrome. *J Hand Surg Br*. 1998;23:499-502. [https://doi.org/10.1016/S0266-7681\(98\)80132-0](https://doi.org/10.1016/S0266-7681(98)80132-0)
  184. Massy-Westropp N, Grimmer K, Bain G. A systematic review of the clinical diagnostic tests for carpal tunnel syndrome. *J Hand Surg Am*. 2000;25:120-127. <https://doi.org/10.1053/jhsu.2000.jhsu025a0120>
  185. Mattioli S, Baldasseroni A, Bovenzi M, et al. Risk factors for operated carpal tunnel syndrome: a multicenter population-based case-control study. *BMC Public Health*. 2009;9:343. <https://doi.org/10.1186/1471-2458-9-343>
  186. Mattioli S, Baldasseroni A, Curti S, et al. Incidence rates of in-hospital carpal tunnel syndrome in the general population and possible associations with marital status. *BMC Public Health*. 2008;8:374. <https://doi.org/10.1186/1471-2458-8-374>
  187. McMillan CR, Binhammer PA. Which outcome measure is the best? Evaluating responsiveness of the Disabilities of the Arm, Shoulder, and Hand Questionnaire, the Michigan Hand Questionnaire and the Patient-Specific Functional Scale following hand and wrist surgery. *Hand (N Y)*. 2009;4:311-318. <https://doi.org/10.1007/s11552-009-9167-x>
  188. Mediouni Z, Bodin J, Dale AM, et al. Carpal tunnel syndrome and computer exposure at work in two large complementary cohorts. *BMJ Open*. 2015;5:e008156. <https://doi.org/10.1136/bmjopen-2015-008156>
  189. Mediouni Z, de Roquemaurel A, Dumontier C, et al. Is carpal tunnel syndrome related to computer exposure at work? A review and meta-analysis. *J Occup Environ Med*. 2014;56:204-208. <https://doi.org/10.1097/JOM.0000000000000080>
  190. Meems M, Den Oudsten B, Meems BJ, Pop V. Effectiveness of mechanical traction as a non-surgical treatment for carpal tunnel syndrome compared to care as usual: study protocol for a randomized controlled trial. *Trials*. 2014;15:180. <https://doi.org/10.1186/1745-6215-15-180>
  191. Michlovitz S, Hun L, Erasala GN, Hengehold DA, Weingand KW. Continuous low-level heat wrap therapy is effective for treating wrist pain. *Arch Phys Med Rehabil*. 2004;85:1409-1416. <https://doi.org/10.1016/j.apmr.2003.10.016>
  192. Mishra S, Prabhakar S, Lal V, Modi M, Das CP, Khurana D. Efficacy of splinting and oral steroids in the treatment of carpal tunnel syndrome: a prospective randomized clinical and electrophysiological study. *Neurol India*. 2006;54:286-290.
  193. Mondelli M, Curti S, Farioli A, et al. Anthropometric measurements as a screening test for carpal tunnel syndrome: receiver operating characteristic curves and accuracy. *Arthritis Care Res (Hoboken)*. 2015;67:691-700. <https://doi.org/10.1002/acr.22465>
  194. Mondelli M, Curti S, Mattioli S, et al. Associations between body anthropometric measures and severity of carpal tunnel syndrome. *Arch Phys Med Rehabil*. 2016;97:1456-1464. <https://doi.org/10.1016/j.apmr.2016.03.028>
  195. Mondelli M, Farioli A, Mattioli S, et al. Severity of carpal tunnel syndrome and diagnostic accuracy of hand and body anthropometric measures. *PLoS One*. 2016;11:e0164715. <https://doi.org/10.1371/journal.pone.0164715>
  196. Mondelli M, Passero S, Giannini F. Provocative tests in different stages of carpal tunnel syndrome. *Clin Neurol Neurosurg*. 2001;103:178-183. [https://doi.org/10.1016/S0303-8467\(01\)00140-8](https://doi.org/10.1016/S0303-8467(01)00140-8)
  197. Musolin K, Ramsey JG, Wassell JT, Hard DL. Prevalence of carpal tunnel syndrome among employees at a poultry processing plant. *Appl Ergon*. 2014;45:1377-1383. <https://doi.org/10.1016/j.apergo.2014.03.005>
  198. Nakamichi K, Tachibana S. Histology of the transverse carpal ligament and flexor tenosynovium in idiopathic carpal tunnel syndrome. *J Hand Surg Am*. 1998;23:1015-1024. [https://doi.org/10.1016/S0363-5023\(98\)80009-9](https://doi.org/10.1016/S0363-5023(98)80009-9)
  199. Nakamichi K, Tachibana S. Hypercholesterolemia as a risk factor for idiopathic carpal tunnel syndrome. *Muscle Nerve*. 2005;32:364-367. <https://doi.org/10.1002/mus.20363>
  200. Nakamichi K, Tachibana S. Small hand as a risk factor for idiopathic carpal tunnel syndrome. *Muscle Nerve*. 1995;18:664-666. <https://doi.org/10.1002/mus.880180616>
  201. Nathan PA, Keniston RC. Carpal tunnel syndrome and its relation to general physical condition. *Hand Clin*. 1993;9:253-261.
  202. Nathan PA, Keniston RC, Lockwood RS, Meadows KD. Tobacco, caffeine, alcohol, and carpal tunnel syndrome in American industry. A cross-sectional study of 1464 workers. *J Occup Environ Med*. 1996;38:290-298.
  203. Nathan PA, Keniston RC, Myers LD, Meadows KD. Obesity as a risk factor for slowing of sensory conduction of the median nerve in industry. A cross-sectional and longitudinal study involving 429 workers. *J Occup Med*. 1992;34:379-383.
  204. Nathan PA, Meadows KD, Doyle LS. Occupation as a risk factor for impaired sensory conduction of the median nerve at the carpal tunnel. *J Hand Surg Br*. 1988;13:167-170. [https://doi.org/10.1016/0266-7681\\_88\\_90130-1](https://doi.org/10.1016/0266-7681_88_90130-1)
  205. Nathan PA, Meadows KD, Istvan JA. Predictors of carpal tunnel syndrome: an 11-year study of industrial workers. *J Hand Surg Am*. 2002;27:644-651. <https://doi.org/10.1053/jhsu.2002.34003>
  206. Neral M, Winger D, Imbriglia J, Wollstein R. Hand shape and carpal tunnel syndrome. *Curr Rheumatol Rev*. 2016;12:239-243. <https://doi.org/10.2174/15733998126661608051>
  207. Nordander C, Ohlsson K, Åkesson I, et al. Exposure-response relationships in work-related musculoskeletal disorders in elbows and hands – a synthesis of group-level data on exposure and response obtained using uniform methods of data collection. *Appl Ergon*. 2013;44:241-253. <https://doi.org/10.1016/j.apergo.2012.07.009>
  208. Nordstrom DL, Vierkant RA, DeStefano F, Layde PM. Risk factors for carpal tunnel syndrome in a general population. *Occup Environ Med*. 1997;54:734-740. <https://doi.org/10.1136/oem.54.10.734>

209. Ntani G, Palmer KT, Linaker C, et al. Symptoms, signs and nerve conduction velocities in patients with suspected carpal tunnel syndrome. *BMC Musculoskelet Disord*. 2013;14:242. <https://doi.org/10.1186/1471-2474-14-242>
210. O'Connor D, Page MJ, Marshall SC, Massy-Westropp N. Ergonomic positioning or equipment for treating carpal tunnel syndrome. *Cochrane Database Syst Rev*. 2012;1:CD009600. <https://doi.org/10.1002/14651858.CD009600>
211. Oktayoglu P, Nas K, Kiliç F, Tasdemir N, Bozkurt M, Yildiz I. Assessment of the presence of carpal tunnel syndrome in patients with diabetes mellitus, hypothyroidism and acromegaly. *J Clin Diagn Res*. 2015;9:OC14-OC18. <https://doi.org/10.7860/JCDR/2015/13149.6101>
212. Ollivere BJ, Logan K, Ellahee N, Miller-Jones JC, Wood M, Nairn DS. Severity scoring in carpal tunnel syndrome helps predict the value of conservative therapy. *J Hand Surg Eur Vol*. 2009;34:511-515. <https://doi.org/10.1177/1753193409102380>
213. Olsen KM, Knudson DV. Change in strength and dexterity after open carpal tunnel release. *Int J Sports Med*. 2001;22:301-303. <https://doi.org/10.1055/s-2001-13815>
214. Oskouei AE, Talebi GA, Shakouri SK, Ghabili K. Effects of neuromobilization maneuver on clinical and electrophysiological measures of patients with carpal tunnel syndrome. *J Phys Ther Sci*. 2014;26:1017-1022. <https://doi.org/10.1589/jpts.26.1017>
215. Ozcakar S, Sigitli D, Avsaroglu H. High wrist ratio is a risk factor for carpal tunnel syndrome. *Clin Anat*. 2018;31:698-701. <https://doi.org/10.1002/ca.23198>
216. Ozer K, Malay S, Toker S, Chung KC. Minimal clinically important difference of carpal tunnel release in diabetic and nondiabetic patients. *Plast Reconstr Surg*. 2013;131:1279-1285. <https://doi.org/10.1097/PRS.0b013e31828bd6ec>
217. Özgen M, Güngen G, Sarsan A, et al. Determination of the position on which the median nerve compression is at the lowest in carpal tunnel syndrome and clinical effectiveness of custom splint application. *Rheumatol Int*. 2011;31:1031-1036. <https://doi.org/10.1007/s00296-010-1414-5>
218. Oztas O, Turan B, Bora I, Karakaya MK. Ultrasound therapy effect in carpal tunnel syndrome. *Arch Phys Med Rehabil*. 1998;79:1540-1544. [https://doi.org/10.1016/S0003-9993\(98\)90416-6](https://doi.org/10.1016/S0003-9993(98)90416-6)
219. Özyüreköçlü T, McCabe SJ, Goldsmith LJ, LaJoie AS. The minimal clinically important difference of the Carpal Tunnel Syndrome Symptom Severity Scale. *J Hand Surg Am*. 2006;31:733-738; discussion 739-740. <https://doi.org/10.1016/j.jhsa.2006.01.012>
220. Padua L, LoMonaco M, Gregori B, Valente EM, Padua R, Tonali P. Neurophysiological classification and sensitivity in 500 carpal tunnel syndrome hands. *Acta Neurol Scand*. 1997;96:211-217. <https://doi.org/10.1111/j.1600-0404.1997.tb00271.x>
221. Page MJ, Massy-Westropp N, O'Connor D, Pitt V. Splinting for carpal tunnel syndrome. *Cochrane Database Syst Rev*. 2012:CD010003. <https://doi.org/10.1002/14651858.CD010003>
222. Page MJ, O'Connor D, Pitt V, Massy-Westropp N. Exercise and mobilisation interventions for carpal tunnel syndrome. *Cochrane Database Syst Rev*. 2012:CD009899. <https://doi.org/10.1002/14651858.CD009899>
223. Palmer KT, Harris EC, Coggon D. Carpal tunnel syndrome and its relation to occupation: a systematic literature review. *Occup Med (Lond)*. 2007;57:57-66. <https://doi.org/10.1093/occmed/kql125>
224. Pascual E, Giner V, Aróstegui A, Conill J, Ruiz MT, Picó A. Higher incidence of carpal tunnel syndrome in oophorectomized women. *Br J Rheumatol*. 1991;30:60-62. <https://doi.org/10.1093/rheumatology/30.1.60>
225. Petit A, Ha C, Bodin J, et al. Risk factors for carpal tunnel syndrome related to the work organization: a prospective surveillance study in a large working population. *Appl Ergon*. 2015;47:1-10. <https://doi.org/10.1016/j.apergo.2014.08.007>
226. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). Available at: <http://www.cebm.net/index.aspx?o=1025>. Accessed March 25, 2019.
227. Pourmemari MH, Shiri R. Diabetes as a risk factor for carpal tunnel syndrome: a systematic review and meta-analysis. *Diabet Med*. 2016;33:10-16. <https://doi.org/10.1111/dme.12855>
228. Pourmemari MH, Viikari-Juntura E, Shiri R. Smoking and carpal tunnel syndrome: a meta-analysis. *Muscle Nerve*. 2014;49:345-350. <https://doi.org/10.1002/mus.23922>
229. Povlsen B, Bashir M, Wong F. Long-term result and patient reported outcome of wrist splint treatment for carpal tunnel syndrome. *J Plast Surg Hand Surg*. 2014;48:175-178. <https://doi.org/10.3109/2000656X.2013.837392>
230. Pransky G, Feuerstein M, Himmelstein J, Katz JN, Vickers-Lahti M. Measuring functional outcomes in work-related upper extremity disorders. Development and validation of the Upper Extremity Function Scale. *J Occup Environ Med*. 1997;39:1195-1202.
231. Premoselli S, Sioli P, Grossi A, Cerri C. Neutral wrist splinting in carpal tunnel syndrome: a 3- and 6-months clinical and neurophysiologic follow-up evaluation of night-only splint therapy. *Eura Medicophys*. 2006;42:121-126.
232. Priganc VW, Henry SM. The relationship among five common carpal tunnel syndrome tests and the severity of carpal tunnel syndrome. *J Hand Ther*. 2003;16:225-236. [https://doi.org/10.1016/S0894-1130\(03\)00038-3](https://doi.org/10.1016/S0894-1130(03)00038-3)
233. Radecki P. A gender specific wrist ratio and the likelihood of a median nerve abnormality at the carpal tunnel. *Am J Phys Med Rehabil*. 1994;73:157-162.
234. Raeissadat SA, Rayegani SM, Rezaei S, et al. The effect of polarized polychromatic noncoherent light (Bioptron) therapy on patients with carpal tunnel syndrome. *J Lasers Med Sci*. 2014;5:39-46.
235. Raji P, Ansari NN, Naghdi S, Forogh B, Hasson S. Relationship between Semmes-Weinstein monofilaments perception test and sensory nerve conduction studies in carpal tunnel syndrome. *Neurorehabilitation*. 2012;31:215-222. <https://doi.org/10.3233/NRE-141150>
236. Rankin IA, Sargeant H, Rehman H, Gurusamy KF. Low-level laser therapy for carpal tunnel syndrome. *Cochrane Database Syst Rev*. 2017:CD012765. <https://doi.org/10.1002/14651858.CD012765>
237. Rempel D, Bach JM, Gordon L, So Y. Effects of forearm pronation/supination on carpal tunnel pressure. *J Hand Surg Am*. 1998;23:38-42. [https://doi.org/10.1016/S0363-5023\(98\)80086-5](https://doi.org/10.1016/S0363-5023(98)80086-5)
238. Rempel D, Evanoff B, Amadio PC, et al. Consensus criteria for the classification of carpal tunnel syndrome in epidemiologic studies. *Am J Public Health*. 1998;88:1447-1451.
239. Rempel D, Tittiranonda P, Burastero S, Hudes M, So Y. Effect of keyboard keyswitch design on hand pain. *J Occup Environ Med*. 1999;41:111-119.
240. Rempel DM, Diao E. Entrapment neuropathies: pathophysiology and pathogenesis. *J Electromyogr Kinesiol*. 2004;14:71-75. <https://doi.org/10.1016/j.jelekin.2003.09.009>
241. Rempel DM, Keir PJ, Bach JM. Effect of wrist posture on carpal tunnel pressure while typing. *J Orthop Res*. 2008;26:1269-1273. <https://doi.org/10.1002/jor.20599>
242. Riccò M, Cattani S, Signorelli C. Personal risk factors for carpal tunnel syndrome in female visual display unit workers. *Int J Occup Med Environ Health*. 2016;29:927-936. <https://doi.org/10.13075/ijomh.1896.00781>
243. Riccò M, Signorelli C. Personal and occupational risk factors for carpal tunnel syndrome in meat processing industry workers in Northern Italy. *Med Pr*. 2017;68:199-209. <https://doi.org/10.13075/mp.5893.00605>
244. Rigouin P, Ha C, Bodin J, et al. Organizational and psychosocial risk factors for carpal tunnel syndrome: a cross-sectional study of French workers. *Int Arch Occup Environ Health*. 2014;87:147-154. <https://doi.org/10.1007/s00420-013-0846-0>

245. Rojviroj S, Sirichativapee W, Kowsuwon W, Wongwiwattananon J, Tamnanthong N, Jeeravipoolvarn P. Pressures in the carpal tunnel. A comparison between patients with carpal tunnel syndrome and normal subjects. *J Bone Joint Surg Br*. 1990;72:516-518.
246. Roll SC, Volz KR, Fahy CM, Evans KD. Carpal tunnel syndrome severity staging using sonographic and clinical measures. *Muscle Nerve*. 2015;51:838-845. <https://doi.org/10.1002/mus.24478>
247. Roquelaure Y, Chazelle E, Gautier L, et al. Time trends in incidence and prevalence of carpal tunnel syndrome over eight years according to multiple data sources: Pays de la Loire study. *Scand J Work Environ Health*. 2017;43:75-85. <https://doi.org/10.5271/sjweh.3594>
248. Roquelaure Y, Ha C, Pelier-Cady MC, et al. Work increases the incidence of carpal tunnel syndrome in the general population. *Muscle Nerve*. 2008;37:477-482. <https://doi.org/10.1002/mus.20952>
249. Roquelaure Y, Mechali S, Dano C, et al. Occupational and personal risk factors for carpal tunnel syndrome in industrial workers. *Scand J Work Environ Health*. 1997;23:364-369. <https://doi.org/10.5271/sjweh.233>
250. Sakthiswary R, Singh R. Has the median nerve involvement in rheumatoid arthritis been overemphasized? *Rev Bras Reumatol Engl Ed*. 2017;57:122-128. <https://doi.org/10.1016/j.rbre.2016.09.001>
251. Salerno DF, Franzblau A, Werner RA, et al. Reliability of physical examination of the upper extremity among keyboard operators. *Am J Ind Med*. 2000;37:423-430. [https://doi.org/10.1002/\(SICI\)1097-0274\(200004\)37:4<423::AID-AJIM12>3.0.CO;2-W](https://doi.org/10.1002/(SICI)1097-0274(200004)37:4<423::AID-AJIM12>3.0.CO;2-W)
252. Schmid AB, Elliott JM, Strudwick MW, Little M, Coppieters MW. Effect of splinting and exercise on intraneural edema of the median nerve in carpal tunnel syndrome—an MRI study to reveal therapeutic mechanisms. *J Orthop Res*. 2012;30:1343-1350. <https://doi.org/10.1002/jor.22064>
253. Schmid AB, Kubler PA, Johnston V, Coppieters MW. A vertical mouse and ergonomic mouse pads alter wrist position but do not reduce carpal tunnel pressure in patients with carpal tunnel syndrome. *Appl Ergon*. 2015;47:151-156. <https://doi.org/10.1016/j.apergo.2014.08.020>
254. Sears ED, Chung KC. Validity and responsiveness of the Jebsen-Taylor Hand Function Test. *J Hand Surg Am*. 2010;35:30-37. <https://doi.org/10.1016/j.jhsa.2009.09.008>
255. Shiri R. Arthritis as a risk factor for carpal tunnel syndrome: a meta-analysis. *Scand J Rheumatol*. 2016;45:339-346. <https://doi.org/10.3109/03009742.2015.1114141>
256. Shiri R. Hypothyroidism and carpal tunnel syndrome: a meta-analysis. *Muscle Nerve*. 2014;50:879-883. <https://doi.org/10.1002/mus.24453>
257. Shiri R. A square-shaped wrist as a predictor of carpal tunnel syndrome: a meta-analysis. *Muscle Nerve*. 2015;52:709-713. <https://doi.org/10.1002/mus.24761>
258. Shiri R, Falah-Hassani K. Computer use and carpal tunnel syndrome: a meta-analysis. *J Neuro Sci*. 2015;349:15-19. <https://doi.org/10.1016/j.jns.2014.12.037>
259. Shiri R, Heliövaara M, Moilanen L, Viikari J, Liira H, Viikari-Juntura E. Associations of cardiovascular risk factors, carotid intima-media thickness and manifest atherosclerotic vascular disease with carpal tunnel syndrome. *BMC Musculoskelet Disord*. 2011;12:80. <https://doi.org/10.1186/1471-2474-12-80>
260. Shiri R, Pourmemari MH, Falah-Hassani K, Viikari-Juntura E. The effect of excess body mass on the risk of carpal tunnel syndrome: a meta-analysis of 58 studies. *Obes Rev*. 2015;16:1094-1104. <https://doi.org/10.1111/obr.12324>
261. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull*. 1979;86:420-428. <https://doi.org/10.1037/0033-2909.86.2.420>
262. Silverstein B, Fan ZJ, Smith CK, et al. Gender adjustment or stratification in discerning upper extremity musculoskeletal disorder risk? *Scand J Work Environ Health*. 2009;35:113-126. <https://doi.org/10.5271/sjweh.1309>
263. Smith-Forbes EV, Howell DM, Willoughby J, Pitts DG, Uhl TL. Specificity of the minimal clinically important difference of the quick Disabilities of the Arm, Shoulder and Hand (QDASH) for distal upper extremity conditions. *J Hand Ther*. 2016;29:81-88; quiz 88. <https://doi.org/10.1016/j.jht.2015.09.003>
264. So H, Chung VCH, Cheng JCK, Yip RML. Local steroid injection versus wrist splinting for carpal tunnel syndrome: a randomized clinical trial. *Int J Rheum Dis*. 2018;21:102-107. <https://doi.org/10.1111/1756-185X.13162>
265. Solomon DH, Katz JN, Bohn R, Mogun H, Avorn J. Nonoccupational risk factors for carpal tunnel syndrome. *J Gen Intern Med*. 1999;14:310-314. <https://doi.org/10.1046/j.1525-1497.1999.00340.x>
266. Soyupek F, Kutluhan S, Uslusoy G, Ilgun E, Eris S, Askin A. The efficacy of phonophoresis on electrophysiological studies of the patients with carpal tunnel syndrome. *Rheumatol Int*. 2012;32:3235-3242. <https://doi.org/10.1007/s00296-011-2171-9>
267. Soyupek F, Yesildag A, Kutluhan S, et al. Determining the effectiveness of various treatment modalities in carpal tunnel syndrome by ultrasonography and comparing ultrasonographic findings with other outcomes. *Rheumatol Int*. 2012;32:3229-3234. <https://doi.org/10.1007/s00296-011-2173-7>
268. Stasinopoulos D, Stasinopoulos I, Johnson MI. Treatment of carpal tunnel syndrome with polarized polychromatic noncoherent light (Bioptron light): a preliminary, prospective, open clinical trial. *Photomed Laser Surg*. 2005;23:225-228. <https://doi.org/10.1089/pho.2005.23.225>
269. Stevens JC, Beard CM, O'Fallon WM, Kurland LT. Conditions associated with carpal tunnel syndrome. *Mayo Clin Proc*. 1992;67:541-548.
270. Szabo RM, Madison M. Carpal tunnel syndrome. *Orthop Clin North Am*. 1992;23:103-109.
271. Talmor M, Patel MP, Spann MD, et al. COX-2 up-regulation in idiopathic carpal tunnel syndrome. *Plast Reconstr Surg*. 2003;112:1807-1814. <https://doi.org/10.1097/01.PRS.0000092065.60454.BE>
272. Tanaka S, Wild DK, Seligman PJ, Halperin WE, Behrens VJ, Putz-Anderson V. Prevalence and work-relatedness of self-reported carpal tunnel syndrome among U.S. workers: analysis of the Occupational Health Supplement data of 1988 National Health Interview Survey. *Am J Ind Med*. 1995;27:451-470. <https://doi.org/10.1002/ajim.4700270402>
273. Taser F, Deger AN, Deger H. Comparative histopathological evaluation of patients with diabetes, hypothyroidism and idiopathic carpal tunnel syndrome. *Türk Neurosurg*. 2017;27:991-997. <https://doi.org/10.5137/1019-5149.JTN.17618-16.1>
274. Thüngen T, Sadowski M, El Kazzi W, Schuind F. Value of Gilliat's pneumatic tourniquet test for diagnosis of carpal tunnel syndrome. *Chir Main*. 2012;31:152-156. <https://doi.org/10.1016/j.main.2012.04.001>
275. Tittiranonda P, Rempel D, Armstrong T, Burastero S. Effect of four computer keyboards in computer users with upper extremity musculoskeletal disorders. *Am J Ind Med*. 1999;35:647-661. [https://doi.org/10.1002/\(SICI\)1097-0274\(199906\)35:6<647::AID-AJIM12>3.0.CO;2-5](https://doi.org/10.1002/(SICI)1097-0274(199906)35:6<647::AID-AJIM12>3.0.CO;2-5)
276. Tulipan JE, Lutsky KF, Maltenfort MG, Freedman MK, Beredjikian PK. Patient-reported disability measures do not correlate with electrodiagnostic severity in carpal tunnel syndrome. *Plast Reconstr Surg Glob Open*. 2017;5:e1440. <https://doi.org/10.1097/GOX.0000000000001440>
277. Ucan H, Yagci I, Yilmaz L, Yagmurlu F, Keskin D, Bodur H. Comparison of splinting, splinting plus local steroid injection and open carpal tunnel release outcomes in idiopathic carpal tunnel syndrome. *Rheumatol Int*. 2006;27:45-51. <https://doi.org/10.1007/s00296-006-0163-y>
278. van Dijk MA, Reitsma JB, Fischer JC, Sanders GT. Indications for requesting laboratory tests for concurrent diseases in patients with carpal tunnel syndrome: a systematic review. *Clin Chem*. 2003;49:1437-1444. <https://doi.org/10.1373/49.9.1437>
279. van Rijn RM, Huisstede BM, Koes BW, Burdorf A. Associations between work-related factors and the carpal tunnel syndrome—a systematic review. *Scand J Work Environ Health*. 2009;35:19-36. <https://doi.org/10.5271/sjweh.1306>

280. Vanti C, Bonfiglioli R, Calabrese M, et al. Upper Limb Neurodynamic Test 1 and symptoms reproduction in carpal tunnel syndrome. A validity study. *Man Ther.* 2011;16:258-263. <https://doi.org/10.1016/j.math.2010.11.003>
281. Vanti C, Bonfiglioli R, Calabrese M, Marinelli F, Violante FS, Pillastrini P. Relationship between interpretation and accuracy of the Upper Limb Neurodynamic Test 1 in carpal tunnel syndrome. *J Manipulative Physiol Ther.* 2012;35:54-63. <https://doi.org/10.1016/j.jmpt.2011.09.008>
282. Vessey MP, Villard-Mackintosh L, Yeates D. Epidemiology of carpal tunnel syndrome in women of childbearing age. Findings in a large cohort study. *Int J Epidemiol.* 1990;19:655-659. <https://doi.org/10.1093/ije/19.3.655>
283. Wainner RS, Fritz JM, Irrgang JJ, Delitto A, Allison S, Boninger ML. Development of a clinical prediction rule for the diagnosis of carpal tunnel syndrome. *Arch Phys Med Rehabil.* 2005;86:609-618. <https://doi.org/10.1016/j.apmr.2004.11.008>
284. Walker WC, Metzler M, Cifu DX, Swartz Z. Neutral wrist splinting in carpal tunnel syndrome: a comparison of night-only versus full-time wear instructions. *Arch Phys Med Rehabil.* 2000;81:424-429. <https://doi.org/10.1053/mr.2000.3856>
285. Wang JC, Liao KK, Lin KP, et al. Efficacy of combined ultrasound-guided steroid injection and splinting in patients with carpal tunnel syndrome: a randomized controlled trial. *Arch Phys Med Rehabil.* 2017;98:947-956. <https://doi.org/10.1016/j.apmr.2017.01.018>
286. Wee AS. Carpal tunnel syndrome: a system for categorizing and grading electrophysiologic abnormalities. *Electromyogr Clin Neurophysiol.* 2001;41:281-288.
287. Weiss ND, Gordon L, Bloom T, So Y, Rempel DM. Position of the wrist associated with the lowest carpal-tunnel pressure: implications for splint design. *J Bone Joint Surg Am.* 1995;77:1695-1699.
288. Werner RA. Evaluation of work-related carpal tunnel syndrome. *J Occup Rehabil.* 2006;16:207-222. <https://doi.org/10.1007/s10926-006-9026-3>
289. Werner RA, Albers JW, Franzblau A, Armstrong TJ. The relationship between body mass index and the diagnosis of carpal tunnel syndrome. *Muscle Nerve.* 1994;17:632-636. <https://doi.org/10.1002/mus.880170610>
290. Werner RA, Franzblau A, Gell N, Hartigan AG, Ebersole M, Armstrong TJ. Incidence of carpal tunnel syndrome among automobile assembly workers and assessment of risk factors. *J Occup Environ Med.* 2005;47:1044-1050.
291. Werner RA, Franzblau A, Johnston E. Comparison of multiple frequency vibrometry testing and sensory nerve conduction measures in screening for carpal tunnel syndrome in an industrial setting. *Am J Phys Med Rehabil.* 1995;74:101-106.
292. Williams TM, Mackinnon SE, Novak CB, McCabe S, Kelly L. Verification of the pressure provocative test in carpal tunnel syndrome. *Ann Plast Surg.* 1992;29:8-11.
293. Wolny T, Linek P. Is manual therapy based on neurodynamic techniques effective in the treatment of carpal tunnel syndrome? A randomized controlled trial. *Clin Rehabil.* 2019;33:408-417. <https://doi.org/10.1177/0269215518805213>
294. Wolny T, Linek P. Neurodynamic techniques versus "sham" therapy in the treatment of carpal tunnel syndrome: a randomized placebo-controlled trial. *Arch Phys Med Rehabil.* 2018;99:843-854. <https://doi.org/10.1016/j.apmr.2017.12.005>
295. Wolny T, Saulicz E, Linek P, Myśliwiec A, Saulicz M. Effect of manual therapy and neurodynamic techniques vs ultrasound and laser on 2PD in patients with CTS: a randomized controlled trial. *J Hand Ther.* 2016;29:235-245. <https://doi.org/10.1016/j.jht.2016.03.006>
296. World Health Organization. *International Classification of Functioning, Disability and Health: ICF.* Geneva, Switzerland: World Health Organization; 2001.
297. World Health Organization. *International Statistical Classification of Diseases and Related Health Problems.* Geneva, Switzerland: World Health Organization; 2009.
298. Wright C, Smith B, Wright S, Weiner M, Wright K, Rubin D. Who develops carpal tunnel syndrome during pregnancy: an analysis of obesity, gestational weight gain, and parity. *Obstet Med.* 2014;7:90-94. <https://doi.org/10.1177/1753495X14523407>
299. Yeudall LT, Fromm D, Reddon JR, Stefanyk WO. Normative data stratified by age and sex for 12 neuropsychological tests. *J Clin Psychol.* 1986;42:918-946. [https://doi.org/10.1002/1097-4679\(198611\)42:6<918::AID-JCLP2270420617>3.0.CO;2Y](https://doi.org/10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2Y)
300. Yildirim P, Gunduz OH. What is the role of Semmes-Weinstein monofilament testing in the diagnosis of electrophysiologically graded carpal tunnel syndrome? *J Phys Ther Sci.* 2015;27:3749-3753. <https://doi.org/10.1589/jpts.27.3749>
301. Yildiz N, Atalay NS, Gungen GO, Sanal E, Akkaya N, Topuz O. Comparison of ultrasound and ketoprofen phonophoresis in the treatment of carpal tunnel syndrome. *J Back Musculoskeletal Rehabil.* 2011;24:39-47. <https://doi.org/10.3233/BMR-2011-0273>
302. You D, Smith AH, Rempel D. Meta-analysis: association between wrist posture and carpal tunnel syndrome among workers. *Saf Health Work.* 2014;5:27-31. <https://doi.org/10.1016/j.shaw.2014.01.003>
303. Zyluk A, Piotuch B. A comparison of DASH, PEM and Levine questionnaires in outcome measurement of carpal tunnel release. *Handchir Mikrochir Plast Chir.* 2011;43:162-166. <https://doi.org/10.1055/s-0031-1273686>



**MORE INFORMATION**  
WWW.JOSPT.ORG

APPENDIX A

**SEARCH STRATEGIES FOR ALL DATABASES SEARCHED**

**MEDLINE and CINAHL**

("carpal tunnel syndrome" OR "median nerve compression") AND (incidence OR prevalence) AND (2008 [Pdat]: 2018 [Pdat]; ("carpal tunnel syndrome" OR "median nerve compression") AND (pathology OR pathophysiology OR pathoanatomy OR histo\*); "carpal tunnel pressure"; ("carpal tunnel syndrome" OR "median nerve compression") AND classification; ("carpal tunnel syndrome" OR "median nerve compression") AND (inflammation OR prostaglandin); ("carpal tunnel syndrome" OR "median nerve compression") AND conservative AND (outcome OR "clinical course")

("carpal tunnel syndrome" OR "median nerve compression") AND "self-report measures"; ("carpal tunnel syndrome" OR "median nerve compression") AND "patient-report measures"; ("carpal tunnel syndrome" OR "median nerve compression") AND "internal consistency"; ("carpal tunnel syndrome" OR "median nerve compression") AND reliability; ("carpal tunnel syndrome" OR "median nerve compression") AND validity; DASH AND ("carpal tunnel syndrome" OR "median nerve compression"); DASH AND "psychometric properties"; "Katz hand diagram" AND ("carpal tunnel syndrome" OR "median nerve compression"); "Brigham & Women's Hospital carpal tunnel questionnaire"; "6-item carpal tunnel syndrome symptoms scale"; QuickDASH AND ("carpal tunnel syndrome" OR "median nerve compression"); QuickDASH AND "psychometric properties"; "Palmar pain scale" AND ("carpal tunnel syndrome" OR "median nerve compression"); "Palmar pain scale" AND "psychometric properties"; "Boston carpal tunnel questionnaire"; "Boston carpal tunnel questionnaire" AND "psychometric properties"; "Michigan hand outcome questionnaire" AND ("carpal tunnel syndrome" OR "median nerve compression"); "Michigan hand outcome questionnaire" AND "psychometric properties"; "patient evaluation measure" AND ("carpal tunnel syndrome" OR "median nerve compression"); SF-36 AND ("carpal tunnel syndrome" OR "median nerve compression"); SF-36 AND "psychometric properties"; "patient-rated wrist evaluation questionnaire" AND ("carpal tunnel syndrome" OR "median nerve compression"); "patient-rated wrist evaluation questionnaire" AND "psychometric properties"; "upper extremity functional scale" AND ("carpal tunnel syndrome" OR "median nerve compression"); "upper extremity functional scale" AND "psychometric properties"; "Mcgill pain questionnaire" AND ("carpal tunnel syndrome" OR "median nerve compression"); "Flinn Performance screening tool" AND ("carpal tunnel syndrome" OR "median nerve compression"); "7 item satisfaction scale" AND ("carpal tunnel syndrome" OR "median nerve compression"); "12 item brief Michigan hand questionnaire" AND ("carpal tunnel syndrome" OR "median nerve compression")

"Impairment measures" AND ("carpal tunnel syndrome" OR "median nerve compression"); "functional outcome measures" AND

("carpal tunnel syndrome" OR "median nerve compression"); "internal consistency" AND ("carpal tunnel syndrome" OR "median nerve compression"); reliability AND ("carpal tunnel syndrome" OR "median nerve compression"); validity AND ("carpal tunnel syndrome" OR "median nerve compression")

("carpal tunnel syndrome" OR "median nerve compression") AND "grip strength" AND "measurement"; ("carpal tunnel syndrome" OR "median nerve compression") AND "grip strength" AND "reliability"; ("carpal tunnel syndrome" OR "median nerve compression") AND "grip strength" AND "measurement" and "standardization"; ("carpal tunnel syndrome" OR "median nerve compression") AND "grip strength" AND "minimal detectable change". ("carpal tunnel syndrome" OR "median nerve compression") AND "grip strength" AND "clinically relevant change". ("carpal tunnel syndrome" OR "median nerve compression") AND "grip strength" AND "responsiveness." The same strategy was used for fingertip pinch, lateral pinch, tripod pinch, manual muscle testing, abductor pollicis brevis strength, range of motion, Grooved Peg Board Test, Functional Dexterity Test, Minnesota Manual Dexterity Test, Minnesota Rate of Manipulation, Moberg Pick Up Test, Purdue Peg Board, 9-hole Peg Test, Jebsen-Taylor Hand Function Test, NK Dexterity Test, Bennett Hand Tool Dexterity Test, Box and Block Test, O'Neil Hand Function Assessment, Rosenbusch Test of Finger Dexterity, Radboud Skills Test, Sequential Occupational Dexterity Test, Smith Hand Function Evaluation, Sollerman Hand Function Test; Southampton Hand Assessment Procedure; Upper Extremity Functional Test; Hand Function Sort; Crawford Small Parts Dexterity Test; Valpar Worksample, shape-texture identification, vibration, sensory testing, Semmes-Weinstein Monofilaments, static and moving 2-point discrimination

("carpal tunnel syndrome" OR "median nerve compression") AND ("risk factors"); ("carpal tunnel syndrome" OR "median nerve compression") AND (obesity); ("carpal tunnel syndrome" OR "median nerve compression") AND "Body Mass Index"; ("carpal tunnel syndrome" OR "median nerve compression") AND (hypothyroidism OR "Thyroid dysfunction" OR "Graves disease"; ("carpal tunnel syndrome" OR "median nerve compression") AND ("Female gender"); ("carpal tunnel syndrome" OR "median nerve compression") AND ("diabetes mellitus"); ("carpal tunnel syndrome" OR "median nerve compression") AND ("rheumatoid arthritis"); ("carpal tunnel syndrome" OR "median nerve compression") AND (osteoarthritis); ("carpal tunnel syndrome" OR "median nerve compression") AND (anthropometrics); ("carpal tunnel syndrome" OR "median nerve compression") AND ("square wrist"); ("carpal tunnel syndrome" OR "median nerve compression") AND ("hand dimensions"); ("carpal tunnel syndrome" OR "median nerve compression") AND ("hand shape"); ("carpal tunnel syndrome" OR "median nerve compression") AND ("family history"); ("carpal tunnel syndrome" OR "median nerve compression") AND ("genetic predisposition"); ("carpal tunnel syndrome" OR "median nerve compression") AND (height); ("carpal tunnel syndrome" OR "median nerve compression") AND

APPENDIX A

(alcohol); (“carpal tunnel syndrome” OR “median nerve compression”) AND (smoking OR tobacco); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“physical activity”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“hormone therapy” OR “oral contraceptives” OR “estrogen”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (hysterectomy OR menopause OR oophorectomy); (“carpal tunnel syndrome” OR “median nerve compression”) AND (parity); (“carpal tunnel syndrome” OR “median nerve compression”) AND (occupational risk factors); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“forceful exertions”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (repetition); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“repetitive work”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (vibration); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“wrist position”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“computer use” OR “keyboard use” or “mouse use”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“psychosocial factors”)

(“carpal tunnel syndrome” OR “median nerve compression”) AND (intervention OR treatment NOT surgical); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“physical therapy” OR “occupational therapy”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (orthoses OR orthosis OR splinting); (“carpal tunnel syndrome” OR “median nerve compression”) AND education; (“carpal tunnel syndrome” OR “median nerve compression”) AND ergonomics; (“carpal tunnel syndrome” OR “median nerve compression”) AND (“electrical stimulation” OR “TENS”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“dry needling”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“low level laser therapy”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (iontophoresis OR phonophoresis); (“carpal tunnel syndrome” OR “median nerve compression”) AND (massage OR “myofascial release”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (mobilization OR “soft tissue mobilization” OR “joint mobilization”); (“carpal tunnel syndrome” OR

“median nerve compression”) AND (“nerve gliding” OR “tendon gliding”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“chiropractic treatment”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“postural training”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (exercise OR yoga OR Pilates); (“carpal tunnel syndrome” OR “median nerve compression”) AND (heat OR “thermal modalities” OR paraffin); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“short wave diathermy or “microwave diathermy”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (“therapeutic exercise”); (“carpal tunnel syndrome” OR “median nerve compression”) AND (ultrasound)

(“carpal tunnel syndrome” OR “median nerve compression”) AND diagnosis; (“carpal tunnel syndrome” OR “median nerve compression”) AND Tinel; (“carpal tunnel syndrome” OR “median nerve compression”) AND Phalen; (“carpal tunnel syndrome” OR “median nerve compression”) AND carpal-compression; AND (“carpal tunnel syndrome” OR “median nerve compression”) AND upper-limb-neurodynamic; (“carpal tunnel syndrome” OR “median nerve compression”) AND scratch-collapse; (“carpal tunnel syndrome” OR “median nerve compression”) AND monofilament; (“carpal tunnel syndrome” OR “median nerve compression”) AND threshold; (“carpal tunnel syndrome” OR “median nerve compression”) AND Semmes-Weinstein; (“carpal tunnel syndrome” OR “median nerve compression”) AND two-point; (“carpal tunnel syndrome” OR “median nerve compression”) AND vibrat\*; (“carpal tunnel syndrome” OR “median nerve compression”) AND finger-flexion; (“carpal tunnel syndrome” OR “median nerve compression”) AND Luthy; (“carpal tunnel syndrome” OR “median nerve compression”) AND lunate-press; (“carpal tunnel syndrome” OR “median nerve compression”) AND pneumatic-compression; (“carpal tunnel syndrome” OR “median nerve compression”) AND Tanzer; (“carpal tunnel syndrome” OR “median nerve compression”) AND tethered-median-nerve

**Cochrane Database of Systematic Reviews**


“Carpal tunnel syndrome” OR “median nerve compression”

Journal of Orthopaedic & Sports Physical Therapy®  
Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.


APPENDIX B

PRISMA FLOW DIAGRAMS

Diagnosis




Outcome Measures




APPENDIX B

Assistive Technology




Orthoses






APPENDIX B

**Thermotherapy**




**Electrotherapy**




APPENDIX B

Light Agents




Sound Agents




APPENDIX B

**Transdermal Drug Delivery**




**Magnet Therapy**



APPENDIX B

Manual Therapy and Stretching



Abbreviation: CTS, carpal tunnel syndrome.

APPENDIX C

**INCLUSION AND EXCLUSION CRITERIA**

**Inclusion Criteria**

We included papers that used the following research designs: systematic reviews, meta-analyses, experimental and quasi-experimental, prospective and retrospective cohort, cross-sectional, and case-series studies pertaining to the following areas:

- Incidence or prevalence of carpal tunnel syndrome in the general and working populations
- Pathoanatomy of carpal tunnel syndrome
- Classification of carpal tunnel syndrome using measures other than electrodiagnostic instruments
- Identification of risk factors for carpal tunnel syndrome
- Diagnostic tests and measures for identifying carpal tunnel syndrome within the scope of physical therapist practice
- Outcome or clinical measures used to assess change in individuals with carpal tunnel syndrome, including the identification of psychometric properties
- Interventions used in the nonsurgical management of carpal tunnel syndrome within the scope of physical therapist practice

We included expert review papers when they were developed using results from basic science, bench, or animal research AND when higher-level papers were not available.

**Exclusion Criteria**

- Studies written in a language other than English
- Studies in which the sample of patients with carpal tunnel syndrome cannot be separated from the remaining sample
- Studies with fewer than 10 participants
- Nonsystematic or narrative reviews

- Low-quality case series that lacked adequate outcome measures
- Studies that included individuals with carpal tunnel syndrome who were younger than 18 years of age
- Basic science, bench, cadaveric, and animal studies when higher-level human studies were available
- Studies without a comparison group when a preponderance of higher-level studies was available
- Studies pertaining to:
  - Acute carpal tunnel syndrome
  - Induction of acute carpal tunnel symptoms in healthy individuals
  - Numbness and tingling related to diseases or conditions other than carpal tunnel syndrome, such as cervical radiculopathy and diabetic polyneuropathy
  - Tests and measures not readily or routinely available to the majority of physical therapist practitioners, such as:
    - Electromyography and nerve conduction
    - Diagnostic ultrasound
    - Magnetic resonance imaging
- Studies on incidence or prevalence greater than 10 years old
- Incidence or prevalence in narrow populations that limits generalizability
- Instrument measurement properties developed in a population other than those with carpal tunnel syndrome
- Interventions outside the scope of physical therapist practice, such as extracorporeal shockwave therapy and prescription medications
- Interventions that were not reproducible based on the description provided by authors
- Interventions assessed in more than 2 level IV studies

APPENDIX D

CRITICAL APPRAISAL SCORES

Provocative Tests

Study	Evaluation Criteria*														Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	
Ahn et al <sup>2</sup>	0	1	0	0	0	0	1	1	1	0	1	1	1	1	8
Al-Dabbagh and Mohamad <sup>3</sup>	0	1	0	1	0	0	1	0	0	0	1	1	0	0	5
Amirfeyz et al <sup>9</sup>	0	1	0	0	0	1	1	1	1	0	0	1	0	0	6
Amirfeyz et al <sup>8</sup>	0	1	0	0	0	0	1	0	1	0	1	1	0	0	5
Baselgia et al <sup>33</sup>	0	1	1	1	0	0	1	1	1	1	1	0	1	1	10
Blok et al <sup>41</sup>	1	1	1	1	1	0	0	1	1	1	1	1	1	1	12
Boland and Kiernan <sup>42</sup>	0	1	1	1	0	0	0	1	1	0	1	1	0	0	7
Bueno-Gracia et al <sup>45</sup>	1	1	1	1	1	1	1	1	1	0	1	1	1	1	13
Calfee et al <sup>50</sup>	0	1	0	1	1	1	1	1	1	1	1	1	1	1	12
Cheng et al <sup>62</sup>	0	1	0	0	0	0	1	1	1	1	1	1	1	1	9
El Miedany et al <sup>89</sup>	0	1	1	1	0	0	1	1	1	0	1	1	0	0	8
Fertl et al <sup>97</sup>	0	1	1	1	0	0	1	1	1	0	1	1	0	0	8
Goloborod'ko <sup>113</sup>	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5
Kasundra et al <sup>144</sup>	0	1	1	1	1	1	1	0	0	0	1	1	0	0	8
Koris et al <sup>153</sup>	0	1	0	1	0	0	0	1	1	0	0	0	1	0	5
LaJoie et al <sup>157</sup>	0	1	1	1	1	1	1	1	1	0	1	1	1	1	12
Ma and Kim <sup>168</sup>	0	1	0	0	0	0	1	1	1	0	1	1	1	1	8
MacDermid et al <sup>170</sup>	1	1	1	1	1	1	1	1	1	1	1	1	1	1	14
Makanji et al <sup>178</sup>	1	1	1	1	1	0	0	0	0	0	1	1	1	1	9
Mondelli et al <sup>196</sup>	0	1	1	1	1	1	1	1	1	0	1	1	0	0	10
Ntani et al <sup>209</sup>	1	1	1	1	1	0	1	1	1	0	0	0	1	1	10
Thüngen et al <sup>274</sup>	1	1	1	1	1	1	1	1	1	0	1	1	0	0	11
Vanti et al <sup>280</sup>	1	1	1	1	0	0	0	1	1	0	1	1	1	1	10
Vanti et al <sup>281</sup>	1	1	1	0	1	0	1	1	1	0	1	1	1	1	11
Wainner et al <sup>283</sup>	1	1	1	1	1	1	1	1	1	1	1	1	1	1	14
Williams et al <sup>292</sup>	0	0	0	0	0	0	0	1	1	0	0	1	1	1	5
Wolny et al <sup>295</sup>	0	0	1	1	0	0	1	1	0	0	0	0	1	0	5

\*Criteria from Law M, MacDermid J. Evidence-Based Rehabilitation: A Guide to Practice. 3rd ed. Thorofare, NJ: SLACK; 2014. Items are scored as follows: 0, criterion not met; 1, criterion met. Items: (1) Independent blind comparison with a reference standard test; (2) Reference standard/true diagnosis selected is considered the gold standard or a reasonable alternative; (3) Reference standard applied to all patients; (4) Actual cases included appropriate spectrum of symptom severity; (5) Noncases might reasonably present for diagnosis; (6) Noncases included appropriate spectrum of patients with alternative diagnosis; (7) Adequate sample size; (8) Description of the test maneuver described in sufficient detail to permit replication; (9) Exact criteria for interpreting test results provided; (10) Reliability of the test documented; (11) Number of positive and negative results reported for both cases and noncases; (12) Appropriate statistics (sensitivity, specificity, likelihood ratios) presented; (13) If test required examiner interpretation, qualifications and skills of examiner were provided; (14) Training, skills, and experience of the examiner were appropriate to the test conducted.

APPENDIX D

Katz Hand Diagram and Provocative Tests: Reliability

Study	Evaluation Criteria*												Total	
	1	2	3	4	5	6	7	8	9	10	11	12		
Calfee et al <sup>50</sup>	2	2	2	2	0	1	2	1	2	2	2	2	2	20
Marx et al <sup>183</sup>	2	2	1	1	0	2	0	2	2	2	2	2	2	18
Priganc and Henry <sup>232</sup>	2	2	1	2	0	2	2	2	2	2	2	2	2	21
Salerno et al <sup>251</sup>	2	2	1	2	0	1	2	2	2	2	2	2	2	20

\*Criteria from Law M, MacDermid J. Evidence-Based Rehabilitation: A Guide to Practice. 3rd ed. Thorofare, NJ: SLACK; 2014. Items are scored as follows: 0, criterion not met; 1, marginally met criterion; 2, met criterion. Items: (1) Comprehensive literature review to justify the research question; (2) Specific inclusion/exclusion criteria; (3) Specific hypotheses; (4) Appropriate scope of measurement properties; (5) Sample-size justification; (6) Minimal loss to follow-up; (7) Detailing the test procedures; (8) Standardization of measurement techniques; (9) Data presented for each hypothesis; (10) Appropriate statistical tests; (11) Range of analyses for each measurement property; (12) Proper presentation of the conclusions and clinical recommendations.

Sensory Testing Measures

Study	Evaluation Criteria*														Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	
Checkosky et al <sup>59</sup>	0	1	0	0	0	0	0	1	0	0	1	1	0	0	4
Clark et al <sup>67</sup>	0	1	1	0	0	0	1	1	1	0	1	1	0	0	7
Elfar et al <sup>88</sup>	1	1	1	0	1	0	0	1	0	0	0	0	1	1	7
Gerr and Letz <sup>107</sup>	1	1	1	1	1	0	1	1	1	0	1	0	1	1	11
Hardy et al <sup>126</sup>	1	1	1	1	1	1	1	0	1	0	0	0	1	1	10
Jetzer <sup>139</sup>	0	1	0	1	1	0	1	0	1	0	0	0	0	0	5
MacDermid et al <sup>171</sup>	1	1	1	1	1	1	0	1	1	1	1	1	1	1	13
MacDermid et al <sup>170</sup>	1	1	1	1	1	1	1	1	1	1	1	1	1	1	14
Marlow et al <sup>182</sup>	0	1	1	1	1	0	1	1	1	0	1	1	1	1	11
Werner et al <sup>291</sup>	1	1	1	1	1	1	1	1	1	0	1	1	1	1	13
Yildirim and Gunduz <sup>300</sup>	1	0	1	1	1	1	1	0	1	0	1	1	1	1	11

\*Criteria from Law M, MacDermid J. Evidence-Based Rehabilitation: A Guide to Practice. 3rd ed. Thorofare, NJ: SLACK; 2014. Items are scored as follows: 0, criterion not met; 1, criterion met. Items: (1) Independent blind comparison with a reference standard test; (2) Reference standard/true diagnosis selected is considered the gold standard or a reasonable alternative; (3) Reference standard applied to all patients; (4) Actual cases included appropriate spectrum of symptom severity; (5) Noncases might reasonably present for diagnosis; (6) Noncases included appropriate spectrum of patients with alternative diagnosis; (7) Adequate sample size; (8) Description of the test maneuver described in sufficient detail to permit replication; (9) Exact criteria for interpreting test results provided; (10) Reliability of the test documented; (11) Number of positive and negative results reported for both cases and noncases; (12) Appropriate statistics (sensitivity, specificity, likelihood ratios) presented; (13) If test required examiner interpretation, qualifications and skills of examiner were provided; (14) Training, skills, and experience of the examiner were appropriate to the test conducted.

Sensory Testing Measures: Reliability

Study	Evaluation Criteria*												Total	
	1	2	3	4	5	6	7	8	9	10	11	12		
Cheung et al <sup>64</sup>	2	2	1	2	2	1	2	2	2	2	2	2	2	22
Grunert et al <sup>†</sup>	2	1	1	2	0	2	2	1	2	0	0	1	1	14
Hubbard et al <sup>‡</sup>	2	2	1	0	0	1	2	1	2	2	2	2	2	17
Marx et al <sup>183</sup>	2	2	1	1	0	2	0	2	2	2	2	2	2	18
Raji et al <sup>235</sup>	2	2	2	2	0	2	2	1	2	2	2	2	2	21

\*Criteria from Law M, MacDermid J. Evidence-Based Rehabilitation: A Guide to Practice. 3rd ed. Thorofare, NJ: SLACK; 2014. Items are scored as follows: 0, criterion not met; 1, marginally met criterion; 2, met criterion. Items: (1) Comprehensive literature review to justify the research question; (2) Specific inclusion/exclusion criteria; (3) Specific hypotheses; (4) Appropriate scope of measurement properties; (5) Sample-size justification; (6) Minimal loss to follow-up; (7) Detailing the test procedures; (8) Standardization of measurement techniques; (9) Data presented for each hypothesis; (10) Appropriate statistical tests; (11) Range of analyses for each measurement property; (12) Proper presentation of the conclusions and clinical recommendations.

<sup>†</sup>Grunert BK, Wertsch JJ, Matloub HS, McCallum-Burke S. Reliability of sensory threshold measurement using a digital vibrogram. *J Occup Med.* 1990;32:100-102. See **TABLE 6** and **APPENDIX E**.

<sup>‡</sup>Hubbard MC, MacDermid JC, Kramer JF, Birmingham TB. Quantitative vibration threshold testing in carpal tunnel syndrome: analysis strategies for optimizing reliability. *J Hand Ther.* 2004;17:24-30. <https://doi.org/10.1197/j.jht.2003.10.004>. See **TABLE 6** and **APPENDIX E**.

APPENDIX D

Outcome Measures

Study	Evaluation Criteria*												Total
	1	2	3	4	5	6	7	8	9	10	11	12	
Alderson and McGall <sup>4</sup>	1	1	1	1	0	1	2	2	2	2	1	1	15
Amadio et al <sup>6</sup>	2	1	2	1	0	1	2	2	2	2	1	2	18
Amirfeyz et al <sup>10</sup>	2	1	2	2	0	1	0	0	2	1	1	2	14
Amirjani et al <sup>12</sup>	2	2	2	1	0	0	2	2	2	2	2	2	19
Amirjani et al <sup>13</sup>	2	2	2	1	1	0	2	2	2	2	0	2	18
Appleby et al <sup>16</sup>	2	2	1	1	0	2	2	2	2	2	1	1	18
Astifidis et al <sup>19</sup>	2	1	2	2	2	2	2	2	2	1	0	2	20
Atalay et al <sup>20</sup>	1	2	1	2	2	2	2	0	2	1	0	1	16
Atroshi et al <sup>22</sup>	2	2	2	2	1	2	2	2	2	2	2	2	23
Atroshi et al <sup>23</sup>	2	1	2	2	2	1	2	1	2	2	2	2	21
Atroshi et al <sup>25</sup>	2	2	1	2	1	1	1	2	2	2	2	2	20
Atroshi et al <sup>26</sup>	2	1	2	1	1	0	2	1	2	2	2	2	18
Baker et al <sup>28</sup>	2	2	0	0	0	2	2	2	2	1	1	2	16
Baker and Livengood <sup>27</sup>	1	1	2	2	2	2	2	2	2	1	2	2	21
Bakhsh et al <sup>30</sup>	2	2	0	2	0	1	1	1	2	2	2	2	17
Bessette et al <sup>38</sup>	2	2	2	1	2	2	1	2	2	2	0	2	20
Boyd et al <sup>43</sup>	2	2	2	2	0	2	2	1	2	2	1	2	20
Chatterjee and Price <sup>58</sup>	2	2	0	0	0	0	1	1	2	2	0	2	12
Cheung et al <sup>64</sup>	2	2	2	2	2	1	2	2	2	2	2	2	23
Coldham et al <sup>72</sup>	2	1	2	1	2	2	2	2	2	2	1	2	21
de la Llave-Rincón et al <sup>81</sup>	2	2	2	2	1	0	2	1	2	2	2	2	20
Dhong et al <sup>83</sup>	1	1	2	2	2	2	1	1	2	2	2	2	20
Fernández-de-las-Peñas et al <sup>95</sup>	2	2	2	2	1	2	2	2	2	2	2	2	23
Gay et al <sup>101</sup>	2	2	2	1	0	2	1	2	2	2	1	2	19
Greenslade et al <sup>118</sup>	2	2	2	1	0	0	1	2	2	2	2	2	18
Hobby et al <sup>134</sup>	1	1	0	2	0	1	2	2	2	2	1	2	16
Hsu et al <sup>135</sup>	2	2	2	1	2	2	2	2	2	2	1	1	21
Jerosch-Herold et al <sup>138</sup>	2	1	1	2	1	2	2	2	1	2	1	2	19
Katz et al <sup>145</sup>	2	2	1	0	0	1	2	0	2	2	1	1	14
Kaye and Reynolds <sup>147</sup>	2	1	2	2	1	2	1	2	2	2	1	2	20
Kotsis and Chung <sup>154</sup>	1	2	0	0	0	2	2	1	2	2	1	1	14
Levine et al <sup>162</sup>	2	1	1	2	0	0	2	2	2	2	1	2	17
Lyrén and Atroshi <sup>167</sup>	2	1	2	2	1	1	2	1	2	2	2	1	19
McMillan and Binhammer <sup>187</sup>	2	0	1	0	0	0	2	2	2	2	1	2	14
Ollivere et al <sup>212</sup>	2	1	2	2	1	2	2	1	2	2	2	2	21
Olsen and Knudson <sup>213</sup>	2	0	2	1	0	2	1	0	2	1	1	2	14
Ozer et al <sup>216</sup>	2	2	2	1	1	2	2	1	2	2	2	2	21
Özyüreköçlü et al <sup>219</sup>	2	2	1	0	0	2	1	2	2	2	2	2	18
Pransky et al <sup>230</sup>	2	1	1	2	1	0	2	1	2	2	1	2	17
Priganc and Henry <sup>232</sup>	2	2	1	0	0	0	2	2	2	2	0	2	15
Sears and Chung <sup>254</sup>	2	1	1	1	0	2	2	1	1	2	2	2	17
Smith-Forbes et al <sup>263</sup>	2	2	2	2	2	0	0	0	2	2	2	2	18
Tulipan et al <sup>276</sup>	2	2	2	2	2	2	2	2	2	2	2	2	24
Zyluk and Piotuch <sup>303</sup>	1	1	1	2	0	1	1	1	2	2	0	2	14

\*Criteria from Law M, MacDermid J. Appendix A: quality appraisal for clinical measurement studies. In: Evidence-Based Rehabilitation: A Guide to Practice. 3rd ed. Thorofare, NJ: SLACK; 2014:325-338. Items are scored as follows: 0, criterion not met; 1, marginally met criterion; 2, met criterion. Items: (1) Comprehensive literature review to justify the research question; (2) Specific inclusion/exclusion criteria; (3) Specific hypotheses; (4) Appropriate scope of measurement properties; (5) Sample-size justification; (6) Minimal loss to follow-up; (7) Detailing the test procedures; (8) Standardization of measurement techniques; (9) Data presented for each hypothesis; (10) Appropriate statistical tests; (11) Range of analyses for each measurement property; (12) Proper presentation of the conclusions and clinical recommendations.



APPENDIX D

Interventions: Assistive Technology

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Schmid et al <sup>253</sup>	2	0	2	2	0	0	0	0	1	2	2	2	2	1	2	2	2	0	2	2	1	1	2	2	32

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

Interventions: Orthoses

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Bulut et al <sup>47</sup>	2	2	2	2	1	0	0	0	0	2	2	1	1	0	2	1	1	0	2	2	1	0	2	1	27
Chesterton et al <sup>63</sup>	2	2	2	2	2	0	2	2	2	2	2	2	1	2	2	2	2	2	2	2	1	2	1	1	42
Courts <sup>75</sup>	1	2	2	2	0	0	0	0	2	2	0	0	1	0	2	1	1	1	1	0	0	0	2	1	21
Ekman-Ordeberg et al <sup>86</sup>	1	0	2	2	0	0	0	0	0	2	0	2	1	0	0	1	1	2	0	0	1	2	1	1	19
Gelberman et al <sup>103</sup>	1	2	1	2	0	0	0	0	0	0	0	2	2	1	1	2	1	1	1	0	0	2	2	2	23
Gerritsen et al <sup>108</sup>	2	2	2	2	2	1	2	2	2	2	0	2	2	2	2	1	2	2	2	0	2	2	2	2	42
Golriz et al <sup>114</sup>	2	2	2	2	1	2	0	0	1	2	1	2	2	0	2	0	1	1	2	0	2	2	2	1	32
Hall et al <sup>125</sup>	2	2	2	2	2	0	0	0	1	2	2	1	2	0	2	2	1	1	1	2	1	0	2	1	31
Keir et al <sup>148</sup>	2	0	0	2	0	0	0	0	2	2	0	2	2	0	0	2	0	0	2	0	2	2	2	2	24
Kuo et al <sup>156</sup>	1	0	0	2	0	0	0	0	2	1	1	0	2	0	0	2	1	0	1	0	2	2	1	1	19
Madjinasab et al <sup>176</sup>	2	2	2	2	1	2	2	0	1	2	2	2	2	0	2	2	0	2	2	0	2	0	2	2	36
Manente et al <sup>179</sup>	1	0	0	2	0	0	0	0	0	1	0	2	2	0	0	1	1	0	2	0	1	1	1	2	17
Mishra et al <sup>192</sup>	2	2	2	2	2	2	2	0	2	2	0	1	2	0	2	2	2	2	2	0	2	2	2	2	39
Özgen et al <sup>217</sup>	2	1	2	2	0	2	2	0	0	2	0	2	2	0	2	1	1	2	2	0	2	0	2	2	31
Rempel et al <sup>237</sup>	2	2	2	2	0	0	0	0	1	2	0	2	1	1	2	1	0	1	1	0	1	1	2	2	26
Schmid et al <sup>252</sup>	2	2	1	2	2	0	0	2	2	2	0	2	1	2	2	2	2	0	2	0	2	1	2	1	34
So et al <sup>264</sup>	1	2	2	2	2	1	0	0	2	2	2	0	1	1	2	2	2	1	2	2	1	0	2	2	34
Ucan et al <sup>277</sup>	2	2	2	2	2	0	0	0	1	2	0	1	1	1	2	2	1	1	2	0	1	0	2	1	28
Walker et al <sup>284</sup>	2	2	2	2	2	0	0	0	2	2	0	1	2	0	2	2	1	1	2	0	2	1	2	1	31
Wang et al <sup>285</sup>	2	2	2	2	2	1	2	2	1	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2	45
Weiss et al <sup>287</sup>	2	1	0	1	0	0	0	0	1	1	0	2	2	0	2	2	1	0	2	0	2	2	1	1	23

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

APPENDIX D

**Interventions: Biophysical Agents (Thermotherapy)**

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Chang et al <sup>157</sup>	2	0	1	2	2	0	2	2	2	2	2	1	2	1	2	2	2	1	2	2	2	2	2	1	39
Frasca et al <sup>199</sup>	2	2	2	2	2	2	0	2	2	2	2	2	0	2	2	2	2	1	2	2	1	2	2	2	42
Incebiyik et al <sup>136</sup>	2	2	2	2	2	0	2	2	1	2	0	2	2	0	2	1	2	0	2	0	2	0	1	1	32
Michlovitz et al <sup>191</sup>	2	2	2	2	1	1	2	2	2	2	0	2	2	2	2	1	0	0	2	2	2	2	1	2	38

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

**Interventions: Biophysical Agents (Electrotherapy)**

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Koca et al <sup>150</sup>	2	2	2	2	1	0	0	2	1	2	0	2	2	0	2	2	2	1	2	0	2	0	1	1	31

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

**Interventions: Biophysical Agents (Light Agents)**

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Raeissadat et al <sup>234</sup>	1	2	2	2	2	0	0	1	0	2	0	2	2	0	2	1	1	1	1	0	1	0	0	0	23
Stasinopoulos et al <sup>268</sup>	1	0	2	2	0	0	0	2	0	2	0	2	2	0	0	1	0	2	1	0	0	2	1	1	21

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

Journal of Orthopaedic & Sports Physical Therapy®  
 Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
 Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

APPENDIX D

**Interventions: Biophysical Agents (Sound Agents)**

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Armagan et al <sup>17</sup>	2	2	2	2	1	2	0	2	0	2	0	2	2	0	2	1	1	0	2	2	1	2	2	2	34
Baysal et al <sup>35</sup>	2	2	2	2	2	0	2	2	2	2	2	1	2	0	0	0	0	2	2	0	2	0	2	0	31
Chang et al <sup>57</sup>	2	2	2	2	2	0	0	2	2	2	2	1	2	0	2	2	2	2	2	1	2	0	1	2	37
Ebenbichler et al <sup>85</sup>	2	2	2	2	2	2	0	2	1	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	44
Oztas et al <sup>218</sup>	2	2	1	2	2	0	0	0	2	2	0	2	2	0	2	2	2	2	2	2	2	1	2	1	34

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

**Interventions: Biophysical Agents (Transdermal Drug Delivery)**

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Amirjani et al <sup>14</sup>	2	2	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	2	46
Bakhtiari et al <sup>31</sup>	2	1	2	2	2	1	0	2	2	2	0	2	2	0	1	2	2	1	1	0	2	2	2	2	35
Gökoğlu et al <sup>112</sup>	1	2	2	2	1	0	0	0	2	2	0	2	2	0	1	1	1	1	2	0	2	2	2	2	30
Karatay et al <sup>142</sup>	1	2	2	2	1	0	0	0	0	0	0	1	0	2	1	1	2	1	0	1	0	1	0	18	
Soyupek et al <sup>266</sup>	2	2	2	2	0	0	2	2	1	2	0	2	2	0	1	1	1	1	1	0	1	0	1	1	27
Soyupek et al <sup>267</sup>	2	2	2	2	0	0	0	2	0	2	0	1	1	0	2	1	1	1	2	0	1	0	2	1	25
Yildiz et al <sup>301</sup>	2	2	2	2	2	2	2	2	2	2	2	1	2	2	2	2	2	1	2	2	2	2	2	2	46

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

**Interventions: Biophysical Agents (Magnet Therapy)**

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Carter et al <sup>54</sup>	2	2	2	2	2	2	2	2	1	2	2	0	1	2	2	1	0	0	1	2	2	2	1	1	36
Colbert et al <sup>71</sup>	2	2	2	2	2	2	2	2	2	2	0	2	2	2	2	2	2	1	2	0	2	2	2	1	42

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

APPENDIX D

Interventions: Manual Therapy and Stretching

Study	Evaluation Criteria*																								Total
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Baker et al <sup>29</sup>	2	2	2	2	2	0	2	2	1	2	0	1	2	2	2	2	2	2	2	0	2	2	1	1	38
Maddali Bongti et al <sup>175</sup>	1	1	2	2	0	0	2	0	0	2	0	2	2	0	0	1	0	2	2	0	2	2	1	1	25
Fernández-de-las-Peñas et al <sup>194</sup>	1	2	2	2	2	1	2	2	2	2	2	1	0	0	0	2	2	2	2	0	2	2	1	36	
Fernández-de-las-Peñas et al <sup>193</sup>	2	2	2	2	2	0	2	2	2	2	2	0	0	2	2	2	2	2	1	2	1	2	1	38	
Wolny and Linek <sup>293</sup>	2	2	2	2	2	2	1	2	2	2	2	0	2	1	2	2	2	1	2	2	2	0	1	40	
Wolny and Linek <sup>294</sup>	2	2	2	2	2	2	2	2	2	2	2	1	2	1	2	2	2	2	2	2	1	2	2	44	

\*Criteria from Joy MacDermid (personal communication). Items are scored as follows: 0, criterion not met; 1, criterion partially met; 2, criterion met. Items: (1) Relevant background work cited, leading to a clear research question; (2) Use of comparison group; (3) Consideration of patient status more than once; (4) Prospective data collection; (5) Randomization; (6) Subjects blinded; (7) Providers blinded; (8) Independent outcomes evaluator; (9) Minimal sample/selection bias; (10) Defined inclusion/exclusion criteria; (11) Enrollment obtained; (12) Appropriate retention; (13) Intervention applied per established principles; (14) Treatment provider biases minimized; (15) Intervention compared to appropriate comparator; (16) Primary outcome defined/appropriate; (17) Secondary outcomes considered; (18) Appropriate follow-up period; (19) Appropriate statistical tests performed, demonstrating intervention-related differences; (20) Establishment of sufficient power for identifying treatment effects; (21) Size and clinical importance of treatment group differences reported; (22) Missing data accounted for in analysis; (23) Clinical and practical significance considered when interpreting results; (24) Conclusions/clinical recommendations supported by the study objectives, analysis, and results.

Systematic Reviews Assessed Using AMSTAR\*

Study	Section of CPG	Evaluation Criteria <sup>1</sup>											Total
		1	2	3	4	5	6	7	8	9	10	11	
Andersen et al <sup>15</sup>	Risk Factors	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	9
Basson et al <sup>34</sup>	Interventions	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	9
Geere et al <sup>102</sup>	Outcome Measures	Yes	Yes	No	No	No	No	No	Yes	Yes	No	Yes	5
Hagberg et al <sup>123</sup>	Risk Factors	Yes	No	No	Yes	No	Yes	No	No	Yes	Yes	No	5
MacDermid and Wessel <sup>173</sup>	Differential Diagnosis	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	No	8
Massy-Westropp et al <sup>184</sup>	Differential Diagnosis	Yes	Yes	No	Yes	No	No	Yes	Yes	No	Yes	No	6
O'Connor et al <sup>210</sup>	Interventions (Ergonomic)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	10
Page et al <sup>222</sup>	Interventions (Therapeutic Exercise)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	11
Page et al <sup>221</sup>	Interventions (Orthoses)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	10
Palmer et al <sup>223</sup>	Risk Factors	Yes	No	Yes	Yes	No	Yes	No	No	No	Yes	No	5
Rankin et al <sup>236</sup>	Interventions	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	11
Sakthiswary and Singh <sup>250</sup>	Risk Factors	Yes	No	Yes	Yes	No	Yes	No	No	Yes	No	Yes	6
van Rijn et al <sup>279</sup>	Risk Factors	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	9

Abbreviations: AMSTAR, A Measurement Tool to Assess Systematic Reviews; CPG, clinical practice guideline.

\*Criteria from Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol.* 2007;7:10. <https://doi.org/10.1186/1471-2288-7-10>

<sup>1</sup>Yes/no. Items: 1, Was an a priori design provided? 2, Was there duplicate study selection and data extraction? 3, Was a comprehensive literature search performed? 4, Was the status of publication (ie, gray literature) used as an inclusion criterion? 5, Was a list of studies (included and excluded) provided? 6, Were the characteristics of the included studies provided? 7, Was the scientific quality of the included studies assessed and documented? 8, Was the scientific quality of the included studies used appropriately in formulating conclusions? 9, Were the methods used to combine the findings of studies appropriate? 10, Was the likelihood of publication bias assessed? 11, Was the conflict of interest included?

APPENDIX E

ARTICLES USED IN DEVELOPING RECOMMENDATIONS

Diagnosis

1. Ahn DS. Hand elevation: a new test for carpal tunnel syndrome. *Ann Plast Surg.* 2001;46:120-124.
2. Al-Dabbagh KAO, Mohamad SA. Sensitivity and specificity of Phalen's test and Tinel's test in patients with carpal tunnel syndrome. *Diyala J Med.* 2013;5:1-14.
3. Amirfeyz R, Gozzard C, Leslie IJ. Hand elevation test for assessment of carpal tunnel syndrome. *J Hand Surg Br.* 2005;30:361-364. <https://doi.org/10.1016/j.jhsb.2005.04.007>
4. Amirfeyz R, Clark D, Parsons B, et al. Clinical tests for carpal tunnel syndrome in contemporary practice. *Arch Orthop Trauma Surg.* 2011;131:471-474. <https://doi.org/10.1007/s00402-010-1150-z>
5. Baselgia LT, Bennett DL, Silbiger RM, Schmid AB. Negative neurodynamic tests do not exclude neural dysfunction in patients with entrapment neuropathies. *Arch Phys Med Rehabil.* 2017;98:480-486. <https://doi.org/10.1016/j.apmr.2016.06.019>
6. Blok RD, Becker SJ, Ring DC. Diagnosis of carpal tunnel syndrome: interobserver reliability of the blinded scratch-collapse test. *J Hand Microsurg.* 2014;6:5-7. <https://doi.org/10.1007/s12593-013-0105-3>
7. Boland RA, Kiernan MC. Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. *J Clin Neurosci.* 2009;16:929-933. <https://doi.org/10.1016/j.jocn.2008.09.004>
8. Bueno-Gracia E, Tricás-Moreno JM, Fanlo-Mazas P, et al. Validity of the Upper Limb Neurodynamic Test 1 for the diagnosis of carpal tunnel syndrome. The role of structural differentiation. *Man Ther.* 2016;22:190-195. <https://doi.org/10.1016/j.math.2015.12.007>
9. Calfee RP, Dale AM, Ryan D, Descatha A, Franzblau A, Evanoff B. Performance of simplified scoring systems for hand diagrams in carpal tunnel syndrome screening. *J Hand Surg Am.* 2012;37:10-17. <https://doi.org/10.1016/j.jhsa.2011.08.016>
10. Checkosky CM, Bolanowski SJ, Cohen JC. Assessment of vibrotactile sensitivity in patients with carpal tunnel syndrome. *J Occup Environ Med.* 1996;38:593-601.
11. Cheng CJ, Mackinnon-Patterson B, Beck JL, Mackinnon SE. Scratch collapse test for evaluation of carpal and cubital tunnel syndrome. *J Hand Surg Am.* 2008;33:1518-1524. <https://doi.org/10.1016/j.jhsa.2008.05.022>
12. Clark D, Amirfeyz R, Leslie I, Bannister G. Often atypical? The distribution of sensory disturbance in carpal tunnel syndrome. *Ann R Coll Surg Engl.* 2011;93:470-473. <https://doi.org/10.1308/003588411X586191>
13. Elfar JC, Yaseen Z, Stern PJ, Kiefhaber TR. Individual finger sensibility in carpal tunnel syndrome. *J Hand Surg Am.* 2010;35:1807-1812. <https://doi.org/10.1016/j.jhsa.2010.08.013>
14. El Miedany Y, Ashour S, Youssef S, Mehanna A, Meki FA. Clinical diagnosis of carpal tunnel syndrome: old tests–new concepts. *Joint Bone Spine.* 2008;75:451-457. <https://doi.org/10.1016/j.jbspin.2007.09.014>
15. Fertl E, Wöber C, Zeitlhofer J. The serial use of two provocative tests in the clinical diagnosis of carpal tunnel syndrome. *Acta Neurol Scand.* 1998;98:328-332. <https://doi.org/10.1111/j.1600-0404.1998.tb01743.x>
16. Gerr F, Letz R. The sensitivity and specificity of tests for carpal tunnel syndrome vary with the comparison subjects. *J Hand Surg Br.* 1998;23:151-155. [https://doi.org/10.1016/S0266-7681\(98\)80163-0](https://doi.org/10.1016/S0266-7681(98)80163-0)
17. Goloborod'ko SA. Provocative test for carpal tunnel syndrome. *J Hand Ther.* 2004;17:344-348. <https://doi.org/10.1197/j.jht.2004.04.004>
18. Grunert BK, Wertsch JJ, Matloub HS, McCallum-Burke S. Reliability of sensory threshold measurement using a digital vibrogram. *J Occup Med.* 1990;32:100-102.
19. Hardy M, Jimenez S, Jabaley M, Horch K. Evaluation of nerve compression with the Automated Tactile Tester. *J Hand Surg Am.* 1992;17:838-842. [https://doi.org/10.1016/0363-5023\(92\)90453-V](https://doi.org/10.1016/0363-5023(92)90453-V)
20. Hubbard MC, MacDermid JC, Kramer JF, Birmingham TB. Quantitative vibration threshold testing in carpal tunnel syndrome: analysis strategies for optimizing reliability. *J Hand Ther.* 2004;17:24-30. <https://doi.org/10.1197/j.jht.2003.10.004>
21. Jetzer TC. Use of vibration testing in the early evaluation of workers with carpal tunnel syndrome. *J Occup Med.* 1991;33:117-120
22. Kasundra GM, Sood I, Bhargava AN, et al. Carpal tunnel syndrome: analyzing efficacy and utility of clinical tests and various diagnostic modalities. *J Neurosci Rural Pract.* 2015;6:504-510. <https://doi.org/10.4103/0976-3147.169867>
23. Koris M, Gelberman RH, Duncan K, Boublick M, Smith B. Carpal tunnel syndrome. Evaluation of a quantitative provocative diagnostic test. *Clin Orthop Relat Res.* 1990:157-161.
24. LaJoie AS, McCabe SJ, Thomas B, Edgell SE. Determining the sensitivity and specificity of common diagnostic tests for carpal tunnel syndrome using latent class analysis. *Plast Reconstr Surg.* 2005;116:502-507. <https://doi.org/10.1097/01.prs.0000172894.21006.e2>
25. Ma H, Kim I. The diagnostic assessment of hand elevation test in carpal tunnel syndrome. *J Korean Neurosurg Soc.* 2012;52:472-475. <https://doi.org/10.3340/jkns.2012.52.5.472>
26. MacDermid JC, Kramer JF, McFarlane RM, Roth JH. Inter-rater agreement and accuracy of clinical tests used in diagnosis of carpal tunnel syndrome. *Work.* 1997;8:37-44. <https://doi.org/10.3233/WOR-1997-8105>
27. MacDermid JC, Kramer JF, Roth JH. Decision making in detecting abnormal Semmes-Weinstein monofilament thresholds in carpal tunnel syndrome. *J Hand Ther.* 1994;7:158-162. [https://doi.org/10.1016/s0894-1130\(12\)80057-3](https://doi.org/10.1016/s0894-1130(12)80057-3)

APPENDIX E

28. MacDermid JC, Wessel J. Clinical diagnosis of carpal tunnel syndrome: a systematic review. *J Hand Ther.* 2004;17:309-319. <https://doi.org/10.1197/j.jht.2004.02.015>
29. Makranji HS, Becker SJ, Mudgal CS, Jupiter JB, Ring D. Evaluation of the scratch collapse test for the diagnosis of carpal tunnel syndrome. *J Hand Surg Eur Vol.* 2014;39:181-186. <https://doi.org/10.1177/1753193413497191>
30. Marlowe ES, Bonner FJ, Jr., Berkowitz AR. Correlation between two-point discrimination and median nerve sensory response. *Muscle Nerve.* 1999;22:1196-1200. [https://doi.org/10.1002/\(Sici\)1097-4598\(199909\)22:9<1196::Aid-Mus5>3.0.Co;2-K](https://doi.org/10.1002/(Sici)1097-4598(199909)22:9<1196::Aid-Mus5>3.0.Co;2-K)
31. Marx RG, Hudak PL, Bombardier C, Graham B, Goldsmith C, Wright JG. The reliability of physical examination for carpal tunnel syndrome. *J Hand Surg Br.* 1998;23:499-502. [https://doi.org/10.1016/S0266-7681\(98\)80132-0](https://doi.org/10.1016/S0266-7681(98)80132-0)
32. Massy-Westropp N, Grimmer K, Bain G. A systematic review of the clinical diagnostic tests for carpal tunnel syndrome. *J Hand Surg Am.* 2000;25:120-127. <https://doi.org/10.1053/jhsu.2000.jhsu025a0120>
33. Mondelli M, Passero S, Giannini F. Provocative tests in different stages of carpal tunnel syndrome. *Clin Neurol Neurosurg.* 2001;103:178-183. [https://doi.org/10.1016/S0303-8467\(01\)00140-8](https://doi.org/10.1016/S0303-8467(01)00140-8)
34. Ntani G, Palmer KT, Linaker C, et al. Symptoms, signs and nerve conduction velocities in patients with suspected carpal tunnel syndrome. *BMC Musculoskelet Disord.* 2013;14:242. <https://doi.org/10.1186/1471-2474-14-242>
35. Priganc VW, Henry SM. The relationship among five common carpal tunnel syndrome tests and the severity of carpal tunnel syndrome. *J Hand Ther.* 2003;16:225-236. [https://doi.org/10.1016/S0894-1130\(03\)00038-3](https://doi.org/10.1016/S0894-1130(03)00038-3)
36. Raji P, Ansari NN, Naghdi S, Forogh B, Hasson S. Relationship between Semmes-Weinstein monofilaments perception test and sensory nerve conduction studies in carpal tunnel syndrome. *Neurorehabilitation.* 2012;31:215-222. <https://doi.org/10.3233/NRE-141150>
37. Salerno DF, Franzblau A, Werner RA, et al. Reliability of physical examination of the upper extremity among keyboard operators. *Am J Ind Med.* 2000;37:423-430. [https://doi.org/10.1002/\(SICI\)1097-0274\(200004\)37:4<423::AID-AJIM12>3.0.CO;2-W](https://doi.org/10.1002/(SICI)1097-0274(200004)37:4<423::AID-AJIM12>3.0.CO;2-W)
38. Thüngen T, Sadowski M, El Kazzi W, Schuind F. Value of Gilliat's pneumatic tourniquet test for diagnosis of carpal tunnel syndrome. *Chir Main.* 2012;31:152-156. <https://doi.org/10.1016/j.main.2012.04.001>
39. Vanti C, Bonfiglioli R, Calabrese M, et al. Upper Limb Neurodynamic Test 1 and symptoms reproduction in carpal tunnel syndrome. A validity study. *Man Ther.* 2011;16:258-263. <https://doi.org/10.1016/j.math.2010.11.003>
40. Vanti C, Bonfiglioli R, Calabrese M, Marinelli F, Violante FS, Pillastrini P. Relationship between interpretation and accuracy of the Upper Limb Neurodynamic Test 1 in carpal tunnel syndrome. *J Manipulative Physiol Ther.* 2012;35:54-63. <https://doi.org/10.1016/j.jmpt.2011.09.008>
41. Wainner RS, Fritz JM, Irrgang JJ, Delitto A, Allison S, Boninger ML. Development of a clinical prediction rule for the diagnosis of carpal tunnel syndrome. *Arch Phys Med Rehabil.* 2005;86:609-618. <https://doi.org/10.1016/j.apmr.2004.11.008>
42. Werner RA, Franzblau A, Johnston E. Comparison of multiple frequency vibrometry testing and sensory nerve conduction measures in screening for carpal tunnel syndrome in an industrial setting. *Am J Phys Med Rehabil.* 1995;74:101-106.
43. Williams TM, Mackinnon SE, Novak CB, McCabe S, Kelly L. Verification of the pressure provocative test in carpal tunnel syndrome. *Ann Plast Surg.* 1992;29:8-11.
44. Wolny T, Saulicz E, Linek P, Myśliwiec A, Saulicz M. Effect of manual therapy and neurodynamic techniques vs ultrasound and laser on 2PD in patients with CTS: a randomized controlled trial. *J Hand Ther.* 2016;29:235-245. <https://doi.org/10.1016/j.jht.2016.03.006>
45. Yildirim P, Gunduz OH. What is the role of Semmes-Weinstein monofilament testing in the diagnosis of electrophysiologically graded carpal tunnel syndrome? *J Phys Ther Sci.* 2015;27:3749-3753. <https://doi.org/10.1589/jpts.27.3749>

**Outcome Measures**

1. Agnew J, Bolla-Wilson K, Kawas CH, Bleecker ML. Purdue Pegboard age and sex norms for people 40 years old and older. *Dev Neuropsychol.* 1988;4:29-35. <https://doi.org/10.1080/87565648809540388>
2. Alderson M, McCall D. The Alderson-McCall hand function questionnaire for patients with carpal tunnel syndrome: a pilot evaluation of a future outcome measure. *J Hand Ther.* 1999;12:313-322. [https://doi.org/10.1016/s0894-1130\(99\)80070-2](https://doi.org/10.1016/s0894-1130(99)80070-2)
3. Amadio PC, Silverstein MD, Ilstrup DM, Schleck CD, Jensen LM. Outcome assessment for carpal tunnel surgery: the relative responsiveness of generic, arthritis-specific, disease-specific, and physical examination measures. *J Hand Surg Am.* 1996;21:338-346. [https://doi.org/10.1016/S0363-5023\(96\)80340-6](https://doi.org/10.1016/S0363-5023(96)80340-6)
4. Amirfeyz R, Pentlow A, Foote J, Leslie I. Assessing the clinical significance of change scores following carpal tunnel surgery. *Int Orthop.* 2009;33:181-185. <https://doi.org/10.1007/s00264-007-0471-1>
5. Amirjani N, Ashworth NL, Gordon T, Edwards DC, Chan KM. Normative values and the effects of age, gender, and handedness on the Moberg Pick-Up Test. *Muscle Nerve.* 2007;35:788-792. <https://doi.org/10.1002/mus.20750>
6. Amirjani N, Ashworth NL, Olson JL, Morhart M, Chan KM. Validity and reliability of the Purdue Pegboard Test in carpal tunnel syndrome. *Muscle Nerve.* 2011;43:171-177. <https://doi.org/10.1002/mus.21856>

Journal of Orthopaedic & Sports Physical Therapy®  
Downloaded from www.jospt.org at on September 25, 2019. For personal use only. No other uses without permission.  
Copyright © 2019 Journal of Orthopaedic & Sports Physical Therapy®. All rights reserved.

APPENDIX E

7. Amirjani N, Ashworth NL, Olson JL, Morhart M, Chan KM. Discriminative validity and test-retest reliability of the Dellon-modified Moberg pick-up test in carpal tunnel syndrome patients. *J Peripher Nerv Syst.* 2011;16:51-58. <https://doi.org/10.1111/j.1529-8027.2011.00312.x>
8. Appleby MA, Neville-Smith M, Parrott MW. Functional outcomes post carpal tunnel release: a modified replication of a previous study. *J Hand Ther.* 2009;22:240-248; quiz 249. <https://doi.org/10.1016/j.jht.2009.03.001>
9. Astifidis RP, Koczan BJ, Dubin NH, Burke FD, Wilgis EFS. Patient satisfaction with carpal tunnel surgery: self-administered questionnaires versus physical testing. *Hand Ther.* 2009;14:39-45. <https://doi.org/10.1258/ht.2009.009007>
10. Atalay NS, Sarsan A, Akkaya N, Yildiz N, Topuz O. The impact of disease severity in carpal tunnel syndrome on grip strength, pinch strength, fine motor skill and depression. *J Phys Ther Sci.* 2011;23:115-118. <https://doi.org/10.1589/jpts.23.115>
11. Atroshi I, Gummesson C, McCabe SJ, Ornstein E. The SF-6D health utility index in carpal tunnel syndrome. *J Hand Surg Eur Vol.* 2007;32:198-202. <https://doi.org/10.1016/J.JHSB.2006.11.002>
12. Atroshi I, Gummesson C, Johnsson R, Sprinchorn A. Symptoms, disability, and quality of life in patients with carpal tunnel syndrome. *J Hand Surg Am.* 1999;24:398-404. [https://doi.org/10.1016/S0363-5023\(99\)70014-6](https://doi.org/10.1016/S0363-5023(99)70014-6)
13. Atroshi I, Lyrén PE, Gummesson C. The 6-item CTS symptoms scale: a brief outcomes measure for carpal tunnel syndrome. *Qual Life Res.* 2009;18:347-358. <https://doi.org/10.1007/s11136-009-9449-3>
14. Atroshi I, Lyrén PE, Ornstein E, Gummesson C. The six-item CTS symptoms scale and palmar pain scale in carpal tunnel syndrome. *J Hand Surg Am.* 2011;36:788-794. <https://doi.org/10.1016/j.jhsa.2011.02.021>
15. Baker NA, Moehling KK, Desai AR, Gustafson NP. Effect of carpal tunnel syndrome on grip and pinch strength compared with sex- and age-matched normative data. *Arthritis Care Res (Hoboken).* 2013;65:2041-2045. <https://doi.org/10.1002/acr.22089>
16. Baker NA, Livengood HM. Symptom severity and conservative treatment for carpal tunnel syndrome in association with eventual carpal tunnel release. *J Hand Surg Am.* 2014;39:1792-1798. <https://doi.org/10.1016/j.jhsa.2014.04.034>
17. Bakhsh H, Ibrahim I, Khan W, Smitham P, Goddard N. Assessment of validity, reliability, responsiveness and bias of three commonly used patient-reported outcome measures in carpal tunnel syndrome. *Ortop Traumatol Rehabil.* 2012;14:335-340. <https://doi.org/10.5604/15093492.1005085>
18. Bessette L, Sangha O, Kuntz KM, et al. Comparative responsiveness of generic versus disease-specific and weighted versus unweighted health status measures in carpal tunnel syndrome. *Med Care.* 1998;36:491-502. <https://doi.org/10.1097/00005650-199804000-00005>
19. Boyd KU, Gan BS, Ross DC, Richards RS, Roth JH, MacDermid JC. Outcomes in carpal tunnel syndrome: symptom severity, conservative management and progression to surgery. *Clin Invest Med.* 2005;28:254-260.
20. Chatterjee JS, Price PE. Comparative responsiveness of the Michigan Hand Outcomes Questionnaire and the Carpal Tunnel Questionnaire after carpal tunnel release. *J Hand Surg Am.* 2009;34:273-280. <https://doi.org/10.1016/j.jhsa.2008.10.021>
21. Cheung DK, MacDermid J, Walton D, Grewal R. The construct validity and responsiveness of sensory tests in patients with carpal tunnel syndrome. *Open Orthop J.* 2014;8:100-107. <https://doi.org/10.2174/1874325001408010100>
22. Coldham F, Lewis J, Lee H. The reliability of one vs. three grip trials in symptomatic and asymptomatic subjects. *J Hand Ther.* 2006;19:318-326; quiz 327. <https://doi.org/10.1197/j.jht.2006.04.002>
23. de la Llave-Rincón AI, Fernández-de-las-Peñas C, Pérez-de-Heredia-Torres M, Martínez-Perez A, Valenza MC, Pareja JA. Bilateral deficits in fine motor control and pinch grip force are not associated with electrodiagnostic findings in women with carpal tunnel syndrome. *Am J Phys Med Rehabil.* 2011;90:443-451. <https://doi.org/10.1097/PHM.0b013e31821a7170>
24. Desrosiers J, Hébert R, Bravo G, Dutil E. The Purdue Pegboard Test: normative data for people aged 60 and over. *Disabil Rehabil.* 1995;17:217-224. <https://doi.org/10.3109/09638289509166638>
25. Dhong ES, Han SK, Lee BI, Kim WK. Correlation of electrodiagnostic findings with subjective symptoms in carpal tunnel syndrome. *Ann Plast Surg.* 2000;45:127-131.
26. Fernández-de-las-Peñas C, Pérez-de-Heredia-Torres M, Martínez-Piédrola R, de la Llave-Rincón AI, Cleland JA. Bilateral deficits in fine motor control and pinch grip force in patients with unilateral carpal tunnel syndrome. *Exp Brain Res.* 2009;194:29-37. <https://doi.org/10.1007/s00221-008-1666-4>
27. Gay RE, Amadio PC, Johnson JC. Comparative responsiveness of the Disabilities of the Arm, Shoulder, and Hand, the Carpal Tunnel Questionnaire, and the SF-36 to clinical change after carpal tunnel release. *J Hand Surg Am.* 2003;28:250-254. <https://doi.org/10.1053/jhsu.2003.50043>
28. Geere J, Chester R, Kale S, Jerosch-Herold C. Power grip, pinch grip, manual muscle testing or thenar atrophy – which should be assessed as a motor outcome after carpal tunnel decompression? A systematic review. *BMC Musculoskelet Disord.* 2007;8:114. <https://doi.org/10.1186/1471-2474-8-114>
29. Gerritsen AA, Korthals-de Bos IB, Laboyrie PM, de Vet HC, Scholten RJ, Bouter LM. Splinting for carpal tunnel syndrome: prognostic indicators of success. *J Neurol Neurosurg Psychiatry.* 2003;74:1342-1344. <https://doi.org/10.1136/jnnp.74.9.1342>
30. Greenslade JR, Mehta RL, Belward P, Warwick DJ. DASH and Boston questionnaire assessment of carpal tunnel syndrome outcome: what is the responsiveness of an outcome questionnaire? *J Hand Surg Br.* 2004;29:159-164. <https://doi.org/10.1016/j.jhsb.2003.10.010>

APPENDIX E

31. Hobby JL, Watts C, Elliot D. Validity and responsiveness of the patient evaluation measure as an outcome measure for carpal tunnel syndrome. *J Hand Surg Br.* 2005;30:350-354. <https://doi.org/10.1016/j.jhsb.2005.03.009>
  32. Hsu HY, Su FC, Kuo YL, Jou IM, Chiu HY, Kuo LC. Assessment from functional perspectives: using sensorimotor control in the hand as an outcome indicator in the surgical treatment of carpal tunnel syndrome. *PLoS One.* 2015;10:e0128420. <https://doi.org/10.1371/journal.pone.0128420>
  33. Jerosch-Herold C, Shepstone L, Miller L, Chapman P. The responsiveness of sensibility and strength tests in patients undergoing carpal tunnel decompression. *BMC Musculoskelet Disord.* 2011;12:244. <https://doi.org/10.1186/1471-2474-12-244>
  34. Katz JN, Gelberman RH, Wright EA, Lew RA, Liang MH. Responsiveness of self-reported and objective measures of disease severity in carpal tunnel syndrome. *Med Care.* 1994;32:1127-1133.
  35. Kaye JJ, Reynolds JM. Carpal tunnel syndrome: using self-report measures of disease to predict treatment response. *Am J Orthop (Belle Mead NJ).* 2007;36:E59-E62.
  36. Kotsis SV, Chung KC. Responsiveness of the Michigan Hand Outcomes Questionnaire and the Disabilities of the Arm, Shoulder and Hand questionnaire in carpal tunnel surgery. *J Hand Surg Am.* 2005;30:81-86. <https://doi.org/10.1016/j.jhsa.2004.10.006>
  37. Levine DW, Simmons BP, Koris MJ, et al. A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. *J Bone Joint Surg Am.* 1993;75:1585-1592.
  38. Lyrén PE, Atroshi I. Using item response theory improved responsiveness of patient-reported outcomes measures in carpal tunnel syndrome. *J Clin Epidemiol.* 2012;65:325-334. <https://doi.org/10.1016/j.jclinepi.2011.08.009>
  39. McMillan CR, Binhammer PA. Which outcome measure is the best? Evaluating responsiveness of the Disabilities of the Arm, Shoulder, and Hand Questionnaire, the Michigan Hand Questionnaire and the Patient-Specific Functional Scale following hand and wrist surgery. *Hand (N Y).* 2009;4:311-318. <https://doi.org/10.1007/s11552-009-9167-x>
  40. Ollivere BJ, Logan K, Ellahee N, Miller-Jones JC, Wood M, Nairn DS. Severity scoring in carpal tunnel syndrome helps predict the value of conservative therapy. *J Hand Surg Eur Vol.* 2009;34:511-515. <https://doi.org/10.1177/1753193409102380>
  41. Olsen KM, Knudson DV. Change in strength and dexterity after open carpal tunnel release. *Int J Sports Med.* 2001;22:301-303. <https://doi.org/10.1055/s-2001-13815>
  42. Ozer K, Malay S, Toker S, Chung KC. Minimal clinically important difference of carpal tunnel release in diabetic and nondiabetic patients. *Plast Reconstr Surg.* 2013;131:1279-1285. <https://doi.org/10.1097/PRS.0b013e31828bd6ec>
  43. Özyüreköçlü T, McCabe SJ, Goldsmith LJ, LaJoie AS. The minimal clinically important difference of the Carpal Tunnel Syndrome Symptom Severity Scale. *J Hand Surg Am.* 2006;31:733-738; discussion 739-740. <https://doi.org/10.1016/j.jhsa.2006.01.012>
  44. Pransky G, Feuerstein M, Himmelstein J, Katz JN, Vickers-Lahti M. Measuring functional outcomes in work-related upper extremity disorders. Development and validation of the Upper Extremity Function Scale. *J Occup Environ Med.* 1997;39:1195-1202.
  45. Priganc VW, Henry SM. The relationship among five common carpal tunnel syndrome tests and the severity of carpal tunnel syndrome. *J Hand Ther.* 2003;16:225-236. [https://doi.org/10.1016/S0894-1130\(03\)00038-3](https://doi.org/10.1016/S0894-1130(03)00038-3)
  46. Sears ED, Chung KC. Validity and responsiveness of the Jebsen-Taylor Hand Function Test. *J Hand Surg Am.* 2010;35:30-37. <https://doi.org/10.1016/j.jhsa.2009.09.008>
  47. Smith-Forbes EV, Howell DM, Willoughby J, Pitts DG, Uhl TL. Specificity of the minimal clinically important difference of the quick Disabilities of the Arm, Shoulder and Hand (QDASH) for distal upper extremity conditions. *J Hand Ther.* 2016;29:81-88; quiz 88. <https://doi.org/10.1016/j.jht.2015.09.003>
  48. Tulipan JE, Lutsky KF, Maltenfort MG, Freedman MK, Beredjikian PK. Patient-reported disability measures do not correlate with electrodiagnostic severity in carpal tunnel syndrome. *Plast Reconstr Surg Glob Open.* 2017;5:e1440. <https://doi.org/10.1097/GOX.0000000000001440>
  49. Yeudall LT, Fromm D, Reddon JR, Stefanyk WO. Normative data stratified by age and sex for 12 neuropsychological tests. *J Clin Psychol.* 1986;42:918-946. [https://doi.org/10.1002/1097-4679\(198611\)42:6<918::AID-JCLP2270420617>3.0.CO;2Y](https://doi.org/10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2Y)
  50. Zyluk A, Piotuch B. A comparison of DASH, PEM and Levine questionnaires in outcome measurement of carpal tunnel release. *Handchir Mikrochir Plast Chir.* 2011;43:162-166. <https://doi.org/10.1055/s-0031-1273686>
- Interventions: Assistive Technology**
1. O'Connor D, Page MJ, Marshall SC, Massy-Westropp N. Ergonomic positioning or equipment for treating carpal tunnel syndrome. *Cochrane Database Syst Rev.* 2012;1:CD009600. <https://doi.org/10.1002/14651858.CD009600>
  2. Schmid AB, Kubler PA, Johnston V, Coppieters MW. A vertical mouse and ergonomic mouse pads alter wrist position but do not reduce carpal tunnel pressure in patients with carpal tunnel syndrome. *Appl Ergon.* 2015;47:151-156. <https://doi.org/10.1016/j.apergo.2014.08.020>
- Interventions: Orthoses**
1. Bulut GT, Caglar NS, Aytakin E, Ozgonenel L, Tutun S, Demir SE. Comparison of static wrist splint with static wrist and metacarpophalangeal splint in carpal tunnel syndrome. *J Back Musculoskelet Rehabil.* 2015;28:761-767. <https://doi.org/10.3233/BMR-140580>
  2. Chesterton LS, Blagojevic-Bucknall M, Burton C, et al. The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial. *Lancet.* 2018;392:1423-1433. [https://doi.org/10.1016/S0140-6736\(18\)31572-1](https://doi.org/10.1016/S0140-6736(18)31572-1)



APPENDIX E

3. Courts RB. Splinting for symptoms of carpal tunnel syndrome during pregnancy. *J Hand Ther.* 1995;8:31-34. [https://doi.org/10.1016/S0894-1130\(12\)80154-2](https://doi.org/10.1016/S0894-1130(12)80154-2)
  4. Ekman-Ordeberg G, Sälgeback S, Ordeberg G. Carpal tunnel syndrome in pregnancy. A prospective study. *Acta Obstet Gynecol Scand.* 1987;66:233-235. <https://doi.org/10.3109/00016348709020753>
  5. Gelberman RH, Hergenroeder PT, Hargens AR, Lundborg GN, Akeson WH. The carpal tunnel syndrome. A study of carpal canal pressures. *J Bone Joint Surg Am.* 1981;63:380-383.
  6. Gerritsen AA, de Vet HC, Scholten RJ, Bertelsmann FW, de Krom MC, Bouter LM. Splinting vs surgery in the treatment of carpal tunnel syndrome: a randomized controlled trial. *JAMA.* 2002;288:1245-1251. <https://doi.org/10.1001/jama.288.10.1245>
  7. Golriz B, Ahmadi Bani M, Arazpour M, et al. Comparison of the efficacy of a neutral wrist splint and a wrist splint incorporating a lumbrical unit for the treatment of patients with carpal tunnel syndrome. *Prosthet Orthot Int.* 2016;40:617-623. <https://doi.org/10.1177/0309364615592695>
  8. Hall B, Lee HC, Fitzgerald H, Byrne B, Barton A, Lee AH. Investigating the effectiveness of full-time wrist splinting and education in the treatment of carpal tunnel syndrome: a randomized controlled trial. *Am J Occup Ther.* 2013;67:448-459. <https://doi.org/10.5014/ajot.2013.006031>
  9. Keir PJ, Bach JM, Rempel DM. Effects of finger posture on carpal tunnel pressure during wrist motion. *J Hand Surg Am.* 1998;23:1004-1009. [https://doi.org/10.1016/S0363-5023\(98\)80007-5](https://doi.org/10.1016/S0363-5023(98)80007-5)
  10. Kuo MH, Leong CP, Cheng YF, Chang HW. Static wrist position associated with least median nerve compression: sonographic evaluation. *Am J Phys Med Rehabil.* 2001;80:256-260. <https://doi.org/10.1097/00002060-200104000-00004>
  11. Madjinasab N, Zadeh NS, Assarzagdegan F, Ali AMA, Pipelzadeh M. Efficacy comparison of splint and oral steroid therapy in nerve conduction velocity and latency median nerve in carpal tunnel syndrome. *Pak J Med Sci.* 2008;24:725-728.
  12. Manente G, Melchionda D, Staniscia T, D'Archivio C, Mazzone V, Macarini L. Changes in the carpal tunnel while wearing the Manu soft hand brace: a sonographic study. *J Hand Surg Eur Vol.* 2013;38:57-60. <https://doi.org/10.1177/1753193412446112>
  13. Mishra S, Prabhakar S, Lal V, Modi M, Das CP, Khurana D. Efficacy of splinting and oral steroids in the treatment of carpal tunnel syndrome: a prospective randomized clinical and electrophysiological study. *Neurol India.* 2006;54:286-290.
  14. Özgen M, Güngen G, Sarsan A, et al. Determination of the position on which the median nerve compression is at the lowest in carpal tunnel syndrome and clinical effectiveness of custom splint application. *Rheumatol Int.* 2011;31:1031-1036. <https://doi.org/10.1007/s00296-010-1414-5>
  15. Page MJ, Massy-Westropp N, O'Connor D, Pitt V. Splinting for carpal tunnel syndrome. *Cochrane Database Syst Rev.* 2012:CD010003. <https://doi.org/10.1002/14651858.CD010003>
  16. Rempel D, Bach JM, Gordon L, So Y. Effects of forearm pronation/supination on carpal tunnel pressure. *J Hand Surg Am.* 1998;23:38-42. [https://doi.org/10.1016/S0363-5023\(98\)80086-5](https://doi.org/10.1016/S0363-5023(98)80086-5)
  17. Rojviroj S, Sirichativapee W, Kowsuwan W, Wongwiwattananon J, Tamnanthong N, Jeeravipoolvarn P. Pressures in the carpal tunnel. A comparison between patients with carpal tunnel syndrome and normal subjects. *J Bone Joint Surg Br.* 1990;72:516-518.
  18. Schmid AB, Elliott JM, Strudwick MW, Little M, Coppieters MW. Effect of splinting and exercise on intraneural edema of the median nerve in carpal tunnel syndrome—an MRI study to reveal therapeutic mechanisms. *J Orthop Res.* 2012;30:1343-1350. <https://doi.org/10.1002/jor.22064>
  19. So H, Chung VCH, Cheng JCK, Yip RML. Local steroid injection versus wrist splinting for carpal tunnel syndrome: a randomized clinical trial. *Int J Rheum Dis.* 2018;21:102-107. <https://doi.org/10.1111/1756-185X.13162>
  20. Ucan H, Yagci I, Yilmaz L, Yagmurlu F, Keskin D, Bodur H. Comparison of splinting, splinting plus local steroid injection and open carpal tunnel release outcomes in idiopathic carpal tunnel syndrome. *Rheumatol Int.* 2006;27:45-51. <https://doi.org/10.1007/s00296-006-0163-y>
  21. Walker WC, Metzler M, Cifu DX, Swartz Z. Neutral wrist splinting in carpal tunnel syndrome: a comparison of night-only versus full-time wear instructions. *Arch Phys Med Rehabil.* 2000;81:424-429. <https://doi.org/10.1053/mr.2000.3856>
  22. Wang JC, Liao KK, Lin KP, et al. Efficacy of combined ultrasound-guided steroid injection and splinting in patients with carpal tunnel syndrome: a randomized controlled trial. *Arch Phys Med Rehabil.* 2017;98:947-956. <https://doi.org/10.1016/j.apmr.2017.01.018>
  23. Weiss ND, Gordon L, Bloom T, So Y, Rempel DM. Position of the wrist associated with the lowest carpal-tunnel pressure: implications for splint design. *J Bone Joint Surg Am.* 1995;77:1695-1699.
- Interventions: Biophysical Agents (Thermotherapy)**
1. Chang YW, Hsieh SF, Horng YS, Chen HL, Lee KC, Horng YS. Comparative effectiveness of ultrasound and paraffin therapy in patients with carpal tunnel syndrome: a randomized trial. *BMC Musculoskelet Disord.* 2014;15:399. <https://doi.org/10.1186/1471-2474-15-399>
  2. Frasca G, Maggi L, Padua L, et al. Short-term effects of local microwave hyperthermia on pain and function in patients with mild to moderate carpal tunnel syndrome: a double blind randomized sham-controlled trial. *Clin Rehabil.* 2011;25:1109-1118. <https://doi.org/10.1177/0269215511400767>
  3. Incebiyik S, Boyaci A, Tutoglu A. Short-term effectiveness of short-wave diathermy treatment on pain, clinical symptoms, and hand function in patients with mild or moderate idiopathic carpal tunnel syndrome. *J Back Musculoskelet Rehabil.* 2015;28:221-228. <https://doi.org/10.3233/BMR-140507>

APPENDIX E

4. Michlovitz S, Hun L, Erasala GN, Hengehold DA, Weingand KW. Continuous low-level heat wrap therapy is effective for treating wrist pain. *Arch Phys Med Rehabil.* 2004;85:1409-1416. <https://doi.org/10.1016/j.apmr.2003.10.016>

**Interventions: Biophysical Agents (Electrotherapy)**

1. Koca I, Boyaci A, Tutoglu A, Ucar M, Kocaturk O. Assessment of the effectiveness of interferential current therapy and TENS in the management of carpal tunnel syndrome: a randomized controlled study. *Rheumatol Int.* 2014;34:1639-1645. <https://doi.org/10.1007/s00296-014-3005-3>

**Interventions: Biophysical Agents (Light Agents)**

1. Raeissadat SA, Rayegani SM, Rezaei S, et al. The effect of polarized polychromatic noncoherent light (Bioptron) therapy on patients with carpal tunnel syndrome. *J Lasers Med Sci.* 2014;5:39-46.

2. Rankin IA, Sargeant H, Rehman H, Gurusamy KF. Low-level laser therapy for carpal tunnel syndrome. *Cochrane Database Syst Rev.* 2017:CD012765. <https://doi.org/10.1002/14651858.CD012765>

3. Stasinopoulos D, Stasinopoulos I, Johnson MI. Treatment of carpal tunnel syndrome with polarized polychromatic noncoherent light (Bioptron light): a preliminary, prospective, open clinical trial. *Photomed Laser Surg.* 2005;23:225-228. <https://doi.org/10.1089/pho.2005.23.225>

**Interventions: Biophysical Agents (Sound Agents)**

1. Armagan O, Bakilan F, Ozgen M, Mehmetoglu O, Oner S. Effects of placebo-controlled continuous and pulsed ultrasound treatments on carpal tunnel syndrome: a randomized trial. *Clinics (São Paulo).* 2014;69:524-528. [https://doi.org/10.6061/clinics/2014\(08\)04](https://doi.org/10.6061/clinics/2014(08)04)

2. Baysal O, Altay Z, Ozcan C, Ertem K, Yologlu S, Kayhan A. Comparison of three conservative treatment protocols in carpal tunnel syndrome. *Int J Clin Pract.* 2006;60:820-828. <https://doi.org/10.1111/j.1742-1241.2006.00867.x>

3. Chang YW, Hsieh SF, Horng YS, Chen HL, Lee KC, Horng YS. Comparative effectiveness of ultrasound and paraffin therapy in patients with carpal tunnel syndrome: a randomized trial. *BMC Musculoskelet Disord.* 2014;15:399. <https://doi.org/10.1186/1471-2474-15-399>

4. Ebenbichler GR, Resch KL, Nicolakis P, et al. Ultrasound treatment for treating the carpal tunnel syndrome: randomised “sham” controlled trial. *BMJ.* 1998;316:731-735. <https://doi.org/10.1136/bmj.316.7133.731>

5. Oztas O, Turan B, Bora I, Karakaya MK. Ultrasound therapy effect in carpal tunnel syndrome. *Arch Phys Med Rehabil.* 1998;79:1540-1544. [https://doi.org/10.1016/S0003-9993\(98\)90416-6](https://doi.org/10.1016/S0003-9993(98)90416-6)

**Interventions: Biophysical Agents (Transdermal Drug Delivery)**

1. Amirjani N, Ashworth NL, Watt MJ, Gordon T, Chan KM. Corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial. *Muscle Nerve.* 2009;39:627-633. <https://doi.org/10.1002/mus.21300>

2. Bakhtiary AH, Fatemi E, Emami M, Malek M. Phonophoresis of dexamethasone sodium phosphate may manage pain and symptoms of patients with carpal tunnel syndrome. *Clin J Pain.* 2013;29:348-353. <https://doi.org/10.1097/AJP.0b013e318255c090>

3. Gökoğlu F, Fındkoğlu G, Yorgancıoğlu ZR, Okumuş M, Ceceli E, Kocaoğlu S. Evaluation of iontophoresis and local corticosteroid injection in the treatment of carpal tunnel syndrome. *Am J Phys Med Rehabil.* 2005;84:92-96. <https://doi.org/10.1097/01.PHM.0000151942.49031.DD>

4. Gurcay E, Unlu E, Gurcay AG, Tuncay R, Cakci A. Assessment of phonophoresis and iontophoresis in the treatment of carpal tunnel syndrome: a randomized controlled trial. *Rheumatol Int.* 2012;32:717-722. <https://doi.org/10.1007/s00296-010-1706-9>

5. Karatay S, Aygul R, Melikoglu MA, et al. The comparison of phonophoresis, iontophoresis and local steroid injection in carpal tunnel syndrome treatment [letter]. *Joint Bone Spine.* 2009;76:719-721. <https://doi.org/10.1016/j.jbspin.2009.02.008>

6. Soyupek F, Kutluhan S, Uslusoy G, Ilgun E, Eris S, Askin A. The efficacy of phonophoresis on electrophysiological studies of the patients with carpal tunnel syndrome. *Rheumatol Int.* 2012;32:3235-3242. <https://doi.org/10.1007/s00296-011-2171-9>

7. Soyupek F, Yesildag A, Kutluhan S, et al. Determining the effectiveness of various treatment modalities in carpal tunnel syndrome by ultrasonography and comparing ultrasonographic findings with other outcomes. *Rheumatol Int.* 2012;32:3229-3234. <https://doi.org/10.1007/s00296-011-2173-7>

8. Yildiz N, Atalay NS, Gungen GO, Sanal E, Akkaya N, Topuz O. Comparison of ultrasound and ketoprofen phonophoresis in the treatment of carpal tunnel syndrome. *J Back Musculoskelet Rehabil.* 2011;24:39-47. <https://doi.org/10.3233/BMR-2011-0273>

**Interventions: Biophysical Agents (Magnet Therapy)**

1. Carter R, Aspy CB, Mold J. The effectiveness of magnet therapy for treatment of wrist pain attributed to carpal tunnel syndrome. *J Fam Pract.* 2002;51:38-40.

2. Colbert AP, Markov MS, Carlson N, Gregory WL, Carlson H, Elmer PJ. Static magnetic field therapy for carpal tunnel syndrome: a feasibility study. *Arch Phys Med Rehabil.* 2010;91:1098-1104. <https://doi.org/10.1016/j.apmr.2010.02.013>

**Interventions: Manual Therapy and Stretching**

1. Baker NA, Moehling KK, Rubinstein EN, Wollstein R, Gustafson NP, Baratz M. The comparative effectiveness of combined lumbrical muscle splints and stretches on symptoms and function in carpal tunnel syndrome. *Arch Phys Med Rehabil.* 2012;93:1-10. <https://doi.org/10.1016/j.apmr.2011.08.013>

2. Basson A, Olivier B, Ellis R, Coppieters M, Stewart A, Mudzi W. The effectiveness of neural mobilization for neuromusculoskeletal conditions: a systematic review and meta-analysis. *J Orthop Sports Phys Ther.* 2017;47:593-615. <https://doi.org/10.2519/jospt.2017.117>

APPENDIX E

3. Maddali Bongi S, Signorini M, Bassetti M, Del Rosso A, Orlandi M, De Scisciolo G. A manual therapy intervention improves symptoms in patients with carpal tunnel syndrome: a pilot study. *Rheumatol Int.* 2013;33:1233-1241. <https://doi.org/10.1007/s00296-012-2507-0>
4. Fernández-de-las Peñas C, Ortega-Santiago R, de la Llave-Rincón AI, et al. Manual physical therapy versus surgery for carpal tunnel syndrome: a randomized parallel-group trial. *J Pain.* 2015;16:1087-1094. <https://doi.org/10.1016/j.jpain.2015.07.012>
5. Fernández-de-las-Peñas C, Cleland J, Palacios-Ceña M, Fuen-salida-Novo S, Pareja JA, Alonso-Blanco C. The effectiveness of manual therapy versus surgery on self-reported function, cervical range of motion, and pinch grip force in carpal tunnel syndrome: a randomized clinical trial. *J Orthop Sports Phys Ther.* 2017;47:151-161. <https://doi.org/10.2519/jospt.2017.7090>
6. Page MJ, O'Connor D, Pitt V, Massy-Westropp N. Exercise and mobilisation interventions for carpal tunnel syndrome. *Cochrane Database Syst Rev.* 2012:CD009899. <https://doi.org/10.1002/14651858.CD009899>
7. Wolny T, Linek P. Neurodynamic techniques versus “sham” therapy in the treatment of carpal tunnel syndrome: a randomized placebo-controlled trial. *Arch Phys Med Rehabil.* 2018;99:843-854. <https://doi.org/10.1016/j.apmr.2017.12.005>
8. Wolny T, Linek P. Is manual therapy based on neurodynamic techniques effective in the treatment of carpal tunnel syndrome? A randomized controlled trial. *Clin Rehabil.* 2019;33:408-417. <https://doi.org/10.1177/0269215518805213>

APPENDIX F

LEVELS OF EVIDENCE TABLE\*

Level	Intervention/Prevention	Pathoanatomic/Risk/ Clinical Course/Prognosis/ Differential Diagnosis	Diagnosis/Diagnostic Accuracy	Prevalence of Condition/ Disorder	Exam/Outcomes
I	Systematic review of high-quality RCTs High-quality RCT <sup>†</sup>	Systematic review of prospective cohort studies High-quality prospective cohort study <sup>‡</sup>	Systematic review of high-quality diagnostic studies High-quality diagnostic study <sup>§</sup> with validation	Systematic review, high-quality cross-sectional studies High-quality cross-sectional study <sup>¶</sup>	Systematic review of prospective cohort studies High-quality prospective cohort study
II	Systematic review of high-quality cohort studies High-quality cohort study <sup>‡</sup> Outcomes study or ecological study Lower-quality RCT <sup>†</sup>	Systematic review of retrospective cohort study Lower-quality prospective cohort study High-quality retrospective cohort study Consecutive cohort Outcomes study or ecological study	Systematic review of exploratory diagnostic studies or consecutive cohort studies High-quality exploratory diagnostic studies Consecutive retrospective cohort	Systematic review of studies that allows relevant estimate Lower-quality cross-sectional study	Systematic review of lower-quality prospective cohort studies Lower-quality prospective cohort study
III	Systematic reviews of case-control studies High-quality case-control study Lower-quality cohort study	Lower-quality retrospective cohort study High-quality cross-sectional study Case-control study	Lower-quality exploratory diagnostic studies Nonconsecutive retrospective cohort	Local nonrandom study	High-quality cross-sectional study
IV	Case series	Case series	Case-control study	...	Lower-quality cross-sectional study
V	Expert opinion	Expert opinion	Expert opinion	Expert opinion	Expert opinion

Abbreviation: RCT, randomized clinical trial.

\*Adapted from Phillips et al.<sup>226</sup> See also APPENDIX G.

<sup>†</sup>High quality includes RCTs with greater than 80% follow-up, blinding, and appropriate randomization procedures.

<sup>‡</sup>High-quality cohort study includes greater than 80% follow-up.

<sup>§</sup>High-quality diagnostic study includes consistently applied reference standard and blinding.

<sup>¶</sup>High-quality prevalence study is a cross-sectional study that uses a local and current random sample or censuses.

<sup>††</sup>Weaker diagnostic criteria and reference standards, improper randomization, no blinding, and less than 80% follow-up may add bias and threats to validity.

APPENDIX G

**PROCEDURES FOR ASSIGNING LEVELS OF EVIDENCE**

- Level of evidence is assigned based on the study design using the Levels of Evidence table (**APPENDIX F**), assuming high quality (eg, for intervention, randomized clinical trial starts at level I)
- Study quality is assessed using the critical appraisal tool, and the study is assigned 1 of 4 overall quality ratings based on the critical appraisal results
- Level of evidence assignment is adjusted based on the overall quality rating:
  - High quality (high confidence in the estimate/results): study remains at assigned level of evidence (eg, if the randomized clinical trial is rated high quality, its final assignment is level I). High quality should include:
    - Randomized clinical trial with greater than 80% follow-up, blinding, and appropriate randomization procedures
    - Cohort study includes greater than 80% follow-up
    - Diagnostic study includes consistently applied reference standard and blinding
    - Prevalence study is a cross-sectional study that uses a local and current random sample or censuses
  - Acceptable quality (the study does not meet requirements for high quality and weaknesses limit the confidence in the accuracy of the estimate): downgrade 1 level
    - Based on critical appraisal results
  - Low quality: the study has significant limitations that substantially limit confidence in the estimate: downgrade 2 levels
    - Based on critical appraisal results
  - Unacceptable quality: serious limitations—exclude from consideration in the guideline
    - Based on critical appraisal results